# INDEX

## Volume Twenty-Eight—January through December 1994

*The Annals of Pharmacotherapy*


| | | | | | |
|---|---|---|---|---|---|
| JANUARY | Pages 1–162 | MAY | Pages 553–688 | SEPTEMBER | Pages 1001–1128 |
| FEBRUARY | Pages 163–298 | Supplement | Pages S1–S40 | OCTOBER | Pages 1129–1216 |
| MARCH | Pages 299–428 | JUNE | Pages 689–824 | NOVEMBER | Pages 1217–1328 |
| APRIL | Pages 429–552 | JULY/AUGUST | Pages 825–1000 | DECEMBER | Pages 1329–1444 |


## SUBJECT INDEX

### A


**Absorption,** cyclosporine, decreased, GoLytely lavage (L) 963; digoxin, tablets, gel caps, elixir, end jejunostomy (CR) 1239; systemic, topical phenytoin sodium (L) 961

**Acetaminophen,** interaction, zidovudine (CR) 327

**Acetylcysteine,** antioxidant, sepsis (CC) 1086

***N*-Acetylcysteine,** serum sickness (L) 285

**Acquired immunodeficiency syndrome,** see also, **Human immunodeficiency virus;** diarrhea, octreotide (L) 806; intestinal cryptosporidiosis, management (AIDS) 767; *Mycobacterium avium* complex, therapeutic drug concentrations (L) 808; pentamidine, pancreatitis (CR) 1025; role of healthcare professionals (L) 286; visceral leishmaniasis, amphotericin B (L) 1305

**Acromegaly,** octreotide effect, lipid metabolism (L) 1198

**Acyclovir,** elimination, breast milk (CR) 585; neurotoxicity (L) 961; oral, immunocompetent patients with varicella (DIAS) 208, kidney failure, neurotoxicity (CR) 460; prophylaxis, herpes simplex, bone marrow transplant/leukemia (RPR) 852

**Adenosine,** supraventricular tachycardia, pregnancy (CR) 1241

**Agranulocytosis,** etodolac (CR) 458

**AIDS,** see **Acquired immunodeficiency syndrome**

**Albendazole,** cutaneous larva migrans (L) 672

**Albumin,** routine administration, nutrition support (TC) 478

**Albuterol,** acute exacerbation, chronic obstructive pulmonary disease (CC) 1380; hypophosphatemia (CC) 628

**Alcohol,** withdrawal, benzodiazepines (L) 971

**Alcoholism,** naltrexone (DIAS) 210

**Aldosterone,** serum concentrations, dopamine administration (RPR) 837

**Allergies,** histamine$_2$-blocking agents (DIAS) 742

**Alopecia,** female, minoxidil (DIAS) 890

**Alteplase,** fibrinogen, thrombin, platelets, complement, blood rheology, neutrophil effects (A) 752

**Alzheimer's disease,** tacrine, review (FF) 744

**American College of Chest Physicians,** guidelines, dilated cardiomyopathy (TC) 607

**American College of Pharmacy Educators,** see **Association News (NC)**

**American Medical Association,** see **Association News (NC)**

**American Pharmacy Association,** see **Association News (NC)**

**Amiloride,** lithium-induced polyuria (DIAS) 888

**Aminoglycosides,** dosing methods (L) 809; nephrotoxicity (L) 1202; once-daily administration (A) 757, (E) 797 (L) 1412; volume of distribution, patient subgroups (TM) 944; with vancomycin, *Staphylococcus epidermidis* endocarditis (DIAS) 737

**Amiodarone,** vasculitis (L) 537

**Amlodipine,** cross-sensitivity, diltiazem (L) 118

**Amoxicillin,** urinary tract infection, pregnancy (O) 248

**Amphotericin B,** 0.25%, otitis externa (CR) 333; lack of nephrotoxicity (L) 1307; nephrotoxicity, intralipid prophylaxis (DIAS) 1182; visceral leishmaniasis, AIDS (L) 1305

**Ampicillin,** erythema multiforme, myocarditis (CR) 730

**An Opinion,** see also, **Editorials; Canaday, Bruce R., Yarborough, Peggy,** Documenting Pharmaceutical Care: Creating a Standard, 1292; **Gerber, David R.,** Optimizing Oxygen Delivery in Critical Illness, 1297; **Hutchinson, Richard A., Schumock, Glen T.,** Need to Develop a Legal and Ethical Base for Pharmaceutical Care, 954; Recommended Treatment for Urinary Tract Infection in Pregnancy, 248; Wolfgang, Alan P., Rupp, Michael T., The Health Security Act: A Case of Good News and Bad News, 802

**Anaphylaxis,** ondansetron (CR) 1029; prophylaxis, contrast media (DIR) 236; triamcinolone acetonide (L) 1310

**Androgens,** Turner syndrome, girls, adult height (RPR) 570

**Anesthesia,** relationship between postoperative nystagmus, nausea (RPR) 179

**Angiotensin II,** intravenous, lisinopril toxicity (CR) 1165

**Anistreplase,** fibrinogen, thrombin, platelets, complement, blood rheology, neutrophil effects (A) 752

**Announcements,** Board of Pharmaceutical Specialties, board certification, pharmacotherapy, 681

**Antacids,** compared with histamine$_2$-antagonists, sucralfate, prostaglandin, meta-analysis (A) 1075

**Antibiotics,** cost, cancer patients (PEC) 105; macrolide, review (DSP) 1255; phlebitis prophylaxis, heparin/hydrocortisone vs. filters (RPR) 11; prophylaxis, dentistry (DIAS) 57; urinary tract infections (A) 1264

**Antibodies, monoclonal,** rheumatoid arthritis (RA) 650

**Anticoagulants,** chronic, dilated cardiomyopathy (TC) 604

**Antidepressants,** interaction, flumazenil, status epilepticus (CR) 1347

**Antifungals,** utilization, post-fluconazole marketing (PEP) 261, pre-fluconazole marketing (PEP) 252

**Antihypertensives,** elderly (G) 369; endstage renal disease (A) 363; prescription, medical record comparison (PEP) 99

**Antiinflammatory drugs, nonsteroidal,** emergency use (L) 1201; indomethacin, colonic ulcer (CR) 883

**Antioxidants,** acetylcysteine, sepsis (CC) 1086; cataract formation (DIAS) 1040

**Antistreptokinase,** antibodies persistence, streptokinase (DIAS) 204

**Anxiety disorder,** pyridoxal phosphate (L) 1411

**Aplastic anemia,** ticlopidine (CR) 1169

**Appendicitis,** acute, cefoperazone/sulbactam pharmacokinetics (RPR) 703

**Aprotinin,** prophylaxis, surgical blood loss (DIAS) 1246

**Arndt, Jack R.,** 1994 merit award, American Association of Colleges of Pharmacy (NC) 162

**Arrhythmias,** flosequinan (L) 403; fluorouracil (DIR) 374

**Arthritis,** rheumatoid, monoclonal antibodies (RA) 650

**Aspirin,** interaction, verapamil (L) 536; toxicity, enema (CR) 467; with heparin, stroke, safety (RPR) 441

**Association News (NC),** Additional Sites Named for Pharmacotherapy Examination, 822; American Medical Association's Board Recommends Therapeutic Interchange, 1216; APhA Clarifies NAFTA's Effect on Pharmacy, 160; APhA Testifies to Strengthen Patient Counseling Laws in California, 1216; Chain Drug Retailers Reject ACPE Declaration, 1216; Clifton J. Latiolais Honor Medal Established to Recognize Outstanding Contributions to Managed Healthcare, 999; Open Hearing Set for Oncology Petition, 161; Pharmacy Coalition Urges President and Congress to Recognize Pharmaceutical Care, 822; Pharmacy Faculty Meet to Discuss Nontraditional Education and Pharm.D. Degrees, 999; Recertification Update, 426; Scope of Pharmacy Defined, 822; Sites Announced for Pharmacotherapy Examination, 427

**Asthma,** acute exacerbations, theophylline (PA) 909; corticosteroids, inhaled, meta-analysis (PA) 1285; cromolyn, children less than 2 years (DIAS) 886; glucocorticoids, inhaled, systemic effects (PA) 904; salmeterol, therapy issues (PA) 1100; theophylline, renal excretion, age-dependent, children (L) 281

**Atovaquone,** intestinal cryptosporidiosis (AIDS) 771

**Atresia, biliary,** children, trimethoprim/sulfamethoxazole pharmacokinetics (L) 405

**Azathioprine,** pregnancy, fetal risks (DIAS) 1355

**Azithromycin,** chlamydia (DIAS) 600; compared with erythromycin (DSP) 1257; intestinal cryptosporidiosis (AIDS) 772

**Azlocillin,** otitis media (PED) 1094

**Aztreonam,** pharmacokinetics, HPLC analysis (RPR) 444


### B


**Benzocaine,** methemoglobinemia (DIR) 643

**Benzodiazepines,** alcohol withdrawal (L) 971; ethanol withdrawal (TC) 67; infantile spasms (PED) 784; pharmacokinetics (TC) 68

**Benzyl alcohol,** with methylprednisolone acetate, epidural administration (DIAS) 59

**Bertino, Joseph S., Jr.,** Anti-Infective Drugs Advisory Committee, FDA (NC) 298

**Beta-agonists,** see **Sympathomimetic agents**

**Beta-blockers,** see **Sympatholytic agents**

**Beta carotene,** cancer prophylaxis (DIAS) 470

**Bezafibrate,** lipoprotein(a) concentrations (TC) 345

**Bile acid sequestrant,** compliance, telephone follow-up (RPR) 29

**Biofeedback,** sympatholytic withdrawal (RPR) 849

**Bioimpedance,** estimation of body water (RPR) 565

**Bitolterol,** acute exacerbation, chronic obstructive pulmonary disease (CC) 1380

**Bleeding,** upper gastrointestinal, ketorolac, oral (L) 1109

**Bleomycin,** intrapleural (DSP) 899; malignant pleural effusions, cost (L) 407

**Board of Pharmaceutical Specialties,** see also, **Association News (NC);** board certification, 681

**Book Reviews,** A Short Course in Clinical Pharmacokinetics (D.A. Noe), 1316; Analgesic and NSAID Induced Kidney Disease (J.H. Stewart), 975; Aspirin and Other Salicylates (J.R. Vane, R.M. Botting), 673; Biological Basis of Substance Abuse (S.G. Korenman, J.D. Barchas), 410; Biotechnology and Pharmacy (J.M. Pezzuto, M.E. Johnson, H.R. Manasse), 813; Cancer: Principles & Practice of Onco$^2$ogy. 4th Edition (V.J. DeVita, Jr., S. Hellman), 121; Chronic Fatigue Syndromes: The Limbic Hypothesis (J.A. Goldstein), 674; Cocaine: Scientific and Social Dimensions (Ciba Foundation Symposium 166), 409; Comorbidity of Addictive and Psychiatric Disorders (N.S. Miller, B. Stimmel), 975; Cutaneous Drug Reactions: An Integral Synopsis of Today's Systemic Drugs. 2nd Edition (K. Zurcher, A. Krebs), 121; Geriatric Dosage Handbook, 1993 (T.P. Semla, J.L. Beizer, M.D. Higbee), 1315; Handbook for the New Health Care Manager: Practical Strategies for Challenging Times (D.N. Lombardi), 1316; Handbook of Nonprescription Drugs. 10th Edition. Case Studies Workbook (American Pharmaceutical Association), 812; Handbook of Therapeutic Interventions, 1315; High Density Lipoproteins: Pathophysiology and Clinical Relevance (Atherosclerosis Reviews, Volume 24) (A.L. Catapano, F. Bernini, A. Corsini), 540; Human Psychopharmacology—Measures and Methods. Volume 4 (I. Hindmarch, P.D. Stonier), 1205; ImmunoFacts: Vaccines & Immunologic

Drugs (J.G. Gravenstein), 287; Medical Audit: Rationale and Practicalities (S.P. Frostick, P.J. Radford, W.A. Wallace), 1205; Molecular and Cellular Approaches to the Treatment of Neurological Disease: Association for Research in Nervous and Mental Disease, Volume 71 (S.G. Waxman), 975; Multicultural Pharmaceutical Education (B. Bleidt), 1317; Planning Pharmaceutical Clinical Trials: Basic Statistical Principles (W.M. Woodding), 1114; Principles and Practice of Psychopharmacotherapy (P.G. Janicak, J.M. Davies, S.H. Preskorn, F.J. Ayd, Jr.), 1414; Progress and Perspectives in Chemoprevention of Cancer (Serono Symposia Publications from Raven Press, Volume 79) (G. DePalo, M. Sporn, U. Veronesi), 813; Promotion of Pharmaceuticals: Issues, Trends, Options (D.S. Pathak, A. Escovitz, S. Kucukarslan), 1415; Pulsatile Drug Delivery: Current Applications and Future Trends (R. Gurny, H.E. Junginger, N.A. Peppas), 1318; Techniques of Patient-Oriented Research (C.Y.C. Pak, P.M. Adams), 1316; Tension-Type Headache: Classification, Mechanisms, and Treatment (J. Olesen, J. Schoenen), 1205; The Cardiomyopathic Heart (M. Nagano, N. Takeda, N.S. Dhalla), 1115; The Cytotoxics Handbook. 2nd Edition (M. Allwood, P. Wright), 1114; The Pharmacologic Approach to the Critically Ill Patient. 3rd Edition (B. Chernow), 1414; The Social Context of the Chronic Pain Sufferer (R. Roy), 1206; The Treatment of Epilepsy: Principles and Practice (E. Wylie), 287; Women—A Force in Pharmacy, Proceedings of the Pharmacy World Congress 1991: International Forum for Women in Pharmacy (M.J. Berg, G.N. Francke, M.R. Rollings), 1206

**Books Received,** 287, 410, 976

**Brodie, Donald C.,** obituary (NC) 552

**Busulfan,** adverse reactions (A) 1059; pharmacokinetics (A) 1056; review (A) 1055

## C

**Calcium-channel antagonists**, ischemic stroke outcome (L) 671

**Campbell, R. Keith,** Outstanding Teacher, American Association of Colleges of Pharmacy (NC) 1126; position statement consensus panel member, American Diabetes Association (NC) 162

**Cancer,** antibiotic therapy, cost (PEC) 105; breast, mortality (NC) 823, paclitaxel (S) S19; chemotherapy, SIADH (L) 1199; head and neck, paclitaxel (S) S20; non–small-cell lung, paclitaxel (S) S19; ovarian, paclitaxel (S) S18; pain, treatment guidelines released (NC) 551; pain control, survey (RPR) 857; prophylaxis, beta carotene (DIAS) 470; small-cell lung, paclitaxel (S) S22

**Captopril,** hypertensive crisis (TC) 352

**Carbamazepine,** SIADH (L) 1199; interaction, metronidazole (L) 1303; mononucleosis syndrome (L) 402

**Carboprost,** hemorrhagic cystitis, cyclophosphamide (CR) 590

**Cardiomyopathy,** dilated, anticoagulation (TC) 604

**Cardoni, Alex A.,** Cornelis Boelhower Memorial Award (NC) 1430

**L-Carnitine,** athletic performance enhancer (L) 973

**Carpal tunnel syndrome,** pyridoxine (DIAS) 1042

**Case Reports,** Abnormal Bone Mineral Metabolism After Long-Term Anticonvulsant Treatment, 47; Acute Renal Failure and Neurotoxicity Following Oral Acyclovir, 460; Acyclovir Excretion in Human Breast Milk, 585; Adenosine Use in Pregnant Women with Supraventricular Tachycardia, 1241; Adverse Interaction Between Clonidine and Verapamil, 881; Agranulocytosis Associated with Etodolac, 458; Aminoglycoside Nephrotoxicity Following Single-Dose Cystoscopy Prophylaxis, 199; Anaphylactoid Reactions Associated with Ondansetron, 1029; Concurrent Use of Foscarnet and Cipro- floxacin May Increase the Propensity for Seizures, 869; Cough Induced by Quinapril with Resolution After Changing to Fosinopril, 720; Creatinine Metabolism Impairment by an Anticonvulsant Drug, Phenacemide, 49; Cyclophosphamide-Induced Facial Discomfort, 197; Delayed Neutropenia with Ticlopidine, 1344; Erythema Multiforme and Hypersensitivity Myocarditis Caused by Ampicillin, 730; Famotidine-Induced Mixed Hepatocellular Jaundice, 40; Fatal Neutropenia and Thrombocytopenia Associated with Ticlopidine, 1236; Fatal Seizures After Flumazenil Administration in a Patient with Mixed Overdose, 1347; Flecainide Distribution, Transplacental Passage, and Accumulation in the Amniotic Fluid During the Third Trimester of Pregnancy, 1031; Fluconazole-Induced Symptomatic Phenytoin Toxicity, 191; Fluvoxamine-Associated Sexual Dysfunction, 872; Gastric Retention of Enteric-Coated Magnesium Chloride Tablets, 874; Heparin-Induced Thrombotic Thrombocytopenia, 43; Hepatitis Following Treatments with Famotidine and Then Cimetidine, 37; High-Dose Clonidine in a Case of Restless Legs Syndrome, 878; Hyperphagia and Weight Loss During Fluoxetine Treatment, 1350; Ifosfamide Extravasation, 1243; Inaccurate Assessment of Drug-Induced Thrombocytopenia: Reason for Concern, 726; Indomethacin-Induced Colonic Ulceration and Bleeding, 883; Lisinopril Overdose and Management with Intravenous Angiotensin II, 1165; Malabsorption of Digoxin Tablets, Gel Caps, and Elixir in a Patient with an End Jejunostomy, 1239; Metronidazole Hypersensitivity, 325; Neurologic Sequelae Associated with Foscarnet Therapy, 1035; Ondansetron for Treating Nausea and Vomiting in the Poisoned Patient, 331; Otic Administration of Amphotericin B 0.25% in Sterile Water, 333; Oxaprozin-Induced Fulminant Hepatitis, 1159; Pancreatitis During Intravenous Pentamidine Therapy in an AIDS Patient with Prior Exposure to Didanosine, 1025; Pharmacokinetics of Zidovudine and Acetaminophen in a Patient on Chronic Acetaminophen Therapy, 327; Pleural Effusion Associated with Chronic Dantrolene Administration, 587; Possible Ciprofloxacin-Induced Acute Cholestatic Jaundice, 1162; Possible Drug Interaction Between Warfarin and Combination of Levamisole and Fluorouracil, 464; Possible Red-Man Syndrome Associated with Systemic Absorption of Oral Vancomycin in a Child with Normal Renal Function, 561; Potential Pharmacokinetic Interaction Between Felbamate and Phenobarbital, 455; Probable Pentamidine-Induced Acute Pancreatitis, 52; Prolonged Thrombocytopenia Associated with Procainamide in an Elderly Patient, 1172; Pronounced Metabolic Response to Modest Theophylline Overdose, 195; Sertraline–Phenelzine Drug Interaction: A Serotonin Syndrome Reaction, 732; Suicide Attempt by Means of Aspirin Enema, 467; Ticlopidine and Fatal Aplastic Anemia in an Elderly Woman, 1169; Treatment of Cyclophosphamide-Induced Hemorrhagic Cystitis with Prostaglandins, 590; Use of Multiple-Dose Activated Charcoal in Phenytoin Toxicity, 201; Vancomycin-Induced Neutropenia During Treatment of Endocarditis in a Pediatric Patient, 723; Worsening of Liver Function with Fluconazole and Review of Azole Antifungal Hepatotoxicity, 1177

**Cataracts,** antioxidants (DIAS) 1040

**Cefactor,** single vs. twice-daily therapy (DIAS) 1353

**Cefixime,** oral, gonorrhea (DIAS) 600

**Cefmenoxime,** compared with ciprofloxacin, bacterial eradication (RPR) 863; dual individualization (PEC) 384

**Cefoperazone,** with sulbactam, pharmacokinetics (RPR) 703

**Ceftazidime,** compared with meropenem (FF) 1050; otitis media (PED) 1094; with vancomycin, stability, peritoneal dialysis (RPR) 572

**Ceftriaxone,** rapid administration, toxicity (L) 807

**Cellulitis,** dobutamine hydrochloride hypersensitivity (L) 964

**Charcoal activated,** aspiration (CC) 915; electrolyte imbalance (CC) 918; gastrointestinal complications (CC) 917; multiple-dose, phenytoin toxicity (CR) 201

***Chlamydia,*** doxycycline, azithromycin (DIAS) 600

**Chlordiazepoxide,** compared with lorazepam, ethanol withdrawal (TC) 69

**Cholestasis,** trimethoprim/sulfamethoxazole (L) 1310

**Cholestyramine,** lipoprotein(a) concentrations (TC) 345

**Chromatography, liquid,** aztreonam degradation, pharmacokinetics (RPR) 444

**Chronic obstructive pulmonary disease,** acute exacerbation, beta-agonists (CC) 1379

**Cilastatin,** with imipenem, compared with meropenem (FF) 1050

**Cimetidine,** compared with cisapride (FF) 492; drug utilization, state prison (PEC) 792; hepatitis (CR) 37; reversal of ranitidine hypergastrinemia (L) 1303

**Ciprofloxacin,** cartilage toxicity, children (DIAS) 336; cholestatic jaundice (CR) 1162; community use, drug utilization evaluation (RPR) 714; compared with cefmenoxime, bacterial eradication (RPR) 863; interaction, foscarnet (CR) 869; intravenous dosing, obesity (L) 806; no interaction, cyclosporine (DIR) 93; oral compared with intravenous, pleural fluid concentrations (RPR) 313; otitis media (PED) 1094; overdose (L) 805

**Cisapride,** adverse reactions (FF) 495; compared with cimetidine (FF) 492; compared with ranitidine (FF) 492; pediatrics (FF) 495; pharmacokinetics (FF) 490; pharmacology (FF) 489; review (FF) 488

**Clarithromycin,** compared with erythromycin (DSP) 1257; ineffective, *Streptococcus* group A (L) 1197; intestinal cryptosporidiosis (AIDS) 773

**Clavulanate,** with ticarcillin, desensitization (L) 1200

**Clearance,** see **Elimination**

**Clindamycin,** otitis media (PED) 1094

**Clinical Nutrition,** Nutritional Support Teams: A Review of Comparative Trials, 227

**Clinical studies,** cisapride (FF) 491; fluoxetine (DSP) 1362; fluvoxamine (DSP) 1362; gabapentin (FF) 1191; interferon beta (FF) 612; meropenem (FF) 1049; nifedipine, pregnancy (A) 1374; paclitaxel (S) S18; paroxetine (DSP) 1362; pediatrics, conducting research (SC) 1105, research needs (E) 1103; rifabutin (FF) 1251; risk reduction (L) 1112; selective serotonin reuptake inhibitors (DSP) 1362; sertraline (DSP) 1362; tacrine (FF) 745; tacrolimus (NDD) 504

**Clobazam,** concentrations, kidney failure (L) 966

**Clonidine,** hypertensive crisis (TC) 353; interaction, verapamil (CR) 881; patch, dermatitis, hydrocortisone cream (DIAS) 889; restless legs syndrome (CR) 878

***Clostridium difficile,*** reporting of incidence (L) 1197

**Communication,** effective, pharmacist–patient (L) 538; patient counseling, drug–nutrient interactions (RPR) 576

**Compatibility, morphine sulfate,** oral, with enteral feeding (RPR) 451; **paclitaxel** (S) S23, polyolefin containers (RPR) 35

**Compliance,** niacin, bile acid sequestrants, telephone follow-up (RPR) 29

**Computers,** CD-ROM, drug information (RA) 1389; medical records, preventing adverse reactions (PI) 523; monitoring, patient-controlled analgesia overdoses (PI) 655; resources, colleges of pharmacy (L) 970

**Concentrations,** aldosterone, dopamine administration (RPR) 837; phenytoin, dosing (L) 808; pleural fluid, ciprofloxacin, intravenous compared with oral (RPR) 313; rifampin, in suspensions, preparation method, storage (RPR) 182; theophylline, electrolyte, glucose abnormalities (RPR) 175; vancomycin, monitoring (RPR) 1335; (E) 1397

**Congestive heart failure,** mortality (NC) 687

**Coronary disease,** incidence, risk factors (NC) 686

**Corrections,** see **Letters**

**Corticosteroids,** inhaled, asthma, meta-analysis (PA) 1285

**Costs,** see **Pharmacoeconomics**

**Creatinine,** increased, phenacemide (CR) 49

**Cremophor EL,** multidrug resistance (S) S12; toxicity (S) S11

**Crismon, M. Lynn,** Specialty Council on Psychopharmacy Practice (NC) 1126

**Critical Care (CC),** Acetylcysteine as a Cytoprotective Antioxidant in Patients with Severe Sepsis: Potential New Use for an Old Drug, 1086; Beta-Agonists in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, 1379; Drug- and Nutrition-Induced Hypophosphatemia: Mechanisms and Relevance in the Critically Ill, 626; Misadventures with Activated Charcoal and Recommendations for Safe Use, 915; Oxygen Transport Goals in the Resuscitation of Critically Ill Patients, 1273

**Critical care,** acetylcysteine, antioxidant, sepsis (CC) 1086; dopamine administration, serum aldosterone concentrations (RPR) 837; famotidine, bolus vs. continuous infusion, gastric pH (RPR) 841; hypophosphatemia, drug- and nutrition-induced (CC) 626; monitoring, oxygen delivery (O) 1297; monitoring techniques, oxygen transport (CC) 1273; recent advances (RA) 245

**Cromolyn,** children less than 2 years (DIAS) 886

**Cryptosporidiosis,** intestinal, management, AIDS (AIDS) 767

**Cushing's syndrome,** dexamethasone self-medication (L) 1411

**Cutaneous larva migrans,** thiabendazole, albendazole, ivermectin (L) 672

**Cyclophosphamide,** facial discomfort (CR) 197; hemorrhagic cystitis, carboprost (CR) 590

**Cyclosporine,** clearance, effect of diltiazem, nifedipine, verapamil (RPR) 1227; compared with tacrolimus (NDD) 505; decreased absorption, GoLytely lavage (L) 963; interaction, probucol (DIR) 940; microemulsion, increased bioavailability (L) 962; monitoring, bone marrow transplantation (TM) 379; no interaction, ciprofloxacin (DIR) 93; pemphigus vulgaris (DIAS) 1183; pregnancy, fetal risks (DIAS) 1356

**Cystitis,** hemorrhagic, cyclophosphamide-induced, carboprost (CR) 590

## D

**D'Angio, Richard G.,** Board Certified Pharmacotherapy Specialist (NC) 1430

**Dantrolene,** pleural effusion (CR) 587

**DEA News (NC),** DEA Creates Mid-Level Practitioner Category, 297

**Deferoxamine,** malaria (DIAS) 602

**Delafuente, Jeffrey,** Fellow, American College of Clinical Pharmacy (NC) 1126

**Dependence,** trimebutine (L) 537

**Depression,** pathogenesis (DSP) 1359

**Dermatitis,** clonidine patch, hydrocortisone cream (DIAS) 889

**Desensitization,** ticarcillin/clavulanate (L) 1200

***N*-Desmethylclobazam,** concentrations, kidney failure (L) 966

**Dexamethasone,** prophylaxis, antenatal respiratory distress syndrome (DIAS) 475; self-medication, Cushing's syndrome (L) 1411; with lorazepam, granisetron, flushing (L) 1306

**Dexamethasone sodium phosphate,** stability, two temperatures (RPR) 1018

**Dexrazoxane,** prophylaxis, doxorubicin cardiotoxicity (A) 1063

**Dextrose,** solutions, with intravenous immunoglobulin, stability (RPR) 1014

**Diagnosis,** narcotic overdose (RPR) 446

**Dialysis,** hemo-, recent advances (RA) 512; peritoneal, stability of ceftazidime, heparin, vancomycin (RPR) 572

**DIAS Rounds,** Amiloride in Lithium-Induced Polyuria, 888; Antenatal Dexamethasone as Prophylaxis of Respiratory Distress Syndrome, 475; Antioxidants May Retard Cataract Formation, 1040; Antistreptokinase Antibodies Following a Dose of Streptokinase, 204; Aprotinin for Prophylaxis of Blood Loss, 1246; Cancer Prevention with Beta Carotene, 470; Combination Sucralfate and Histamine$_2$-Antagonist Therapy, 597; Cromolyn Use in Young Children, 886; Cyclosporine for the Treatment of Pemphigus Vulgaris, 1183; Deferoxamine Treatment of Malaria, 602; Doxycycline-Induced Esophageal Ulceration, 1185; Efficacy of Fluoxetine in Trichotillomania, 1245; Epidural Administration of Methylprednisolone Acetate Preserved with Benzyl Alcohol, 59; Estrogen Therapy of Uremic Bleeding, 60; Fluorescein as a Circulation Determinant, 891; Guanethidine for Reflex Sympathetic Dystrophy, 338; High-Dose Interferon Alfa-2A for the Treatment of Chronic Hepatitis C, 341; Histamine$_2$-Antagonists in Allergic Disorders, 742; Hydrocortisone Cream in Clonidine Patch Dermatitis, 889; Interaction of Histamine$_2$-Receptor Antagonists and Ethanol, 55; Intralipid in Prophylaxis of Amphotericin B Toxicity, 1182; Is Somatostatin Effective in the Treatment of Acute Bleeding Caused by Esophageal Varices?, 739; Lidocaine in Status Epilepticus, 1248; Minoxidil Use in Female Alopecia, 890; Naltrexone in the Treatment of Alcohol Dependence, 210; Neonatal Group B Streptococcal Infection

Prevention, 474; Nitroglycerin Use in Variceal Hemorrhage, 206; Oral Acyclovir in Immunocompetent Patients with Varicella, 208; Oral Treatment of Gonorrhea and Chlamydia, 600; Outcomes of Pregnancy and the Management of Immunosuppressive Agents to Minimize Fetal Risks in Organ Transplant Patients, 1355; Possible Synergy Between Aminoglycosides and Vancomycin in the Treatment of *Staphylococcus epidermidis* Endocarditis?, 737; Potential Quinolone-Induced Cartilage Toxicity in Children, 336; Prophylactic Topical Antibiotics in Dentistry, 57; Prostaglandins for the Treatment of Hepatorenal Syndrome, 54; Pyridoxine in Carpal Tunnel Syndrome, 1045; Rectal Use of Vancomycin, 1357; Single Daily Dosage of Lithium Carbonate, 472; Tamoxifen-Induced Ocular Toxicity, 740; Treatment for HIV Wasting Syndrome, 595; Triazolam Treatment Controversy, 1038; Twice-Daily Cefaclor Therapy, 1353; Use of Silver Sulfadiazine in Stevens-Johnson Syndrome, 736

**Diazepam,** compared with lorazepam, ethanol withdrawal (TC) 69; gynecomastia (L) 671; rhabdomyolysis (L) 1200

**Didanoside,** HIV wasting syndrome (DIAS) 596

**Diethylstilbestrol,** hypophosphatemia (CC) 628

**Digoxin,** tablets, gel caps, elixir, malabsorption (CR) 1239

**Diltiazem,** cross-sensitivity, amlodipine (L) 118; effect on cyclosporine clearance (RPR) 1227

***N,N*-Dimethylglycine,** athletic performance enhancer (L) 973

**Dispensing,** errors, costs (L) 965, minimization (L) 969

**Diuretics,** with pravastatin, diabetes mellitus (L) 964

**Dobutamine hydrochloride,** dermal cellulitis (L) 964

**Documentation,** pharmacotherapy, standards (O) 1292

**Dolubisio, James T.,** 1994 Remington Honor Medal (NC) 162

**Dopamine,** serum aldosterone concentrations (RPR) 837

**Dosage,** aminoglycosides, different methods (L) 809; beta-agonists, chronic obstructive pulmonary disease (CC) 1380; ciprofloxacin, obesity (L) 806; heparin, obesity (L) 1110; lithium, empiric vs. predictive (RPR) 1148

**Dosage administration route, depot,** leuprolide acetate, leukopenia (L) 283; **enema,** aspirin, toxicity (CR) 467; **epidural,** methylprednisolone acetate/benzyl alcohol (DIAS) 59; **inhaled,** corticosteroids, meta-analysis (PA) 1285; **intraperitoneal,** paclitaxel (S) S17, (S) S20, (S) S23; **intrapleural,** bleomycin (DSP) 899, doxycycline (DSP) 898, minocycline (DSP) 900, talc (DSP) 900, talc USP, sterilization (L) 1309; **intravenous,** ciprofloxacin, compared with oral, pleural fluid concentrations (RPR) 313, heparin/hydrocortisone vs. filters (RPR) 11, magnesium, myocardial infarction (TC) 212, nimodipine, safety, tolerance (RPR) 1143; **nasal,** growth hormone (RPR) 845; **otic,** amphotericin B 0.25%, otitis externa (CR) 333; **rectal,** vancomycin (DIAS) 1357; **topical,** phenytoin sodium, systemic absorption (L) 961; **transdermal,** nicotine, stroke (L) 402

**Dosage form,** cream, hydrocortisone, clonidine patch dermatitis (DIAS) 889; microemulsion, cyclosporine, increased bioavailability (L) 962; suspension, rifampin, preparation method, storage (RPR) 182

**Dosage schedules,** intermittent bolus vs. continuous infusion, famotidine (RPR) 841; once-daily, aminoglycosides (A) 757, (E) 797 (L), 1412, lithium carbonate (DIAS) 472, (L) 1311; twice-daily, cefaclor (DIAS) 1353

**Doxorubicin,** cardiotoxicity, dexrazoxane prophylaxis (A) 1063

**Doxycycline,** chlamydia (DIAS) 600; esophageal ulceration (DIAS) 1185; intrapleural (DSP) 898; oral, gonorrhea (DIAS) 600

**Dronabinol,** HIV wasting syndrome (DIAS) 595

**Drug abuse,** educational method, "smart pill" (E) 390

**Drug information,** adverse reactions, reporting (RA) 1393; CD-ROM technology (RA) 1389; drug use evaluation (RA) 1392; responses, accuracy (RPR) 707

**Drug interactions,** acetaminophen–zidovudine (CR) 327
antidepressants–flumazenil (CR) 1347
aspirin–verapamil (L) 536
carbamazepine–metronidazole (L) 1303
ciprofloxacin–foscarnet (CR) 869
clonidine–verapamil (CR) 881
cyclosporine–probucol (DIR) 940
erythromycin–tacrolimus (L) 280
ethanol–histamine$_2$-receptor antagonists (DIAS) 55
felbamate–phenobarbital (CR) 455
felbamate–warfarin (L) 805, (L) 1412
fluconazole–phenytoin (CR) 191
fluconazole–warfarin (L) 1111
fluorouracil/levamisole–warfarin (CR) 464
fluoxetine, review (DSP) 1365
flumazenil–antidepressants (CR) 1347
fluvoxamine, review (DSP) 1365
foscarnet–ciprofloxacin (CR) 869
histamine$_2$-receptor antagonists–ethanol (DIAS) 55
levamisole/fluorouracil–warfarin (CR) 464
loxapine–sumatriptan (L) 1199
metronidazole–carbamazepine (L) 1303
niacin–nicotine (L) 1113
nicotine–niacin (L) 1113
nutritients–drugs, patient counseling (RPR) 576
paroxetine, review (DSP) 1365
phenelzine–sertraline (CR) 732
phenobarbital–felbamate (CR) 455
phenytoin–fluconazole (CR) 191
probucol–cyclosporine (DIR) 940
sertraline–phenelzine (CR) 732
sertraline, review (DSP) 1365
sumatriptan–loxapine (L) 1199
tacrolimus–erythromycin (L) 280
verapamil–aspirin (L) 536
verapamil–clonidine (CR) 881
warfarin–felbamate (L) 805, (L) 1412
warfarin–fluconazole (L) 1111
warfarin–fluorouracil/levamisole (CR) 464
warfarin–levamisole/fluorouracil (CR) 464
zidovudine–acetaminophen (CR) 327

**Drug Interactions and Reactions Update,** Benzocaine-Induced Methemoglobinemia: Report of a Severe Reaction and Review of the Literature, 643 Does Ciprofloxacin Interact with Cyclosporine?, 93 Fluorouracil Cardiotoxicity, 374 Interaction Between Probucol and Cyclosporine in Renal Transplant Patients, 940 Prevention of Anaphylactoid Reactions in High-Risk Patients Receiving Radiographic Contrast Media, 236

**Drug Selection Perspectives,** New Macrolide Antibiotics: Usefulness in Infections Caused by Mycobacteria Other Than *Mycobacterium tuberculosis*, 1255; Pleural Effusions: Pathophysiology and Management, 894; Selective Serotonin Reuptake Inhibitors: Pharmacologic Profiles and Potential Therapeutic Distinctions, 1359

**Drug use evaluation,** recent advances (RA) 1392

**Drug utilization,** antifungals, prior to fluconazole marketing (PEP) 252; community-based, ciprofloxacin (RPR) 714; state prison, cimetidine, ranitidine, sucralfate (PEC) 792

**Drugs, adverse reactions, *N*-acetylcysteine,** serum sickness (L) 285; **activated charcoal,** constipation, intestinal obstruction (CC) 917; **acyclovir,** neurotoxicity (L) 961, oral, kidney failure, neurotoxicity (CR) 460; **amiodarone,** vasculitis (L) 537; **ampicillin,** erythema multiforme, myocarditis (CR) 730; **benzocaine,** methemoglobinemia (DIR) 643; **busulfan,** review (A) 1059; **carbamazepine,** mononucleosis syndrome (L) 402, SIADH (L) 1199; **chemotherapy,** SIADH (L) 1199; **cimetidine,** hepatitis (CR) 37; **ciprofloxacin,** cartilage toxicity, children (DIAS) 336, cholestatic jaundice (CR) 1162; **cisapride,** review (FF) 495; **cyclophosphamide,** facial discomfort (CR) 197; **dantrolene,** pleural effusion (CR) 587; **dexamethasone,** Cushing's syndrome, self-medication (L) 1411, flushing (L) 1306; **diazepam,** gynecomastia (L) 671, rhabdomyolysis (L) 1200; **diuretics,** with pravastatin, diabetes mellitus (L) 964; **dobutamine hydrochloride,** cellulitis (L) 964; **doxycycline,** esophageal ulceration (DIAS) 1185; **enalapril,** gynecomastia (L) 671; **erythromycin,** with terfenadine, torsades de pointes (L) 282; **etodolac,** agranulocytosis (CR) 458; **famotidine,** hepatitis (CR) 37, mixed hepatocellular jaundice (CR) 40, neutropenia, thrombocytopenia (L) 406; **floxequinan,** ventricular arrhythmias (L) 403; **fluconazole,** hepatotoxicity (CR) 1177; **fluorouracil,** cardiotoxicity (DIR) 374; **fluoxetine,** review (DSP) 1364; **fluvoxamine,** review (DSP) 1364, sexual dysfunction (CR) 872; **fluoxetine,** hyperphagia, weight loss (CR) 1350; **foscarnet,** seizures, paresthesia (CR) 1035; **gabapentin,** review (FF) 1193; **gentamicin,** nephrotoxicity (CR) 199; **glucocorticoids,** inhaled, review (PA) 904; **granisetron,** flushing (L) 1306; **hemodialysis,** potential problems (RPR) 316, 320; **heparin,** thrombotic thrombocytopenia (CR) 43; **ifosfamide,** extravasation (CR) 1243; **inaccurate assessment** (CR) 726; **indomethacin,** colonic ulcers (CR) 883; **interferon beta,** review (FF) 613; **ketorolac,** oral, upper gastrointestinal bleeding (L) 1109; **ketorolac tromethamine,** weight gain (L) 284; **leptazol,** seizures (L) 285; **leuprolide acetate,** depot, leukopenia (L) 283; **lorazepam,** flushing (L) 1306, rhabdomyolysis (L) 1200; **maprotiline,** hypoglycemia, diabetes (L) 406; **meropenem,** review (FF) 1051; **metronidazole,** hypersensitivity (CR) 325, peripheral neuropathy (L) 536; **monitoring** (RA) 1393; **naproxen,** dyspnea, edema (L) 1110; **nicotine,** transdermal, stroke (L) 402; **nifedipine,** exfoliative dermatitis, pedal edema (L) 967; **norfloxacin,** cartilage toxicity, children (DIAS) 337; **ondansetron,** anaphylaxis (CR) 1029, extrapyramidal reaction (L) 280; **oxaprozin,** hepatitis (CR) 1159; **paroxetine,** review (DSP) 1364; **pentamidine,** intravenous, pancreatitis (CR) 1025, pancreatitis (CR) 52, torsades de pointes (L) 282; **pertussis vaccines,** review (PED) 935; **phenacemide,** increased creatinine (CR) 49; **phenytoin,** hypocalcemia (CR) 47; **pravastatin,** with diuretics, diabetes mellitus (L) 964; **procainamide,** thrombocytopenia (CR) 1172; **prophylaxis,** computer-based medical records (PI) 523; **pyridoxal phosphate,** anxiety disorder (L) 1411; **quinapril,** cough (CR) 720; **quinolones,** cartilage toxicity (DIAS) 336; **reporting,** *Clostridium difficile* (L) 1197, Hong Kong (IR) 1400; **rifabutin,** review (FF) 1252; **rifampin,** thrombocytopenia (L) 1304; **selective serotonin reuptake inhibitors** (DSP), review (DSP) 1364; **sertraline,** review (DSP) 1364; **sodium valproate,** neonatal fibrinogen depletion (L) 1307; **tacrine,** review (FF) 747; **tacrolimus,** review (NDD) 506; **tenoxicam,** hepatitis (L) 1309; **terfenadine,** with erythromycin, torsades de pointes (L) 282; **ticlopidine,** aplastic anemia (CR) 1169, neutropenia, delayed (CR) 1344, neutropenia, thrombocytopenia (CR) 1236; **tranexamic acid,** bullous eruption (L) 1305; **triamcinolone acetonide,** anaphylaxis (L) 1310; **triazolam,** safety concerns (DIAS) 1038; **trimethoprim/sulfamethoxazole,** cholestasis (L) 1310; **vaccines,** review (PED) 638; **vancomycin,** neutropenia (CR) 723, red-man syndrome (CR) 581

**Drugs, body distribution,** aminoglycosides, patient subgroups (TM) 944

**Drugs, over-the-counter,** switch from prescription (E) 392

**Dual individualization,** cefmenoxime (PEC) 384

**Dukes, George E. Jr.,** scholar in residence stipend (NC) 1430

## E-F

**Economics,** see **Pharmacoeconomics**

**Editorials,** see also, **An Opinion; Doering, Paul L., Hall, Kevin R.,** Using the "Smart Pill" to Teach About Substance Abuse, 390; **Gonzalez, Edgar R., Grillo, Joseph A.,** Over-the-Counter Histamine$_2$-Blocker Therapy, 392; **Nahata, Milap C.,** Need for Conducting Research on Medications Unlabeled for Use in Pediatric Patients, 1103, Pharmacist's Role in Improving Immunization Status Among Preschool Children, 952; **Rotschafer, John C., Rybak, Michael J.,** Single Daily Dosing of Aminoglycosides: A Commentary, 797; **Sorofman, Bernard A., Milavetz, Gary,** Meta-Analysis and the Scientific Research that Precedes It, 1290; **Pryka, Randy D.,** Vancomycin Serum Concentration Monitoring: A Continued Debate, 1397; **Stringer, Kathleen A., Lindenfeld Jo Ann,** The GUSTO Trial: Is the Open-Artery Hypothesis Proven?, 97; **Whitney, Harvey A.K. Jr.,** Death with Indignity Legalized, 1395

**Education,** continuing, B.S.Pharm. graduates (RPR) 21; drug abuse, "smart pill" method (E) 390; faculty, degrees earned (RC) 1404; patient, telephone follow-up, niacin, bile acid sequestrants (RPR) 29; pharmacy, clinical interventions by students (ET) 665, computer resources (L) 970, immunization requirements (RPR) 1153; physicians, pharmacists, psychologists, assessment of tardive dyskinesia (RPR) 185

**Education and Training,** Clinical Interventions Provided by Doctor of Pharmacy Students, 665

**Educational Events,** 128, 174, 424, 549, 685, 821, 974, 1124, 1213, 1326, 1427

**Electrolytes,** abnormalities, theophylline concentrations (RPR) 175; imbalance, activated charcoal-induced (CC) 918

**Elimination,** acyclovir, breast milk (CR) 585; cyclosporine, effect of diltiazem, nifedipine, verapamil (RPR) 1227; renal, theophylline, children (L) 281; vancomycin, long-term therapy (L) 116

**Ellsworth, Alan J.,** Fellow, American Society of Hospital Pharmacists (NC) 824

**Enalapril,** gynecomastia (L) 671

**Endocarditis,** prophylaxis, topical antibiotics, dentistry (DIAS) 57; *Staphylococcus epidermidis,* aminoglycosides/vancomycin (DIAS) 737

**Enoxaparin,** compared with unfractionated heparin, total hip replacement, cost (PEC) 271; postoperative thromboembolic complications (L) 810

**Epilepsy,** gabapentin, review (FF) 1188

**Epinephrine,** hypophosphatemia (CC) 628

**Equipment,** in-line filters, compared with heparin/hydrocortisone, phlebitis (RPR) 11; polyolefin containers, paclitaxel stability, compatibility (RPR) 35

**Erstad, Brian L.,** Fellow, American Society of Hospital Pharmacists (NC) 824; Outstanding Teacher, American Association of Colleges of Pharmacy (NC) 1126

**Erythromycin,** compared with other macrolide antibiotics (DSP) 1256; interaction, tacrolimus (L) 280; intestinal cryptosporidiosis (AIDS) 772; with terfenadine, torsades de pointes (L) 282

**Esmolol,** myocardial infarction, safety (RPR) 701

**Esophageal varices,** somatostatin (DIAS) 739

**Estrogen,** Turner syndrome, adult height, girls (RPR) 570; uremic bleeding (DIAS) 60

**Ethanol,** interaction, histamine$_2$-receptor antagonists (DIAS) 55; withdrawal, benzodiazepines (TC) 67

**Etodolac,** agranulocytosis (CR) 458

**Euthanasia,** legalized in Oregon (E) 1395

**Evening primrose oil,** rheumatoid arthritis, analysis (L) 973

**Extravasation,** ifosfamide (CR) 1243; vindesine (L) 967

**Famotidine,** gastric pH, bolus vs. continuous infusion (RPR) 841; hepatitis (CR) 37; mixed hepatocellular jaundice (CR) 40; neutropenia, thrombocytopenia (L) 406

**FDA News (NC),** FDA Proposes Financial Disclosure for Clinical Investigators, 1327

**Felbamate,** interaction, phenobarbital (CR) 455, warfarin (L) 805, (L) 1412

**Fellowships and Residencies, California,** University of Southern California, 1325; **Connecticut,** Hartford Hospital, 683, 1325, 1422; **Maryland,** FDA Center for Drug Evaluation and Research, 1123, 1213; **New York,** Veterans Affairs Medical Center, 683; **Ohio,** Ohio State University, 296; **Oregon,** Veterans Affairs Medical Center, 296, 549

**Fibrinogen,** neonatal depletion, sodium valproate (L) 1307

**Finger, Kenneth F.,** obituary (NC) 1126

**Finley, Rebecca S.,** President-elect, American Society of Hospital Pharmacists (NC) 1431

**Flecainide,** pharmacokinetics, pregnancy (CR) 1031

**Floxacin,** stage IV pressure ulcers (L) 117

**Fletcher, Courtney V.,** grant, National Institutes of Allergy and Infectious Diseases (NC) 1000

**Floxequinan,** ventricular arrhythmias (L) 403

**Fluconazole,** hepatotoxicity (CR) 1177; interaction, phenytoin (CR) 191, warfarin (L) 1111

**Flumazenil,** interaction, antidepressants, status epilepticus (CR) 1347
**Fluorescein,** circulation determinant (DIAS) 891
**Fluorouracil,** cardiotoxicity (DIR) 374; with levamisole, interaction, warfarin (CR) 464
**Fluoxetine,** adverse reactions (DSP) 1364; cost (DSP) 1366; hyperphagia, weight loss (CR) 1350; interactions, review (DSP) 1365; pharmacokinetics (DSP) 1360; review (DSP) 1359; trichotillomania (DIAS) 1245
**Fluvastatin,** cost (L) 1111
**Fluvoxamine,** adverse reactions (DSP) 1364; cost (DSP) 1366; interactions, review (DSP) 1365; pharmacokinetics (DSP) 1360; review (DSP) 1359; sexual dysfunction (CR) 872
**Formulary Forum,** Cisapride: A Gastrointestinal Prokinetic Drug, 488; Gabapentin: A New Agent for the Management of Epilepsy, 1188; Interferon Beta for Multiple Sclerosis, 610; Meropenem: A New Carbapenem Antimicrobial, 1045; Rifabutin: A Review with Emphasis on Its Role in the Prevention of Disseminated *Mycobacterium avium* Complex Infection, 1250; Tacrine: First Drug Approved for Alzheimer's Disease, 744
**Foscarnet,** interaction, ciprofloxacin (CR) 869; seizures, paresthesia (CR) 1035
**Fosinopril,** resolution of quinapril-induced cough (CR) 720

## G-I

**Gabapentin,** adverse reactions (FF) 1193; cost (FF) 1194; pharmacokinetics (FF) 1189; pharmacology (FF) 1189; review (FF) 1188
**Gal, Peter,** Board Certified Pharmacotherapy Specialist (NC) 1430
**Gastric retention,** magnesium chloride, enteric coated (CR) 874
**Gemfibrozil,** lipoprotein(a) concentrations (TC) 345
**General News (NC),** Astra Merck and Applied Microbiology Announce Exclusive Agreement to Develop Ulcer Cure Products, 687; General Accounting Office Reviews Entry-Level Pharm.D., 162; New Cancer Pain Guidelines Released, 551; Pharmacoeconomic Model Created to Track Costs of Anesthesia Delivery, 162
**Gentamicin,** nephrotoxicity (CR) 199; otitis media (PED) 1094
**Geriatrics,** hypertension, systolic (G) 367
**Geriatrics and Gerontology,** Treating Isolated Systolic Hypertension in the Elderly, 367
**Girls,** Turner syndrome, estrogens, androgens, adult height (RPR) 570
**Glibenclamide,** recurrent hypoglycemia (L) 119
**Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries,** evaluation (E) 97
**Glucocorticoids,** inhaled, systemic effects (PA) 904
**Glucose,** theophylline concentrations (RPR) 175
**GoLytely,** lavage, decreased cyclosporine absorption (L) 963
**Goldspiel, Barry R.,** Public Health Service Clinical Pharmacist of the Year (NC) 1216
**Gonorrhea,** oral therapy, cefixime, quinolones, doxycycline (DIAS) 600
**Granisetron,** with dexamethasone, lorazepam, flushing (L) 1306
**Granulocyte colony-stimulating factor,** LDH elevation (L) 118
**Grasela, Thaddeus,** chairman, Pharmacy Department, SUNY (NC) 824
**Graves, Nina,** Associate Dean, University of Minnesota College of Pharmacy (NC) 428
**Growth hormone,** nasal administration, four preparations compared (RPR) 845
**Guanethidine,** reflex sympathetic dystrophy (DIAS) 338
**Gynecomastia,** diazepam (L) 671; enalapril (L) 671
**$H_2$-receptor antagonists,** see **Histamine$_2$-receptor antagonists**
***Haemophilus influenzae* type B,** incidence (NC) 686
***Haemophilus influenzae* type B conjugate vaccines,** review (PED) 634
**Health Security Act,** pharmacy practice issues (O) 802
**Heart failure, congestive,** Koreans, theophylline pharmacokinetics (IR) 396
**Heim-Duthoy, Karen L.,** Fellow, American College of Clinical Pharmacy (NC) 1126
**Hemodialysis,** population, drug use (RPR) 316,320
**Hemorrhage,** variceal, nitroglycerin (DIAS) 206
**Heparin,** dosage, obesity (L) 1110; infusion rates (L) 1312; thrombotic thrombocytopenia (CR) 43; unfractionated, compared with enoxaparin, total hip replacement, cost (PEC) 271; with aspirin, stroke, safety (RPR) 441; with ceftazidime, vancomycin, stability, peritoneal dialysis (RPR) 572; with hydrocortisone, compared with filters, phlebitis (RPR) 11
**Hepatitis,** cimetidine (CR) 37; famotidine (CR) 37; oxaprozin (CR) 1159; tenoxicam (L) 1309
**Hepatitis B vaccines,** review (PED) 637
**Hepatitis C,** from intravenous immunoglobulin (NC) 1215; interferon alfa-2A (DIAS) 341
**Hepatorenal syndrome,** prostaglandins (DIAS) 54
**Hepatotoxicity,** fluconazole (CR) 1177
**Herpes simplex,** prophylaxis, acyclovir, bone marrow transplant/leukemia (RPR) 852
**Higuchi, William I.,** editor, *Journal of Pharmaceutical Sciences* (NC) 162
**Hip replacement, total,** enoxaparin compared with unfractionated heparin, cost (PEC) 271
**Histamine$_2$-receptor antagonists,** allergic disorders (DIAS) 742; compared with antacids, sucralfate, pirenzepine, meta-analysis (A) 1075; interaction, ethanol (DIAS) 55; prescription to over-the-counter switch (E) 392; with sucralfate, gastrointestinal disorders (DIAS) 597
**HIV,** see **Human immunodeficiency virus**
**HIV and AIDS,** Update on the Management of Intestinal Cryptosporidiosis in AIDS, 767
**Holdsworth, Mark T.,** Board Certified Pharmacotherapy Specialist (NC) 1430
**Hong Kong,** adverse reaction reporting, pharmacists' attitudes (IR) 1400
**Hormones,** infantile spasms (PED) 786
**Human immunodeficiency virus,** mortality, 1991–1992 (NC) 160; therapy, Medicaid policies (PEC) 528; wasting syndrome, didanosine (DIAS) 596, dronabinol (DIAS) 595, megestrol acetate (DIAS) 596, parenteral nutrition (DIAS) 596, zidovudine (DIAS) 596; zidovudine prophylaxis, mother-to-infant transmission (NC) 998
**Hydralazine,** compared with nifedipine, pregnancy (A) 1375
**Hydrazine,** production in children (RPR) 1340
**Hydrocortisone,** cream, clonidine patch dermatitis (DIAS) 889; with heparin, compared with filters, phlebitis (RPR) 11
**Hydrogen ion concentration,** gastric, bolus vs. continuous famotidine (RPR) 841
**Hyperglycemia,** theophylline (RPR) 177
**Hypersensitivity,** metronidazole (CR) 325
**Hypertension,** beta-blocker therapy (A) 617; beta-blocker withdrawal (RPR) 849; crisis, captopril (TC) 352, clonidine (TC) 353, labetalol (TC) 354, nifedipine (TC) 354; diuretic therapy (A) 617; endstage renal disease, review (A) 359; nifedipine, pregnancy (A) 1371; systolic, elderly (G) 367; treatment guidelines (A) 621; women (A) 620
**Hypocalcemia,** phenytoin (CR) 47
**Hypoglycemia,** maprotiline, diabetes (L) 406; recurrent, glibenclamide (L) 119
**Hypokalemia,** theophylline (RPR) 177
**Hypomagnesemia,** review (A) 220; theophylline (RPR) 177
**Hyponatremia,** theophylline (RPR) 177
**Hypophosphatemia,** drug-nutrition-induced, critically ill (CC) 626; theophylline (RPR) 177
**Ibuprofen,** oral, compared with intramuscular ketorolac, acute pain (RPR) 309
**Iceland,** pharmacy practice (IR) 112
**Ifosfamide,** extravasation (CR) 1243
**Imipenem,** with cilastatin, compared with meropenem (FF) 1050
**Immunization,** childhood, review (PED) 633; preschool children, pharmacist's role (E) 952; requirements, pharmacy students (RPR) 1153; two-year-old children (NC) 823
**Immunocompetence,** varicella, oral acyclovir (DIAS) 208
**Immunoglobulin,** intravenous, hepatitis C (NC) 1215, with dextrose, total parenteral nutrition, stability (RPR) 1014
**Inappropriate ADH syndrome,** induced by different drugs (L) 1199
**Indomethacin,** colonic ulcers (CR) 883
**Infantile spasms,** review (PED) 779
**Infection,** postoperative bleeding (L) 1308
**Interferon alfa-2A,** hepatitis C (DIAS) 341
**Interferon beta,** adverse reactions (FF) 613; cost (FF) 614; multiple sclerosis, review (FF) 610; pharmacokinetics (FF) 612; pharmacology (FF) 611
**International Normalized Ratio,** warfarin monitoring (TM) 242
**International Reports,** Pharmacists as Members of the Healthcare Team in Israel: Sectoral Differences, 276; Pharmacists' Attitudes Toward Adverse Drug Reaction Reporting in Hong Kong, 1400; Pharmacy in Iceland, 112; Theophylline Disposition in Korean Patients with Congestive Heart Failure, 396
**Intralipid,** prophylaxis, amphotericin B nephrotoxicity (DIAS) 1182
**Iron,** toxicity, total iron binding capacity (TC) 63
**Isoniazid,** children, hydrazine production (RPR) 1340; psychosis (L) 1311
**Israel,** pharmacists, members of healthcare team (IR) 276
**Ivermectin,** cutaneous larva migrans (L) 672

## J-L

**Jaundice,** cholestatic, ciprofloxacin (CR) 1162; mixed hepatocellular, famotidine (CR) 40
**Jejunostomy, end,** digoxin malabsorption (CR) 1239
**Ketorolac,** gastrointestinal ulceration (L) 539; intramuscular, compared with oral ibuprofen, acute pain (RPR) 309; oral, upper gastrointestinal bleeding (L) 1109; parenteral, children (RPR) 1009; tromethamine, weight gain (L) 284
**Kidney failure,** acyclovir, oral (CR) 460; clobazam, *N*-desmethylclobazam concentrations (L) 966; endstage, relationship to hypertension, review (A) 359; with bacterial pneumonia, risk factors (PEP) 515
**Korea,** congestive heart failure, theophylline pharmacokinetics (IR) 396
**Labetalol,** hypertensive crisis (TC) 354
**Lactation,** acyclovir elimination (CR) 585
**Lamy, Peter P.,** obituary (NC) 688
**Leishmaniasis,** visceral, AIDS, amphotericin B (L) 1305
**Leptazol,** seizures (L) 285
**Letters,** AIDS Epidemic: Can the African Countries Be Optimistic?, 285; Acute Hepatitis Caused by Tenoxicam, 1309; Acute Rheumatic Fever Despite Clarithromycin Treatment of Beta-Hemolytic Streptococcal Tonsillitis, 1197; Addictive Potential of Trimebutine, 537; Adverse Effects Associated with Dexamethasone, Lorazepam, and Granisetron, 1306; Age-Dependent Changes of Renal Excretion of Theophylline in Asthmatic Children, 281; Alternatives to Intravenous Tetracycline Hydrochloride for Malignant Pleural Effusions, 968; Amphotericin B for Visceral Leishmaniasis Resistant to Pentavalent Antimonial Drugs in AIDS, 1305; Anaphylactic Shock Caused by Triamcinolone Acetonide, 1310; Anxiety Disorder and Pyridoxal Phosphate—A Possible Association, 1411; Bullous Eruption Induced by Tranexamic Acid, 1305; Can Drug Administration Errors Be Minimized?, 969; Cholestasis: Hepatocellular Reaction to Trimethoprim/Sulfamethoxazole, 1310; Clarification: Controversies in the Management of *Mycobacterium avium* Complex Infection in AIDS, 808; Clobazam and *N*-Desmethylclobazam Serum Concentrations in Endstage Renal Failure and Hemodialysis, 966;
**Comments/Author Replies,** A Practical Alternative to Conventional Aminoglycoside Dosing, 809, Alcohol Withdrawal: What is the Benzodiazepine of Choice?, 971, Aminoglycoside Nephrotoxicity Following Single-Dose Cystoscopy Prophylaxis, 1202, Clinical Rules for Phenytoin Dosing, 808, Cost in Treating Malignant Pleural Effusions with Bleomycin, 407, Enoxaparin—The Low-Molecular-Weight Heparin for Prevention of Postoperative Thromboembolic Complications, 810, Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist, 539, Evening Primrose Oil in the Treatment of Rheumatoid Arthritis—Proper Application of Statistical Analysis, 973, Heparin Infusion Rates, 1312, Isoniazid-Induced Psychosis, 1311, Ketorolac and Gastrointestinal Ulceration, 539, *N,N*-Dimethylglycine and L-Carnitine as Performance Enhancers in Athletes, 973, NSAID Use and Efficacy in the Emergency Department, 1201, Niacin, Nicotine, and Flushing, 1113, Ondansetron for Treating Nausea and Vomiting in the Poisoned Patient, 1203, Risk Reduction from Clinical Trials Adjusted on an Annual Basis, 1112, Single Daily Dosing of Aminoglycosides, 1412, Single Daily Dosage of Lithium Carbonate, 1311, Vancomycin Serum Concentration Monitoring, 972; Communication Strategies for the Pharmacist—Personal Axioms, 538; Warfarin–Felbamate Interaction, 1412
Computer Resources for Student Use at US Colleges of Pharmacy, 970;
**Corrections,** Author's Name, 974, Clinical Intervention by Doctor of Pharmacy Students, 973, Dexrazoxane, 1413, ImmunoFacts Review, 811, Measured Versus Estimated Creatinine Clearance in Patients with Low Serum Creatinine Values, 811;
Costs Associated with Recurrent Hypoglycemia Caused by Dispensing Error, 965; Current Treatment Recommendations for Cutaneous Larva Migrans, 672; Cushing's Syndrome Caused by Analgesic/Dexamethasone Preparation, 1411; Decreased Cyclosporine Absorption After Treatment with GoLytely Lavage Solution in a Kidney Transplant Patient, 963; Delayed Treatment of Vindesine Extravasation, 967; Dermal Cellulitis—A Hypersensitivity Reaction from Dobutamine Hydrochloride, 964; Dermatologic Cross-Sensitivity Between Diltiazem and Amlodipine, 118; Drug-Induced Torsades de Pointes: A Possible Interaction of Terfenadine and Erythromycin, 282; Dyspnea and Periorbital Edema Following an Increase in Naproxen Dose, 1110; Dystonic Reaction Associated with Sumatriptan, 1199; Effect of Octreotide on Plasma Lipid Metabolism in Acromegaly, 1198; Extrapyramidal Reaction Caused by Ondansetron, 280; Floroxacin Treatment of Stage IV Pressure Ulcers with Associated Osteomyelitis, 117; Fluconazole–Warfarin Interaction, 1111; Fluvastatin Cost Considerations, 1111; Gynecomastia Associated with Enalapril and Diazepam, 671; Hazards of Rapid Administration of Ceftriaxone, 807; Heparin Dosing in the Morbidly Obese Patient, 1110; Hypoglycemia Caused by Maprotiline in a Patient Taking Oral Antidiabetics, 406; Hyponatremia and Benzodiazepines Result in Rhabdomyolysis, 1200; Increased Cyclosporine Bioavailability from a Microemulsion Formulation in a Liver Transplant Recipient, 962; Interaction Between FK506 and Erythromycin, 280; Intravenous Ciprofloxacin Dosing in a Morbidly Obese Patient, 806; Is It Safe to Combine a Selective Serotonin Reuptake Inhibitor with Selegiline?, 405; Lack of Nephrotoxicity with the Administration of Amphotericin B in a Lipid Emulsion, 1307; Leptazol-Induced Seizures, 285; Leukopenia Induced by Leuprolide Acetate Depot, 283; Lysol: A Substance for Potential Abuse, 970; Multisystem Hypersensitivity Reaction to Carbamazepine, 402; Neonatal Fibrinogen Depletion Caused by Sodium Valproate, 1307; New (Renamed) Critical Care Journal, 807; New Versus Old Placebos, 1201; Nifedipine-Induced Exfoliative Dermatitis and Pedal Edema, 967; Oral Acyclovir and Neurologic Adverse Effects in End-

stage Renal Disease, 961; Palliative High-Dose Octreotide in a Case of Severe AIDS-Related Diarrhea, 806; Peripheral Neuropathy Induced by Metronidazole, 536; Pharmaceutical Care and Women's Health Issues—The Challenge for the 1990s, 969; Pharmaceutical Care at Tayside, Scotland, 120; Possible Interaction Between Metronidazole and Carbamazepine, 1303; Possible Pravastatin and Diuretics-Induced Diabetes Mellitus, 964; Prior Calcium-Channel Antagonist Use and Ischemic Stroke Outcomes, 671; Quality Improvement for Routine Screening and Diagnosis of Diarrheal Illness Identified from Adverse Drug Reaction Reporting, 1197; Recurrent Glibenclamide-Induced Hypoglycemia: the Importance of Obtaining a Comprehensive Medication History, 119; Reversal of Ranitidine-Induced Hypergastrinemia by Cimetidine, 1303; Reversible Neutropenia and Thrombocytopenia During Famotidine Treatment, 406; Rifampin-Induced Severe Thrombocytopenia in a Patient with Pulmonary Tuberculosis, 1304; Sertraline Overdose, 1307; Serum Sickness-Like Illness Associated with *N*-Acetylcysteine Therapy, 285; Severe Bleeding in Postoperative Patients with Infections, 1308; Significance of Granulocyte Colony-Stimulating Factor-Induced Increases in LDH, 118; Sterilization of Talc USP for Intrapleural Use, 1309; Stroke Following Application of a Nicotine Patch, 402; Syndrome of Inappropriate Antidiuretic Hormone Secretion Induced by Different Drugs, 1199; Systemic Absorption of Topical Phenytoin Sodium, 961; Ticarcillin/Clavulanate Desensitization Protocol, 1200; Trimethoprim/Sulfamethoxazole Kinetics in Children with Biliary Atresia, 405; Twelve-Gram Overdose of Ciprofloxacin with Mild Symptomatology, 805; Upper Gastrointestinal Bleeding Associated with Oral Ketorolac Therapy, 1109; Vancomycin Clearance: an Effect of Prolonged Therapy, 116; Vasculitis Associated with Amiodarone Treatment, 537; Ventricular Arrhythmias Associated with Flosequinan, 403; Verapamil–Aspirin Interaction, 536; Warfarin–Felbamate Interaction: First Report, 805; Weight Gain Associated with Long-Term Oral Ketorolac Tromethamine, 284

**Leukemia,** paclitaxel (S) S20; prophylaxis, herpes simplex, acyclovir (RPR) 852

**Leuprolide acetate,** depot, leukopenia (L) 283

**Levamisole,** with fluorouracil, interaction, warfarin (CR) 464

**Lidocaine,** status epilepticus (DIAS) 1248

**Lipids,** metabolism, octreotide in acromegaly (L) 1198

**Lipoprotein(a),** atherosclerosis, review (TC) 343

**Lisinopril,** toxicity, angiotensin II (CR) 1165

**Literature,** promotional, accuracy (RPR) 1231

**Lithium,** dosage, empiric vs. predictive (RPR) 1148; polyuria, amiloride therapy (DIAS) 888

**Lithium carbonate,** once-daily dosage (L) 1311; single daily dosage (DIAS) 472

**Lorazepam,** compared with chlordiazepoxide, ethanol withdrawal (TC) 69; compared with diazepam, ethanol withdrawal (TC) 69; rhabdomyolysis (L) 1200; with dexamethasone, granisetron, flushing (L) 1306

**Lovastatin,** lipoprotein(a) concentrations (TC) 345

**Loxapine,** interaction, sumatriptan (L) 1199

**Lymphomas,** paclitaxel (S) S20

**Lysol,** substance abuse (L) 970

## M-N

**Magnesium,** deficiency (A) 220; intravenous, myocardial infarction (TC) 212

**Magnesium chloride,** gastric retention (CR) 874

**Malaria,** deferoxamine (DIAS) 602

**Maprotiline,** hypoglycemia, diabetes (L) 406

**Marshall, E.K. Jr.,** pharmacokinetics (SC) 1300

**Martineau, Pierre,** Board Certified Pharmacotherapy Specialist (NC) 1430

**Measles,** incidence (NC) 160, (NC) 1327

**Measles vaccine,** review (PED) 638

**Medicaid,** policies, HIV-related therapy (PEC) 528

**Megestrol acetate,** HIV wasting syndrome (DIAS) 596

**Melanoma, malignant,** paclitaxel (S) S20

**Meningitis,** tuberculous, isoniazid, hydrazine production in children (RPR) 1340

**Meropenem,** adverse reactions (FF) 1051; compared with ceftazidime (FF) 1050; compared with imipenem/cilastatin (FF) 1050; pharmacokinetics (FF) 1048; pharmacology (FF) 1045; review (FF) 1045

**Mestranol,** hypophosphatemia (CC) 628

**Metaproterenol,** acute exacerbation, chronic obstructive pulmonary disease (CC) 1380

**Methemoglobinemia,** benzocaine (DIR) 643

**Methylprednisolone,** hypophosphatemia (CC) 628

**Methylprednisolone acetate,** with benzyl alcohol, epidural administration (DIAS) 59

**Metronidazole,** hypersensitivity (CR) 325; interaction, carbamazepine (L) 1303; peripheral neuropathy (L) 536

**Mezlocillin,** otitis media (PED) 1095

**Migraine,** costs, managed healthcare (PEC) 659

**Milavetz, Gary,** Chairman-elect, Clinical/Pharmacotherapeutic Practice Section, American Pharmaceutical Association Academy of Pharmacy Practice and Management (NC) 162

**Minocycline,** intrapleural (DSP) 900

**Minoxidil,** female alopecia (DIAS) 890

**Mirtallo, Jay M.,** Board Certified Nutrition Support Pharmacist (NC) 824

**Morphine sulfate,** oral, compatibility, enteral feeding (RPR) 451

**Multiple sclerosis,** interferon beta, review (FF) 610

**Mutnik, Alan H.,** Fellow, American Society of Hospital Pharmacists (NC) 824

**Mycobacteria,** macrolide antibiotics, review (DSP) 1255

***Mycobacterium avium* complex,** AIDS, therapeutic drug concentrations (L) 808

***Mycobacterium tuberculosis,*** mycobacteriology (A) 74

**Myocardial infarction,** GUSTO trial, evaluation (E) 97; antistreptokinase antibodies persistance, streptokinase (DIAS) 204; esmolol therapy, safety (RPR) 701; magnesium, intravenous (TC) 212; thrombolytic drugs (A) 752

**Nahata, Milap C.,** Director, Pediatric Pharmacology Care Laboratory, NIH (NC) 1430; Outstanding Teacher, American Association of Colleges of Pharmacy (NC) 1126

**Naltrexone,** alcoholism (DIAS) 210

**Naproxen,** dyspnea, edema (L) 1110

**Narcotics,** toxicity, diagnosis (RPR) 446

**Nausea,** postoperative, relationship to nystagmus (RPR) 179

**Neomycin,** lipoprotein(a) concentrations (TC) 345

**Nephrotoxicity,** gentamicin (CR) 199

**Neuropathy,** peripheral, metronidazole (L) 536

**Neurotoxicity,** acyclovir (L) 961; acyclovir, oral (CR) 460

**Neutropenia,** famotidine (L) 406; ticlopidine (CR) 1236, delayed (CR) 1344; vancomycin, child (CR) 723

**New Drug Developments,** Tacrolimus, a New Immunosuppressant—A Review of the Literature, 501

**News and Comments,** see also, **Association News, FDA News, General News, Obituaries, Organization News, Research and Education News, USPHS-CDC News, VIP News;** 160, 297, 426, 551, 686, 822, 998, 1125, 1215, 1327, 1428

**Niacin,** compliance, telephone follow-up (RPR) 29; interaction, nicotine (L) 1113; lipoprotein(a) concentrations (TC) 345

**Niceritrol,** lipoprotein(a) concentrations (TC) 345

**Nicotine,** interaction, niacin (L) 1113; patch, stroke (L) 402

**Nifedipine,** compared with hydralazine, pregnancy (A) 1375; effect on cyclosporine clearance (RPR) 1227; exfoliative dermatitis, pedal edema (L) 967; hypertensive crisis (TC) 354; pharmacokinetics, (A) 1372; pregnancy (A) 1371

**Nimodipine,** intravenous, safety, tolerance (RPR) 1143

**Nitroglycerin,** variceal hemorrhage (DIAS) 206

**Norfloxacin,** cartilage toxicity, children (DIAS) 337

**North Carolina,** survey, cancer pain control (RPR) 857

**Nutrition,** albumin, routine administration (TC) 478; enteral, compatibility, oral morphine sulfate (RPR) 451; interaction, drugs, patient counseling (RPR) 576; parenteral, HIV wasting syndrome (DIAS) 596, with intravenous immunoglobulin, stability (RPR) 1014; support teams, benefits (CN) 227

**Nystagmus,** postoperative, relationship to nausea (RPR) 179

## O-P

**Obesity,** ciprofloxacin, intravenous dosing (L) 806; heparin, dosage (L) 1110

**Obituaries (NC),** Brodie, Donald C., 552; Finger, Kenneth F., 1126; Lamy, Peter P., 688

**Octreotide,** acromegaly, lipid metabolism (L) 1198; diarrhea, AIDS (L) 806; intestinal cryptosporidiosis, AIDS (AIDS) 769

**Ocular toxicity,** tamoxifen (DIAS) 740

**Omnibus Budget Reconciliation Act of 1990,** pharmacist attitudes toward voluntarism (RPR) 1020

**Ondansetron,** anaphylaxis (CR) 1029; extrapyramidal reaction (L) 280; in poisoning (L) 1203; pediatrics, postmarketing surveillance (PED) 85; poison-associated vomiting (CR) 331; stability, polypropylene syringes (RPR) 712

**Opinion,** see **An Opinion; Editorials**

**Organization News (NC),** ASHP Name Change, 1328; Board of Directors Initiates Name Change, 427; Board of Pharmaceutical Specialties, 1126; New National Organization Established for Women's Health, 427; SIDP New Orleans Annual Meeting, 427

**Oregon,** legalized suicide (E) 1395

**Otitis externa,** amphotericin B 0.25% (CR) 333

**Otitis media,** chronic suppurative, azlocillin (PED) 1094, ceftazidime (PED) 1094, ciprofloxacin (PED) 1094, clindamycin (PED) 1094, gentamicin (PED) 1094, mezlocillin (PED) 1095; chronic suppurative, review (PED) 1089

**Oxaprozin,** hepatitis (CR) 1159

**Oxygen,** delivery, critical care, monitoring (O) 1297; transport, monitoring in critical care (CC) 1273

**Paclitaxel,** Phase I trials (S) S8; administration (S) S23; clinical trials (S) S18; compatibility (S) S23, polyolefin containers (RPR) 35; intraperitoneal administration (S) S17, (S) S20; pharmacokinetics (S) S15; preparation (S) S23; stability (S) S23, polyolefin containers (RPR) 35; toxicity (S) S27

**Pain,** acute, oral ibuprofen compared with intramuscular ketorolac (RPR) 309; cancer, control, survey (RPR) 857, treatment guidelines released (NC) 551; reflex sympathetic dystrophy, guanethidine (DIAS) 338

**Pancreatitis,** pentamidine (CR) 52, intravenous (CR) 1025

**Paromomycin,** intestinal cryptosporidiosis (AIDS) 773

**Paroxetine,** adverse reactions (DSP) 1364; cost (DSP) 1366; interactions, review (DSP) 1365; pharmacokinetics (DSP) 1360; review (DSP) 1359

**Patient-controlled analgesia,** overdoses, computerized identification (PI) 655

**Pediatrics,** ampicillin, erythema multiforme, myocarditis (CR) 730; biliary atresia, trimethoprim/sulfamethoxazole pharmacokinetics (L) 405; cisapride (FF) 495; cromolyn, children less than 2 years (DIAS) 886; group B streptococcal infection, prophylaxis (DIAS) 474; hydrazine production, tuberculous meningitis (RPR) 1340; ketorolac, parenteral (RPR) 1009; ondansetron, postmarketing surveillance (PED) 85; otitis media, chronic suppurative, review (PED) 1089; quinolones, cartilage toxicity (DIAS) 336; red-man syndrome, vancomycin (CR) 581; research, conducting studies (SC) 1105; research needed (E) 1103; respiratory distress syndrome, prophylaxis, dexamethasone (DIAS) 475; sodium valproate, neonatal fibrinogen depletion (L) 1307; theophylline, age-dependent renal excretion (L) 281; vancomycin, neutropenia (CR) 723

**Pediatrics (PED),** Chronic Suppurative Otitis Media, 1089; Multicenter Postmarketing Surveillance of Ondansetron Therapy in Pediatric Patients, 85; Treatment of Infantile Spasms, 779; Update on Childhood Immunizations, 623; Whole-Cell and Acellular Pertussis Vaccines, 925

**Pemphigus vulgaris,** cyclosporine (DIAS) 1183

**Pentamidine,** intravenous, pancreatitis (CR) 1025; pancreatitis (CR) 52; torsades de pointes (L) 282

**Personnel Placement,** see separate section: **ADVERTISERS**

**Pertussis vaccines,** acellular, review (PED) 633; acellular, whole-cell, review (PED) 925; adverse reactions (PED) 935

**pH,** see **Hydrogen ion concentration**

**Pharmacists,** bachelor of science, practice patterns, continuing education (RPR) 21; healthcare team members, Israel (IR) 276; immunization role, preschool children (E) 952; training, assessment of tardive dyskinesia (RPR) 185

**Pharmacodynamics,** cefmenoxime, dual individualization (PEC) 384; nifedipine, pregnancy (A) 1373

**Pharmacoeconomics,** cefmenoxime, dual individualization (PEC) 384; cost, benzodiazepines (TC) 68, bleomycin, malignant pleural effusions (L) 407, enoxaparin compared with unfractionated heparin, total hip replacement (PEC) 271, fluvastatin (L) 1111, gabapentin (FF) 1194, rifabutin (FF) 1252; cost justification, pharmacotherapy (O) 954; costs, interferon beta (FF) 614, medication dispensing errors (L) 965, migraine headache (PEC) 659; human immunodeficiency virus, therapy, Medicaid policies (PEC) 528; quality improvement, antibiotics, cancer patients (PEC) 105; study evaluation, checklist (L) 539

**Pharmacoeconomics (PEC),** Antiulcer Prescribing Program in a State Correctional System, 792; Assessment of Cost-Effective Antibiotic Therapy in the Management of Infections in Cancer Patients, 105; Healthcare Resource Use and Costs Associated with Migraine in a Managed Healthcare Setting, 659; Medicaid Policies for HIV-Related Drug Therapies: Perspectives of the State Affiliates of the American Pharmaceutical Association, 528; Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia, 384; Prevention of Deep-Vein Thrombosis Following Total Hip Replacement Surgery with Enoxaparin Versus Unfractionated Heparin: A Pharmacoeconomic Evaluation, 271

**Pharmacoepidemiology,** antihypertensives, prescription, medical record comparison (PEP) 99; drug utilization, antifungals, pre-, post-fluconazole marketing (PEP) 252,261; hemodialysis population, drug use (RPR) 316,320; risk factors, kidney failure with bacterial pneumonia (PEP) 515

**Pharmacoepidemiology (PEP),** Comparison of Prescription and Medical Records in Reflecting Patient Antihypertensive Drug Therapy, 99; Risk Factors for Acute Renal Insufficiency in Patients with Suspected or Documented Bacterial Pneumonia, 515; Use of Antifungal Therapy in Hospitalized Patients: I. Results Prior to the Marketing of Fluconazole, 252; Use of Antifungal Therapy in Hospitalized Patients: II. Results After the Marketing of Fluconazole, 261

**Pharmacoinformatics,** Identification of Patient-Controlled Analgesia Overdoses in Hospitalized Patients: A Computerized Method of Monitoring Adverse Events, 655; Preventing Adverse Drug Events in Hospitalized Patients, 523

**Pharmacokinetics,** aminoglycosides, patient subgroups (TM) 944; aztreonam, degradation, HPLC analysis (RPR) 444; benzodiazepines (TC) 68; busulfan (A) 1056; cefmenoxime, dual individualization (PEC) 384; cefoperazone, with sulbactam (RPR) 703; cisapride (FF) 490; flecainide, pregnancy (CR) 1031; fluoxetine (DSP) 1360; fluvoxamine (DSP) 1360, gabapentin (FF) 1189; interferon beta (FF) 612; meropenem (FF) 1048; nifedipine, pregnancy (A) 1372; paclitaxel (S) S15; paroxetine (DSP) 1360; rifabutin (FF) 1251; selective serotonin reuptake inhibitors (DSP) 1360; sertraline (DSP) 1360; sulbactam, with cefoperazone (RPR) 703; tacrine (FF) 745; tacrolimus (NDD) 502; theophylline, Koreans with congestive heart failure (IR) 396; trimethoprim/sulfamethoxazole, children, biliary atresia (L) 405

**Pharmacology,** cisapride (FF) 489; gabapentin (FF) 1189; meropenem (FF) 1045; rifabutin (FF) 1250; tacrine (FF) 744; tacrolimus (NDD) 502

**Pharmacotherapy,** cost justification (O) 954; doctor of pharmacy students, clinical interventions (ET) 665; documentation, standards (O) 1292; ethical standards (O) 955; Health Security Act issues (O) 802; Specialty Certification Examination (NC) 822; women's health care (L) 969
**Pharmacy,** community, drug utilization, ciprofloxacin (RPR) 714; education, practice, Iceland (IR) 112; hospital, Scotland (L) 120
**Phenacemide,** increased creatinine (CR) 49
**Phenelzine,** interaction, sertraline (CR) 732
**Phenobarbital,** interaction, felbamate (CR) 455
**Phenytoin,** dosing, free concentrations (L) 808; hypocalcemia (CR) 47; interaction, fluconazole (CR) 191; sodium, topical, systemic absorption (L) 961; toxicity, multiple-dose activated charcoal (CR) 201
**Physicians,** training, assessment of tardive dyskinesia (RPR) 185
**Pirenzepine,** compared with histamine$_2$-antagonists, meta-analysis (A) 1075
**Placebos,** patient knowledge (L) 1201
**Plague,** human, India, incidence (NC) 1327
**Pleural effusions,** chemical pleurodesis (DSP) 896; clinical manifestations (DSP) 895; dantrolene (CR) 587; malignant, bleomycin, cost (L) 407; review (DSP) 894; treatment alternatives (L) 968
**Pleurodesis,** chemical (DSP) 896
**Pneumonia,** bacterial, with kidney failure, risk factors (PEP) 515
**Poliomyelitis,** eradication goal (NC) 1428
**Poliovirus vaccines,** review (PED) 637
**Ponte, Charles D.,** BPS Council on Nutrition Support Pharmacy Practice (NC) 824
**Postmarketing surveillance,** ondansetron, pediatrics (PED) 85
**Pravastatin,** lipoprotein(a) concentrations (TC) 345; with diuretics, diabetes mellitus (L) 964
**Prednisone,** pregnancy, fetal risks (DIAS) 1355
**Pregnancy,** adenosine, supraventricular tachycardia (CR) 1241; flecainide, pharmacokinetics (CR) 1031; hypertension, nifedipine (A) 1371; management of immunosuppressive agents, organ transplant (DIAS) 1355; pruritus treatment (RPR) 17; urinary tract infection, treatment recommendaiions (O) 248
**Probucol,** interaction, cyclosporine (DIR) 940
**Procainamide,** thrombocytopenia (CR) 1172
**Prophylaxis,** amphotericin B nephrotoxicity, intralipid (DIAS) 1182; anaphylaxis, contrast media (DIR) 236; aprotinin, surgical blood loss (DIAS) 1246; cancer, beta carotene (DIAS) 470; dexrazoxane, doxorubicin cardiotoxicity (A) 1063; endocarditis, topical antibiotics, dentistry (DIAS) 57; gentamicin, nephrotoxicity (CR) 199; graft-vs.-host disease, cyclosporine monitoring (TM) 379; herpes simplex, bone marrow transplant/leukemia, acyclovir (RPR) 852; neonatal group B streptococcal infection (DIAS) 474; respiratory distress syndrome, dexamethasone (DIAS) 475; stress gastritis, meta-analysis (A) 1073
**Prostaglandin,** compared with antacids, meta-analysis (A) 1075; hemorrhagic cystitis, cyclophosphamide-induced (CR) 590; hepatorenal syndrome (DIAS) 54
**Pruritus,** treatment, pregnancy (RPR) 17
**Pseudomembranous colitis,** vancomycin, rectal (DIAS) 1357
**Psychologists,** training, assessment of tardive dyskinesia (RPR) 185
**Psychosis,** isoniazid (L) 1311
**Pulmonary and Allergy,** Meta-Analysis of Controlled Trials of Drug Therapy in Mild Chronic Asthma: The Role of Inhaled Corticosteroids, 1285; Salmeterol: Its Place in Asthma Management, 1100; Therapeutic Controversies in the Treatment of Asthma, 904
**Pyridoxine,** carpal tunnel syndrome (DIAS) 1042
**Pyridoxal phosphate,** anxiety disorder (L) 1411

## Q-R

**Quinapril,** cough, resolution with fosinopril (CR) 720
**Quinolones,** cartilage toxicity, children (DIAS) 336; oral, gonorrhea (DIAS) 600; tuberculosis (A) 76**Ranitidine,** compared with cisapride (FF) 492; drug utilization, state prison (PEC) 792; hypergastrinemia, cimetidine reversal (L) 1303; inaccurate cause of thrombocytopenia (CR) 726
**Recent Advances,** Monoclonal Antibodies in the Treatment of Rheumatoid Arthritis, 650; Pharmacotherapeutic Consequences of Recent Advances in Hemodialysis Therapy, 512; Recent Advances in Critical Care, 245; Selected Topics in Drug Information Access and Practice: An Update, 1389
**Records,** prescription compared with medical, antihypertensives (PEP) 99
**Red-man syndrome,** vancomycin, oral, child (CR) 581
**Research,** meta-analysis (E) 1290; schools of pharmacy (RC) 1405; student attitudes (RC) 1408
**Research Opportunities (NC),** Contemporary Issues in Human Subject Protection, 428; Diabetes Interdisciplinary Research Programs, 428; Phase I Clinical Trials of Anticancer Agents, 427; Predoctoral Fellowship Awards for Minority Students, 428; Recent Trends in Human Subjects Research, 428
**Research and Education News (NC),** ACPE-Accredited Pharmacy Programs, 1430; 1993 Open Hearings Compiled and Schedule Set for 1994, 551; Clinical Pharmacy Research Award, 298; Core Grants for Clinical Nutrition Research Units, 1125; Drug Discovery for Opportunistic Infections Associated with AIDS, 1429; Ethical Issues in Human Subject Research: Catastrophic Diseases and Minorities, 161; Funding Strategies for Fiscal Year 1994, 552; Grant Program in Childhood Acute Lymphoblastic Leukemia, 161; PHS Grants and Contracts Orientation Course, 551; Prescription Drug Use, Abuse, and Diversion, 1000; Recent Trends in Human Subjects Research, 161; Research Grant Supplements for Individuals with Disabilities, 551; Research on Effectiveness of Children's Mental Health Services, 1429; Research Supplements for Underrepresented Minorities, 161; Research Transition Grant Program in Clinical Mental Health Services, 552; Rockefeller Foundation's $1 Million Sexually Transmitted Disease Challenge, 551; Small Grants for Historically Black Colleges and Universities, 1328; Small Grants for New Alcoholism Treatment Researchers, 824; Specialized Programs of Research Excellence in Prostate Cancer, 1328; Specialized Research Center Programs to Support Research in Reproduction, 1428; Strategic Program for Innovative Research on AIDS Treatment, 1125; Tuberculosis Research Grants, 1428
**Research/Practice Reports,** Adult Height in Girls with Turner Syndrome Treated with Low-dose Estrogens and Androgens, 570; Assessing the Accuracy of Drug Information Responses from Drug Information Centers, 707; Assessment of 24-Hour Gastric pH Measurements in Trauma Patients Receiving Intravenous Famotidine by Intermittent Bolus Versus Continuous Infusion Administration, 841; Assessment of Methods and Outcomes: Using Modified Inpatient Ciprofloxacin Criteria in Community-Based Drug Use Evaluation, 714; Attitudes of Healthcare Professionals Toward Patient Counseling on Drug–Nutrient Interactions, 576; Chronic Hemodialysis Patients. Part 1: Characterization and Drug-Related Problems, 316; Chronic Hemodialysis Patients. Part 2: Reducing Drug-Related Problems Through Application of the Focused Drug Therapy Review Program, 320; Clinical Experience with Ketorolac in Children, 1009; Close Clinical Observation Minimizes the Complications of Beta-Blocker Withdrawal, 849; Compatibility of Oral Morphine Sulfate Solution with Enteral Feeding Products, 451; Difficulties in Diagnosing Narcotic Overdoses in Hospitalized Patients, 446; Drug Degradation During HPLC Analysis of Aztreonam: Effect on Pharmacokinetic Parameter Estimation, 444; Effect of Calcium-Channel Blockers on Cyclosporine Clearance and Use in Renal Transplant Patients, 1227; Effect of Preparation Method and Storage on Rifampin Concentration in Suspensions, 182; Estimation of Total Body and Extracellular Water Using Single- and Multiple-Frequency Bioimpedance, 565; Evaluating the Accuracy of Citations in Drug Promotional Brochures, 1231; Evaluation of Recent Pharmacy Graduates' Practice Patterns, Professional Lifelong Learning, Pharmacy Organization Memberships, and Salary, 21; How Well Do Physicians, Pharmacists, and Psychologists Assess Tardive Dyskinesia Movements?, 185; Hydrazine Production in Children Receiving Isoniazid for the Treatment of Tuberculous Meningitis, 1340; Immunization Requirements for Pharmacy Students, 1153; Impact of Vancomycin Therapeutic Drug Monitoring on Patient Care, 1335; Implementation and Evaluation of a Standardized Herpes Simplex Virus Prophylaxis Protocol on a Leukemia/Bone Marrow Transplant Unit, 852; Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area Under the Inhibitory Curve Is More Rapid for Ciprofloxacin Than for Cefmenoxime, 863; Metabolic Correlates of Theophylline Therapy: A Concentration-Related Phenomenon, 175; NSAID Use and Efficacy in the Emergency Department: Single Doses of Oral Ibuprofen Versus Intramuscular Ketorolac, 309; Nasal Absorption of Growth Hormone in Normal Subjects: Studies with Four Different Formulations, 845; Omnibus Budget Reconciliation Act of 1990 and Voluntarism: Logistic Regression Analysis of Pharmacist Responsibility, 1020; Paclitaxel Stability and Compatibility in Polyolefin Containers, 35; Penetration of Intravenous and Oral Ciprofloxacin into Sterile and Empyemic Human Pleural Fluid, 313; Peripheral Intravenous Line Survival and Phlebitis Prevention in Patients Receiving Intravenous Antibiotics: Heparin/Hydrocortisone Versus In-Line Filters, 11; Pharmacy-Perceived Barriers to Cancer Pain Control: Results of the North Carolina Cancer Pain Initiative Pharmacist Survey, 857; Postoperative Nystagmus and Nausea, 179; Preliminary Comparison of Predictive and Empiric Lithium Dosing: Impact on Patient Outcome, 1148; Safety and Tolerance of Intravenous Nimodipine, 1143; Safety of Combination Aspirin and Anticoagulation in Acute Ischemic Stroke, 441; Safety of Esmolol in Patients with Acute Myocardial Infarction Treated with Thrombolytic Therapy Who Had Relative Contraindications to Beta-Blocker Therapy, 701; Serum Aldosterone Concentrations and Urine Output in Oliguric Intensive Care Unit Patients Receiving Low-Dose Dopamine, 837; Stability and Activity of Intravenous Immunoglobulin with Neonatal Dextrose and Total Parenteral Nutrient Solutions, 1014; Stability of Ceftazidime and Vancomycin Alone and in Combination in Heparinized and Non-heparinized Peritoneal Dialysis Solution, 572; Stability of Diluted Dexamethasone Sodium Phosphate Injection at Two Temperatures, 1018; Stability of Ondansetron Stored in Polypropylene Syringes, 712; Steady-State Pharmacokinetics of Cefoperazone and Sulbactam in Patients with Acute Appendicitis, 703; Strategy of Treatment of Pruritus During Pregnancy, 17; Telephone Contacts Do Not Improve Adherence to Niacin or Bile Acid Sequestrant Therapy, 29
**Restless legs syndrome,** clonidine (CR) 878
**Review Articles,** Beyond Thrombolysis: Other Effects of Thrombolytic Drugs, 752; Busulfan, 1055; Changing Perspectives of Stress Gastritis Prophylaxis, 1073; Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity, 1063; Hypertension and Endstage Renal Disease, 359; Hypertension: Are Beta-Blockers and Diuretics Appropriate First-Line Therapies?, 617; Infection Caused by Mycobacterium tuberculosis, 72; Magnesium Homeostasis and Clinical Disorders of Magnesium Deficiency, 220; Management of Bacterial Urinary Tract Infections in Adults, 1264; Once-Daily Administration of Aminoglycosides, 757; Use of Nifedipine in the Hypertensive Diseases of Pregnancy, 1371
**Rhabdomyolysis,** diazepam, lorazepam (L) 1200
**Rheumatic fever,** clarithromycin ineffective (L) 1197
**Rheumatoid arthritis,** evening primrose oil, statistical analysis (L) 973
**Rho Chi Lecture,** Pharmacy Faculties of the 21st Century, 1404; Some Contributions and Guidance for Future Graduate Students, 957
**Rifabutin,** adverse reactions (FF) 1252; cost (FF) 1252; pharmacokinetics (FF) 1251; pharmacology (FF) 1250; review (FF) 1250
**Rifampin,** concentration in suspensions, preparation method, storage (RPR) 182; thrombocytopenia (L) 1304
**Rifamycins,** tuberculosis (A) 77
**Rodriguez de Bittner, Magaly,** Board Certified Pharmacotherapy Specialist (NC) 1430
**Roentgenographic agents,** prophylaxis of anaphylaxis (DIR) 236
**Rudis, Maria I.,** Board Certified Pharmacotherapy Specialist (NC) 1430
**Rybak, Michael,** Outstanding Teacher, American Association of Colleges of Pharmacy (NC) 1126

## S

**Safety,** intravenous nimodipine (RPR) 1143
**Salmeterol,** asthma, therapy issues (PA) 1100
**Scotland,** pharmacy practice (L) 120
**Seifert, Charles F.,** Fellow, American College of Clinical Pharmacy (NC) 1126
**Seizures,** fatal, flumazenil (CR) 1347; foscarnet–ciprofloxacin interaction (CR) 869; leptazol (L) 285
**Selective serotonin reuptake antagonists,** adverse reactions (DSP) 1364; cost (DSP) 1366; interactions (DSP) 1365; pharmacokinetics (DSP) 1360; review (DSP) 1359; with selegiline, Parkinson's disease (L) 405
**Selegiline,** with selective serotonin reuptake inhibitors, Parkinson's disease (L) 405
**Sepsis,** acetylcysteine, antioxidant (CC) 1086
**Sertraline,** adverse reactions (DSP) 1364; cost (DSP) 1366; interaction, phenelzine (CR) 732; interactions, review (DSP) 1365; pharmacokinetics (DSP) 1360; review (DSP) 1359; toxicity (L) 1307
**Sex disorders,** fluvoxamine (CR) 872
**SIADH,** see **Inappropriate ADH syndrome**
**Silver sulfadiazine,** Stevens-Johnson syndrome (DIAS) 736
**Sodium valproate,** neonatal fibrinogen depletion (L) 1307
**Somatostatin,** esophageal varices (DIAS) 739
**Special Contribution,** Conducting Pediatric Research, 1105; Genesis of Clinical Pharmacokinetic/Pharmacodynamic Concepts: E.K. Marshall, Jr.'s Role, 1300
**Spiramycin,** intestinal cryptosporidiosis (AIDS) 771
**Stability,** ceftazidime, with vancomycin, heparin, peritoneal dialysis (RPR) 572; dexamethasone sodium phosphate, two temperatures (RPR) 1018; heparin, with ceftazidime, vancomycin, peritoneal dialysis (RPR) 572; intravenous immunoglobulin, dextrose, total parenteral nutrition (RPR) 1014; ondansetron, polypropylene syringes (RPR) 712; paclitaxel (S) S23, polyolefin containers (RPR) 35; vancomycin, with ceftazidime, heparin, peritoneal dialysis (RPR) 572
**Status epilepticus,** flumazenil (CR) 1347; lidocaine (DIAS) 1248
**Sterilization,** talc USP, intrapleural (L) 1309
**Stevens-Johnson syndrome,** silver sulfadiazine (DIAS) 736
***Streptococcus,*** Group A, United Kingdom (NC) 998; group A, clarithromycin ineffective (L) 1197; group B, neonatal prophylaxis (DIAS) 474
***Streptococcus pneumoniae,*** penicillin-resistant, incidence (NC) 822
**Streptokinase,** GUSTO trial, evaluation (E) 97; antistreptokinase antibodies, persistence of elevated titers (DIAS) 204; fibrinogen, thrombin, platelets, complement, blood rheology, neutrophil effects (A) 752

**Stringer, Kathleen A.,** Clinical Pharmacy Post-Pharm.D. Fellowship in the Biomedical Sciences (NC) 1000
**Stroke,** aspirin with heparin, safety (RPK) 441; ischemic, outcome, calcium-channel antagonists (L) 671; nicotine patch (L) 402
**Substance abuse,** Lysol (L) 970; alcohol withdrawal, benzodiazepines (L) 971; ethanol, benzodiazepine treatment (TC) 67
**Sucralfate,** compared with histamine$_2$-antagonists, antacids, meta-analysis (A) 1075; drug utilization, state prison (PEC) 792; with histamine$_2$-antagonists, gastrointestinal disorders (DIAS) 597
**Suicide,** assisted, legalized in Oregon (E) 1395
**Sulbactam,** with cefoperazone, pharmacokinetics (RPR) 703
**Sulfamethoxazole,** with trimethoprim, cholestasis (L) 1310, pharmacokinetics, children, biliary atresia (L) 405
**Sumatriptan,** interaction, loxapine (L) 1199
**Surgery,** blood loss, aprotinin prophylaxis (DIAS) 1246; postoperative bleeding, infections (L) 1308; relationship between postoperative nystagmus, nausea (RPR) 179
**Sympatholytic agents,** hypertension (A) 617; withdrawal (RPR) 849
**Sympathomimetic agents,** acute exacerbation, chronic obstructive pulmonary disease (CC) 1379; regular vs. prn use, asthma (PA) 911
**Syringes,** polypropylene, ondansetron stability (RPR) 712

## T

**Tachycardia,** supraventricular, adenosine in pregnancy (CR) 1241
**Tacrine,** Alzheimer's disease, review (FF) 744; adverse reactions (FF) 747; pharmacokinetics (FF) 745; pharmacology (FF) 744
**Tacrolimus,** adverse reactions (NDD) 506; compared with cyclosporine (NDD) 505; interaction, erythromycin (L) 280; pharmacokinetics (NDD) 502; pharmacology (NDD) 502; pregnancy, fetal risks (DIAS) 1356; review (NDD) 501
**Talc,** intrapleural (DSP) 900; Talc USP
**Tamoxifen,** ocular toxicity (DIAS) 740
**Tardive dyskinesia,** assessment, physician, pharmacist, psychologist training (RPR) 185
**Team,** nutrition support, benefits (CN) 227
**Tenoxicam,** hepatitis (L) 1309
**Terbutaline,** acute exacerbation, chronic obstructive pulmonary disease (CC) 1380; hypophosphatemia (CC) 628
**Terfenadine,** with erythromycin, torsades de pointes (L) 282
**Theophylline,** asthma, acute exacerbations (PA) 909; electrolyte, glucose abnormalities (RPR) 175; hypophosphatemia (CC) 628; pharmacokinetics, Koreans with congestive heart failure (IR) 396; renal excretion, age, children (L) 281; toxicity (CR) 195
**Therapeutic Controversies,** Alcohol Withdrawal: What Is the Benzodiazepine of Choice?, 67; Intravenous Magnesium Therapy in Acute Myocardial Infarction, 212; Is There a Role for Albumin Administration in Nutrition Support?, 478; Lipoprotein(a): Physiologic Function, Association with Atherosclerosis, and Effects of Lipid-Lowering Drug Therapy, 343; Oral Antihypertensives for Hypertensive Urgencies, 352; Reassessment of Measuring Total Iron Binding Capacity in Acute Iron Overdose, 63; Should All Patients with Dilated Cardiomyopathy Receive Chronic Anticoagulation?, 604; Treatment of Bacterial Vaginosis, 483
**Therapeutic Monitoring (TM),** Aminoglycoside Pharmacokinetics: Volume of Distribution in Specific Adult Patient Subgroups, 944; Cyclosporine Monitoring Improves Graft-Versus-Host Disease Prophylaxis After Bone Marrow Transplantation, 379; Monitoring Warfarin Therapy with the International Normalized Ratio, 242
**Therapeutic monitoring,** cyclosporine, bone marrow transplantation (TM) 379; vancomycin (L) 972, (RPR) 1335, (E) 1397; warfarin, International Normalized Ratio (TM) 242
**Thiabendazole,** cutaneous larva migrans (L) 672
**Thrombocytopenia,** famotidine (L) 406; procainamide (CR) 1172; rifampin (L) 1304; thrombotic, heparin (CR) 43; ticlopidine (CR) 1236
**Thrombophlebitis,** prophylaxis, heparin/hydrocortisone vs. filters (RPR) 11
**Ticarcillin,** with clavulanate, desensitization (L) 1200
**Ticlopidine,** aplastic anemia (CR) 1169; neutropenia, delayed (CR) 1344; neutropenia, thrombocytopenia (CR) 1236
**Tissue plasminogen activator,** GUSTO trial, evaluated (E) 97
**Tolerance,** intravenous nimodipine (RPR) 1143
**Total iron binding capacity,** reliability, iron toxicity (TC) 63
**Toxicity,** aspirin, enema (CR) 467; ceftriaxone, rapid administration (L) 807; ciprofloxacin, overdose (L) 805; iron, total iron binding capacity (TC) 63; lisinopril, angiotensin II (CR) 1165; narcotic, diagnosis (RPR) 446; ondansetron, poison-associated nausea, vomiting (CR) 331; paclitaxel (S) 527; phenytoin, multiple-dose activated charcoal (CR) 201; sertraline (L) 1307; theophylline (CR) 195
**Tranexamic acid,** bullous eruption (L) 1305
**Transplantation,** bone marrow, cyclosporine monitoring (TM) 379, prophylaxis, herpes simplex, acyclovir (RPR) 852; cyclosporine, effect of diltiazem, nifedipine, verapamil (RPR) 1227; pregnancy, fetal risks (DIAS) 1355
**Triamcinolone acetonide,** anaphylaxis (L) 1310
**Triazolam,** safety concerns (DIAS) 1038
**Trichotillomania,** fluoxetine (DIAS) 1245
**Trimebutine,** addictive potential (L) 537
**Trimethoprim,** with sulfamethoxazole, cholestasis (L) 1310, pharmacokinetics, children, biliary atresia (L) 405
**Tuberculosis,** epidemiology (A) 73; expanded surveillance (NC) 998; meningitis, hydrazine production in children, isoniazid (RPR) 1340; quinolones (A) 76; review (A) 72; rifabutin (FF) 1250; rifamycins (A) 77
**Turner syndrome,** adult height, girls (RPR) 570

## U-V

**Ulcers,** colonic, indomethacin (CR) 883; esophageal, doxycycline (DIAS) 1185; pressure, fleroxacin (L) 117
**Uremia,** bleeding, estrogens (DIAS) 60
**Urinary tract infection,** management (A) 1264; pregnancy, treatment recommendations (O) 248; treatment (A) 1267
**USPHS-CDC News (NC),** Absence of Reported Measles—US, November 1993, 160; Certification of Poliomyelitis Eradication—the Americas, 1994, 1428; Characterization and Treatment of Genetic Metabolic Diseases, 687; Deaths from Breast Cancer—United States, 1991, 823; Expanded Tuberculosis Surveillance and Tuberculosis Morbidity—US, 1993, 998; Human Plague—India, 1327; Invasive Group A Streptococcal Infections—United Kingdom, 1994, 998; Measles—US, First 26 Weeks, 1994, 1327; Medical-Care Expenditures Attributable to Cigarette Smoking—US, 1993, 1215; Mortality Patterns—US 1991, 297; Mortality from Congestive Heart Failure—US, 1980–1990, 687; Outbreak of Hepatitis C Associated with Intravenous Immunoglobulin Administration—US, October 1993–June 1994, 1215; Prevalence of Adults with No Known Major Risk Factors for Coronary Heart Disease—Behavioral Risk Factor Surveillance System, 1992, 686; Prevalence of Penicillin-Resistant *Streptococcus pneumoniae*—Connecticut, 1992–1993, 822; Progress Toward Elimination of *Hemophilus influenzae* Type b Disease Among Infants and Children—US 1987–1993, 686; Reduction in Alcohol-Related Traffic Fatalities—US, 1990–1991, 426; Reported Vaccine-Preventable Diseases—US 1993, and the Childhood Immunization Initiative, 688; Resurgence of Pertussis—US, 1993, 298; Update: Influenza Activity, 1994, 1328; Update: Mortality Attributable to HIV Infection Among Persons Aged 25–44 Years—US, 1991 and 1992, 160; Vaccination Coverage of 2-Year-Old Children—United States, 1992–1993, 823; Zidovudine for the Prevention of HIV from Mother to Infant, 998
**Vaccines,** adverse reactions (PED) 638; combination, review (PED) 635
**Vaginosis, bacterial,** treatment (TC) 484
**Valproic acid,** infantile spasms (PED) 784
**Vancomycin,** clearance, long-term therapy (L) 116; neutropenia, child (CR) 723; rectal administration (DIAS) 1357; red-man syndrome, child (CR) 581; therapeutic monitoring (L) 972, (RPR) 1335, (E) 1397; with aminoglycosides, *Staphylococcus epidermidis* endocarditis (DIAS) 737; with ceftazidime, heparin, stability, peritoneal dialysis (RPR) 572
**Vanderveen, Randall L.,** Fellow, American Society of Hospital Pharmacists (NC) 824
**Varicella,** immunocompetent patients, oral acyclovir (DIAS) 208
**Varicella zoster vaccine,** review (PED) 636
**Verapamil,** effect on cyclosporine clearance (RPR) 1227; interaction, aspirin (L) 536, clonidine (CR) 881
**Vigabatrin,** infantile spasms (PED) 785
**Vindesine,** extravasation (L) 967
**VIP News (NC),** Arndt, Jack R., 162; Bertino, Joseph S. Jr., 298; Campbell, R. Keith, 162, 1126; Cardoni, Alex A., 1430; Crismon, M. Lynn, 1126; D'Angio, Richard G., 1430; Delafuente, Jeffrey, 1126; Doluisio, James T., 824; Dukes, George E., 1430; Ellsworth, Alan J., 824; Erstad, Brian L., 824, 1126; Finley, Rebecca S., 1430; Fletcher, Courtney V., 1000; Gal, Peter, 1430; Goldspiel, Barry R., 1216; Grasela, Thaddeus, 824; Graves, Nina, 428; Heim-Duthoy, Karen L., 1126; Higuchi, William I., 162; Holdsworth, Mark T., 1430; Martineau, Pierre, 1430; Milavetz, Gary, 162; Mirtallo, Jay M., 824; Mutnik, Alan H., 824; Nahata, Milap, 1126, 1430; Ponte, Charles, 824; Rodriguez de Bittner, Megaly, 1430; Rudis, Maria I., 1430; Rybak, Michael, 1126; Seifert, Charles F., 1126; Stringer, Kathleen A., 1000; Vanderveen, Randall L., 824; Vlasses, Peter H., 1000, 1430; Wells, Barbara G., 1126; Zarowitz, Barbara J., 688
**Vlasses, Peter H.,** Board Certified Pharmacotherapy Specialist (NC) 1430; Board of Pharmaceutical Specialties appointment (NC) 1000

## W-Z

**Warfarin,** interaction, felbamate (L) 805, (L) 1412, fluconazole (L) 1111, levamisole/fluorouracil (CR) 464; monitoring, International Normalized Ratio (TM) 242
**Water,** body, estimation, bioimpedance (RPR) 565
**Weight loss,** with hyperphagia, fluoxetine (CR) 1350
**Wells, Barbara G.,** Specialty Council on Psychopharmacy Practice (NC) 1126
**Withdrawal,** beta-blockers (RPR) 849
**Women,** health issues (L) 969; hypertension (A) 620
**Zarowitz, Barbara J.,** ACCP president-elect (NC) 688
**Zidovudine,** HIV wasting syndrome (DIAS) 596; interaction, acetaminophen (CR) 327; intestinal cryptosporidiosis (AIDS) 774; prophylaxis, mother-to-infant HIV transmission (NC) 998

# AUTHOR INDEX

## A-B

**Abate, Marie A.** (coauthor) see **Baker, Danial E.,** 1389
**Aboko-Cole, Vivian C.** (coauthor) see **Cramer, Richard L.,** 458
**Adams, James M.** (coauthor) see **Lindsay, Christine A.,** 1014
**Afshar, Mary** (coauthor) see **Larijani, Ghassem E.,** 179
**Agiri, Olakunbi A.** (coauthor) see **Kuhl, David A.,** 1379
**Aguar, Mª Carmen** (coauthor) see **Sauleda, Jaume,** 52
**Akbas, Oral** (coauthor) see **Sungur, Cem,** 1309
**Akpolat, Tekin** (coauthor) see **Oymak, Oktay,** 406
**Alcácer, Federico** (coauthor) see **Rodilla, Francisco,** 1305
**Alderman, Christopher P.** (author) Abnormal Bone Mineral Metabolism After Long-Term Anticonvulsant Treatment (CR) 47
**Alzamora, Mónica** (coauthor) see **Mateu, Javier,** 1243
**Amato, Mary G.** (author) book review, 1315
**Ament, Paul W.** (author) Famotidine-Induced Mixed Hepatocellular Jaundice (CR) 40
**Anand, Ajay J.** (author) Fluorouracil Cardiotoxicity (DIR) 374
**Andrews, Carlota O.** (author) Gabapentin: A New Agent for the Management of Epilepsy (FF) 1188; (author) Pleural Effusions: Pathophysiology and Management (DSP) 894
**Aran, Xavier** (coauthor) see **Sauleda, Jaume,** 52
**Ariano, Robert E.** (coauthor) see **Gin, Alfred S.,** 1412
**Arik, Nurul** (coauthor) see **Oymak, Oktay,** 406
**Artigas, Antoni** (coauthor) see **Saura, Pilar,** 1308
**Ascione, Frank J.** (coauthor) see **Kaplan, Barbara,** 316, 320
**Ashley, Jeffrey V.** (coauthor) see **Verzino, Ellen M.,** 536
**Ates, Bahri** (coauthor) see **Sungur, Cem,** 1309
**Ausman, Robert K.** (coauthor) see **Whipple, Julianne K.,** 446, 655
**Autret, Elisabeth** (coauthor) see **Jonville-Bera, Annie-Pierre,** 964
**Aznar, Julia** (coauthor) see **Rodilla, Francisco,** 1305
**Baboolal, Susan M.** (author) Comment: NSAID Use and Efficacy in the Emergency Department (L) 1201
**Bachtel, Michelle D.** (coauthor) see **Mahoney, Janelle M.,** 587
**Baciewicz, Anne M.** (author) Cholestasis: Hepatocellular Reaction to Trimethoprim/Sulfamethoxazole (L) 1310; (author) Fluconazole–Warfarin Interaction (L) 1111
**Baker, Brian A.** (author) Dermatologic Cross-Sensitivity Between Diltiazem and Amlodipine (L) 118
**Baker, Carol J.** (coauthor) see **Lindsay, Christine A.,** 1014
**Baker, Danial E.** (author) Selected Topics in Drug Information Access and Practice: An Update (RA) 1389
**Bakst, Cindy M.** (coauthor) see **Loughlin, Kathleen A.,** 600
**Balano, Kirsten Brossier** (coauthor) see **Schweitzer, Michele S.,** 886
**Ballow, Charles H.** (coauthor) see **Goss, Thomas F.,** 863
**Baltassat, Pierre** (coauthor) see **Cahen, Rémi,** 49
**Banfield, Christopher R.** (coauthor) see **Glue, Paul,** 1412
**Barat, C.** (coauthor) see **Haramburu, Françoise,** 17
**Barone, Joseph A.** (author) Cisapride: A Gastrointestinal Prokinetic Drug (FF) 488
**Barry, William L.** (coauthor) see **Chapron, Dennis J.,** 874
**Bartlome, Patricia** (coauthor) see **Watson, Amy Rich,** 341
**Barton, Terri L.** (coauthor) see **Bublin, Janice G.,** 1357; (coauthor) see **Miller, Linda M.,** 740; (coauthor) see **Yanchick, Jillmarie K.,** 1245
**Basran, Gurnam S.** (coauthor) see **Joseph, Joe,** 313
**Bass, Joeby** (coauthor) see **Udezani, George O.,** 451
**Bass, Sheron B.** (coauthor) see **Evans, R. Scott,** 523
**Bates, Richard D.** (author) Once-Daily Administration of Aminoglycosides (A) 757
**Baud, Eric B.** (coauthor) see **Baciewicz, Anne M.,** 1111
**Bavoux, Françoise** (author) Neonatal Fibrinogen Depletion Caused by Sodium Valproate (L) 1307; (coauthor) see **Haramburu, Francoise,** 17
**Beaird, Sandra L.** (author) Assessing the Accuracy of Drug Information Responses from Drug Information Centers (RPR) 707

**Becker, Evelyn S.** (coauthor) see **Ritchie, David J.,** 767
**Begaud, Bernard** (coauthor) see **Haramburu, Françoise,** 17
**Beijnen, Jos H.** (coauthor) see **Burger, David M.,** 327
**Beis, Sara** (author) book review, 813
**Beizer, Judith L.** (coauthor) see **Sherman, Olga,** 1162
**Belitsky, Philip** (coauthor) see **Sketris, Ingrida S.,** 1227
**Benito, Pedro** (author) Effect of Octreotide on Plasma Lipid Metabolism in Acromegaly (L) 1198
**Bennett, Michelle** (coauthor) see **Krick, Stacie E.,** 857
**Bera, Frédéric J.** (coauthor) see **Jonville-Bera, Annie-Pierre,** 964
**Bergeron, Luc** (author) Possible Red-Man Syndrome Associated with Systemic Absorption of Oral Vancomycin in a Child with Normal Renal Function (CR) 581
**Berning, Shaun E.** (coauthor) see **Peloquin, Charles A.,** 72
**Bertch, Karen E.** (author) book review, 540
**Bertino, Joseph S., Jr.** (author) Correction: Measured Versus Estimated Creatinine Clearance in Patients with Low Serum Creatinine Values (L) 811
**Bess, David Todd** (coauthor) see **Capers, Christi C.,** 116
**Betageri, Guru V.** (author) book review, 1318
**Bierman, Robert H.** (coauthor) see **Barone, Joseph A.,** 488
**Biglin, Kevin E.** (author) Drug-Induced Torsades de Pointes: A Possible Interaction of Terfenadine and Erythromycin (L) 282
**Bird, Rebecca D.** (author) Alcohol Withdrawal: What Is the Benzodiazepine of Choice? (TC) 67
**Birdwell, Stephen W.** (author) book review, 1205
**Birmingham, Mary C.** (coauthor) see **Goss, Thomas F.,** 863
**Biron, Pierre** (author) Comment: Risk Reduction from Clinical Trials Adjusted on an Annual Basis (L) 1112
**Bishop, Tracy D.** (coauthor) see **Vaughan, Leigh M.,** 1309
**Bjornson, Darrel C.** (coauthor) see **Rovers, John P.,** 714
**Blackwelder, Nicole** (coauthor) see **Grasela, Thaddeus H. Jr.,** 261
**Blais, Diane** (author) book review, 1206
**Blake, Kathryn V.** (coauthor) see **Kamada, Alan K.,** 1100
**Blanchard, Edward B.** (coauthor) see **Eisele, George,** 849
**Blunt, Jeffrey R.** (coauthor) see **Beaird, Sandra L.,** 707
**Boccara, J.F.** (coauthor) see **Bavoux, Françoise,** 1307
**Bokar, Joseph A.** (coauthor) see **Baciewicz, Anne M.,** 1111
**Bond, C.A.** (author) Evaluation of Recent Pharmacy Graduates' Practice Patterns, Professional Lifelong Learning, Pharmacy Organization Memberships, and Salary (RPR) 21
**Bootman, J. Lyle** (coeditor) see **McGhan, William F.,** 105, 271, 384, 528, 659, 792
**Borne, Ronald F.** (author) Pharmacy Faculties of the 21st Century (RC) 1404
**Boucher, François D.** (coauthor) see **Bergeron, Luc,** 581
**Bourget, Phillippe** (author) Flecainide Distribution, Transplacental Passage, and Accumulation in the Amniotic Fluid During the Third Trimester of Pregnancy (CR) 1031
**Boyd, John W.** (coauthor) see **Purdum, Preston P. III,** 1159
**Boyd, Wendy M.** (coauthor) see **Cutler, Neal R.,** 117
**Boyer, M.** (coauthor) see **Haramburu, Françoise,** 17
**Braun, Bennett G.** (coauthor) see **Fichtner, Christopher G.,** 1350
**Bressler, Linda R.** (coauthor) see **Kosirog-Glowacki, Jane L.,** 197
**Briscoe-Dwyer, Leigh** (author) Dyspnea and Periorbital Edema Following an Increase in Naproxen Dose (L) 1110
**Broquetas, Joan M³** (coauthor) see **Sauleda, Jaume,** 52
**Brown, David F.** (author) Sertraline Overdose (L) 1307
**Brown, Glen R.** (author) Drug- and Nutrition-Induced Hypophosphatemia: Mechanisms and Relevance in the Critically Ill (CC) 626
**Brown, Thomas E.R.** (author) Hypertension and Endstage Renal Disease (A) 359
**Bruder-Holt, Rebecca** (coauthor) see **Grasela, Thaddeus H. Jr.,** 261
**Bublin, Janice G.** (author) Rectal Use of Vancomycin (DIAS) 1357
**Bucci, Kathryn K.** (coauthor) see **Mallet, Louise,** 1153
**Buchanan, Robert J.** (author) Medicaid Policies for HIV-Related Drug Therapies: Perspectives of the State Affiliates of the American Pharmaceutical Association (PEC) 528
**Buck, Marcia L.** (author) Clinical Experience with Ketorolac in Children (RPR) 1009
**Buggia, Isabella** (author) Busulfan (A) 1055
**Buisán, María-José** (coauthor) see **Mateu, Javier,** 1243
**Burdette, Michelle** (coauthor) see **Verzino, Ellen M.,** 536
**Burger, David M.** (author) Pharmacokinetics of Zidovudine and Acetaminophen in a Patient on Chronic Use of Acetaminophen Therapy (CR) 327
**Burgess, David S.** (coauthor) see **Friedrich, Lawrence V.,** 444
**Burke, John P.** (coauthor) see **Evans, R. Scott,** 523
**Burnakis, Thomas G.** (author) Inaccurate Assessment of Drug-Induced Thrombocytopenia: Reason for Concern (CR) 726
**Burris, Howard A., III** (author) Preclinical Pharmacology and Phase I Clinical Trials, (S) S7
**Bursztyn, Michael** (coauthor) see **Jaffe, Ronen,** 881

## C

**Caballero, M.E. Esperanza-Jiménez** (coauthor) see **Carrión-Carrión, Carmen,** 1305; (coauthor) see **Gutierrez, Rosario,** 537
**Cacchione, Joseph G.** (coauthor) see **Baker, Brian A.,** 118
**Cadle, Richard M.** (author) Fluconazole-Induced Symptomatic Phenytoin Toxicity (CR) 191
**Caglar, Sali** (coauthor) see **Oymak, Oktay,** 406
**Cahen, Rémi** (author) Creatinine Metabolism Impairment by an Anticonvulsant Drug, Phenacemide (CR) 49
**Calañas, A.** (coauthor) see **Benito, Pedro,** 1198
**Caldwell, James B.** (author) Intravenous Ciprofloxacin Dosing in a Morbidly Obese Patient (L) 806
**Camacho, Angélica** (coauthor) see **Lares-Asseff, Ismael,** 405
**Camafort-Babkowski, Miguel** (coauthor) see **Fernández-Real, Jose Manuel,** 1200
**Camp, Kimberly A.** (author) Potential Quinolone-Induced Cartilage Toxicity in Children (DIAS) 336
**Canaday, Bruce R.** (author) Documenting Pharmaceutical Care: Creating a Standard (O) 1292
**Capellà, Dolors** (coauthor) see **Llop, Roser,** 671
**Capers, Christi C.** (author) Vancomycin Clearance: The Effect of Prolonged Therapy (L) 116
**Carlson, James A.** (author) Fatal Neutropenia and Thrombocytopenia Associated with Ticlopidine (CR) 1236
**Carré, Pierre** (coauthor) see **Jonville-Bera, Annie-Pierre,** 964
**Carrión-Carrión, Carmen** (author) Bullous Eruption Induced by Tranexamic Acid (L) 1305; (coauthor) see **Gutierrez, Rosario,** 537
**Carroll, Maria A.** (coauthor) see **Ehrenpreis, Eli D.,** 1239
**Carson, John J.** (author) Ventricular Arrhythmias Associated with Flosequinan (L) 403
**Carter, Barry L.** (coauthor) see **Brown, Thomas E.R.,** 359
**Carter, Charles A.** (author) Comment: Enoxaparin—The Low-Molecular-Weight Heparin for Prevention of Postoperative Thromboembolic Complications (L) 810
**Casado, Mariano** (coauthor) see **Carrión-Carrión, Carmen,** 1305; (coauthor) see **Gutierrez, Rosario,** 537
**Cason, Dick M.** (coauthor) see **Keith, Matthew R.,** 792
**Cassidy, Regina W.** (coauthor) see **Capers, Christi C.,** 116
**Castano, Maria C.** (coauthor) see **McIntire, Lynn C.,** 1200
**Casto, Daniel T.** (author) Stability of Ondansetron Stored in Polypropylene Syringes (RPR) 712; (coauthor) see **Haines, Stuart T.,** 779
**Cat, Loan K.** (author) Treatment for HIV Wasting Syndrome (DIAS) 595
**Cernek, Paul K.** (author) Dermal Cellulitis—A Hypersensitivity Reaction from Dobutamine Hydrochloride (L) 964
**Chan, Juliana C.N.** (coauthor) see **Chan, Thomas Y.K.,** 119
**Chan, Thomas Y.K.** (author) Correction: Author's Name (L) 974; (author) Cushing's Syndrome Caused by Analgesic/Dexamethasone Preparation (L) 1411; (author) Recurrent Glibenclamide-Induced Hypoglycemia: the Importance of Obtaining a Comprehensive Medication History (L) 119; (coauthor) see **Lee, Kenneth K.C.,** 1400
**Chandler, Sonja W.** (coauthor) see **Miller, Lisa J.,** 590
**Chapron, Dennis J.** (author) Gastric Retention of Enteric-Coated Magnesium Chloride Tablets (CR) 874
**Cheng, Judy W.M.** (author) Should All Patients with Dilated Cardiomyopathy Receive Chronic Anticoagulation? (TC) 604
**Chesser, Stephen L.** (author) Antistreptokinase Antibodies Following a Dose of Streptokinase (DIAS) 204
**Chin, Alfred** (author) Paclitaxel Stability and Compatibility in Polyolefin Containers (RPR) 35
**Chohan, Patricia S.** (coauthor) see **Dick, Michael R.,** 837
**Choi, Simon S.L.** (coauthor) see **Chan, Thomas Y.K.,** 119
**Choudhury, Taffik** (coauthor) see **Knowles, Sandra,** 325
**Christensen, Dale B.** (author) Comparison of Prescription and Medical Records in Reflecting Patient Antihypertensive Drug Therapy (PEP) 99
**Christiansen, Jens Sandahl** (coauthor) see **Laursen, Torben,** 845
**Cimino, Michael A.** (author) Assessment of Cost-Effective Antibiotic Therapy in the Management of Infections in Cancer Patients (PEC) 105
**Classen, David C.** (coauthor) see **Evans, R. Scott,** 523
**Cleary, John D.** (author) Pharmacy in Iceland (IR) 112
**Clewell, Jerry D.** (author) Prostaglandins for the Treatment of Hepatorenal Syndrome (DIAS) 54
**Clouse, Jon C.** (author) Healthcare Resource Use and Costs Associated with Migraine in a Managed Healthcare Setting (PEC) 659
**Cohen, Henry** (author) Twelve-Gram Overdose of Ciprofloxacin with Mild Symptomatology (L) 805
**Colaizzi, John L.** (coauthor) see **Barone, Joseph A.,** 488
**Colbert, James, Jr.** (coauthor) see **Shinohara, Y. Todd,** 723
**Colditz, Graham A.** (coauthor) see **Menzin, Joseph H.,** 271
**Cole, Patricia L.** (coauthor) see **Hagley, Michael T.,** 1241
**Coleman, Rebecca L.** (coauthor) see **Cat, Loan K.,** 595
**Coley, Kim Coccodrilli** (coauthor) see **McCarthy, Michelle W.,** 1246
**Coley, Rebecca M.R.** (coauthor) see **Beaird, Sandra L.,** 707; (coauthor) see **Keng, Arlene,** 1231
**Collier, Dean S.** (coauthor) see **Shaefer, Mark S.,** 280
**Colomina, Javier** (coauthor) see **Rodilla, Francisco,** 672, 1305
**Colucci, Robert D.** (coauthor) see **Garcia, Guadalupe,** 1199; (coauthor) see **Glue, Paul,** 1412
**Connelly, Julie F.** (author) Interferon Beta for Multiple Sclerosis (FF) 610
**Conner, Dale P.** (author) book review, 121
**Connors, John E.** (coauthor) see **Plastino, Kristen A.,** 737
**Constance, Thomas D.** (coauthor) see **Biglin, Kevin E.,** 282
**Copa, Alan K.** (coauthor) see Welty, Timothy E., 1335
**Copeland, Debra A.** (author) Pyridoxine in Carpal Tunnel Syndrome (DIAS) 1042
**Copfer, Amy L.** (coauthor) see **Kintzel, Polly E.,** 333
**Corpas, María S.** (coauthor) see **Benito, Pedro,** 1198
**Cramer, Richard L.** (author) Agranulocytosis Associated with Etodolac (CR) 458
**Crismon, M. Lynn** (author) book review, 975; (author) Tacrine: First Drug Approved for Alzheimer's Disease (FF) 744
**Critchley, Julian A.J.H.** (coauthor) see **Chan, Thomas Y.K.,** 119; (coauthor) see **Lee, Kenneth K.C.,** 1400
**Cropp, Anne B.** (author) book review, 1115
**Croze, Sheila M.** (author) Oral Acyclovir in Immunocompetent Patients with Varicella (DIAS) 208
**Cumbo, Thomas J.** (coauthor) see **Goss, Thomas F.,** 863
**Currie, Mark S.** (coauthor) see **Landrum, Elizabeth M.,** 1172
**Cutler, Neal R.** (author) Fleroxacin Treatment of Stage IV Pressure Ulcers with Associated Osteomyelitis (L) 117; (coauthor) see **Sramek, John J. Jr.,** 1143
**Cziraky, Mark J.** (coauthor) see **Spinler, Sarah A.,** 343

## D-E

**Dager, William E.** (author) Aminoglycoside Pharmacokinetics: Volume of Distribution in Specific Adult Patient Subgroups (TM) 944; (author) book review, 1316
**Dahl, Stephen L.** (author) book review, 673
**Dang, Ken** (coauthor) see **Lindsay, Christine A.,** 1014
**D'Angio, Richard G.** (author) Is There a Role for Albumin Administration in Nutrition Support? (TC) 478
**Danon, Yehuda L.** (coauthor) see **Garty, Ben Zion,** 730
**Danziger, Larry H.** (author) Steady-State Pharmacokinetics of Cefoperazone and Sulbactam in Patients with Acute Appendicitis (RPR) 703
**Dasta, Joseph F.** (coauthor) see **Dick, Michael R.,** 837; (coauthor) see **Zarowitz, Barbara J.,** 245; (editor) Critical Care, 626, 915, 1086, 1273, 1379
**Dattani, Bella H.** (author) Nitroglycerin Use in Variceal Hemorrhage (DIAS) 206
**Davis, Hillel** (coauthor) see **Dorevitch, Abraham,** 872
**Davis, Robin L.** (coauthor) see **Hashimoto, Fred,** 37
**Day, Rosemary A.** (coauthor) see **Roberts, Gregory W.,** 11
**de Clavijo, Irene V.** (author) Update on Childhood Immunizations (PED) 633
**De Lecea, Carlos** (coauthor) see **Gallart, Lluis,** 969
**De Lucas-Laguna, Raúl** (coauthor) see **Carrión-Carrión, Carmen,** 1305; (coauthor) see **Gutierrez, Rosario,** 537
**DeJong, Douglas J.** (author) book review, 1316
**del Carmen López, María** (coauthor) see **Lares-Asseff, Ismael,** 405; (coauthor) see **Mataix, Angel L.,** 961
**Del Pozo-Losada, Jesús** (coauthor) see **Carrión-Carrión, Carmen,** 1305; (coauthor) see **Gutierrez, Rosario,** 537
**Delafuente, Jeffrey C.** (author) Monoclonal Antibodies in the Treatment of Rheumatoid Arthritis (RA) 650
**Delage, F.** (coauthor) see **Haramburu, Françoise,** 17
**Delouis, Christine** (coauthor) see **Bourget, Phillippe,** 1031
**Dick, Michael R.** (author) Serum Aldosterone Concentrations and Urine Output in Oliguric Intensive Care Unit Patients Receiving Low-Dose Dopamine (RPR) 837
**DiMeglio, Lourdes S.** (coauthor) see **Chin, Alfred,** 35
**DiSalvo, Raymond P.** (coauthor) see **Haverkos, Gregory P.,** 1347
**Doering, Paul L.** (author) Using the "Smart Pill" to Teach About Substance Abuse (E) 390; (coauthor) see **Levin, Anne C.,** 1371
**Donald, Peter R.** (author) Hydrazine Production in Children Receiving Isoniazid for the Treatment of Tuberculous Meningitis (RPR) 1340
**Dorevitch, Abraham** (author) Fluvoxamine-Associated Sexual Dysfunction (CR) 872
**Dorr, Robert T.** (author) Pharmacology and Toxicology of Cremophor EL Diluent (S) S11; (coauthor) see **Koeller, Jim M.** S5, S31; (coeditor) see **Koeller, Jim M.,** (S)
**Dougherty, J. Patrick** (coauthor) see **Ohri, Linda K.,** 970
**Draghi, Eva** (coauthor) see **Zogno, Maria G.,** 406
**Dressler, Carolyn M.** (author) Comment: Cost in Treating Malignant Pleural Effusions with Bleomycin (L) 407
**Druckenbrod, Richard W.** (author) book review, 1315
**Duarte, Jacinto** (coauthor) see **Mataix, Angel L.,** 961
**Dufresne, Robert L.** (coauthor) see **Ghaeli, Padideh,** 1038
**Durán, Jose A.** (coauthor) see **Merino, Nieves,** 402
**Egli, Douglas** (coauthor) see **Hashimoto, Fred,** 37
**Ehrenpreis, Eli D.** (author) Malabsorption of Digoxin Tablets, Gel Caps and Elixir in a Patient with an End Jejunostomy (CR) 1239
**Eisele, George** (author) book review, 975; (author) Close Clinical Observation Minimizes the Complications of Beta-Blocker Withdrawal (RPR) 849
**Ely, Daniel S.** (coauthor) see **Howard, Carol E.,** 201
**Engelberg, Ruth** (coauthor) see **Christensen, Dale B.,** 99
**Erickson, Steven R.** (coauthor) see **Slaughter, Richard L.,** 665

**Erramouspe, John** (author) Neonatal Group B Streptococcal Infection Prevention (DIAS) 474
**Erstad, Brian L.** (author) Oxygen Transport Goals in the Resuscitation of Critically Ill Patients (CC) 1273
**Etzel, Joseph V.** (coauthor) see **Briscoe-Dwyer, Leigh,** 1110
**Evans, Barbara L.** (coauthor) see **Sharif, M. Nabi,** 720
**Evans, R. Lee** (coauthor) see **Marken, Patricia A.,** 1148
**Evans, R. Scott** (author) Preventing Adverse Drug Events in Hospitalized Patients (PI) 523

## F

**Fagan, Susan C.** (author) Safety of Combination Aspirin and Anticoagulation in Acute Ischemic Stroke (RPR) 441
**Fan-Havard, Patty** (author) Concurrent Use of Foscarnet and Ciprofloxacin May Increase the Propensity of Seizures (CR) 869
**Farmer, Kevin C.** (author) book review, 1415
**Faraon, May S.** (coauthor) see **Biglin, Kevin E.,** 282
**Farver, Debra K.** (author) Delayed Neutropenia with Ticlopidine (CR) 1344
**Fell, Robert E.** (coauthor) see **Paladino, Joseph A.,** 384
**Fermont, Laurent** (coauthor) see **Bourget, Phillippe,** 1031
**Fernández-Galinski, Susana** (coauthor) see **Gallart, Lluis,** 969
**Fernández-Real, Jose Manuel** (author) Hyponatremia and Benzodiazepines Result in Rhabdomyolysis (L) 1200
**Ferriols, Francisco** (coauthor) see **Rodilla, Francisco,** 1305
**Fichtner, Christopher G.** (author) Hyperphagia and Weight Loss During Fluoxetine Treatment (CR) 1350
**Figueras, Albert** (coauthor) see **Llop, Roser,** 671
**Finlay, Christine F.** (coauthor) see **Roberts, Gregory W.,** 11
**Finley, Patrick, R.** (author) Selective Serotonin Reuptake Inhibitors: Pharmacologic Profiles and Potential Therapeutic Distinctions (DSP) 1359
**Finley, Rebecca S.** (author) Patient Care Issues: The Management of Paclitaxel-Related Toxicities (S) S27
**Fischer, James H.** (coauthor) see **Andrews, Carlota O.,** 1188
**Fitzsimmons, William E.** (coauthor) see **Ghalie, Richard.** 379
**Flack, John M.** (author) Metabolic Correlates of Theophylline Therapy: A Concentration-Related Phenomenon (RPR) 175
**Flanchaum, Louis** (coauthor) see **Dick, Michael R.,** 837
**Fletcher, Courtney V.** (coeditor) see **Goodwin, Diane S.,** 767
**Floren, Leslie Carstensen** (author) Antioxidants May Retard Cataract Formation (DIAS) 1040
**Foisy, Michelle M.** (author) Pancreatitis During Intravenous Pentamidine Therapy in an AIDS Patient with Prior Exposure to Didanosine (CR) 1025
**Forrest, Alan** (coauthor) see **Goss, Thomas F.,** 863
**Forster, Eliot R.** (author) Comment: Ondansetron for Treating Nausea and Vomiting in the Poisoned Patient (L) 1203
**Foster, Jessica A.** (author) Doxycycline-Induced Esophageal Ulceration (DIAS) 1185
**Fournier-Perhilou, Anne-Isabelle** (coauthor) see **Bavoux, Françoise,** 1307
**Fox, Carol J.** (coauthor) see **Ament, Paul W.,** 40
**Francisco, Dalmacio H.** (coauthor) see **Cohen, Henry,** 805
**Franco, Mercedes** (coauthor) see **Mateu, Javier,** 1243
**Francois, Bernard** (coauthor) see **Cahen, Rémi,** 49
**Francoual, Christine** (coauthor) see **Bavoux, Françoise,** 1307
**Frenia, Maureen L.** (author) Use of Silver Sulfadiazine in Stevens-Johnson Syndrome (DIAS) 736
**Friedrich, Lawrence V.** (author) Drug Degradation During HPLC Analysis of Aztreonam: Effect on Pharmacokinetic Parameter Estimation (RPR) 444
**Friesen, Edwin G.** (coauthor) see **Wiedrick, James E.D.,** 1109
**Frighetto, Luciana** (coauthor) see **Rayani, Shelina A.,** 852
**Frydman, René** (coauthor) see **Bourget, Phillippe,** 1031
**Fuentes, Maria Jose** (coauthor) see **Mataix, Angel L.,** 961
**Fuller, Dennis K.** (author) Author's Reply: Cost in Treating Malignant Pleural Effusions with Bleomycin (L) 407; (author) Comment: Aminoglycoside Nephrotoxicity Following Single-Dose Cystoscopy Prophylaxis (L) 1202
**Fuller, Matthew A.** (coauthor) see **Goldman, Morton P.,** 809

## G

**Gal, Peter** (coauthor) see **Kandrotas, Robert J.,** 1312
**Galende, Ines** (coauthor) see **Sucristán, José Antonio,** 539
**Gales, Barry J.** (author) Nutritional Support Teams: A Review of Comparative Trials (CN) 227
**Gales, Mark A.** (author) Combination Sucralfate and Histamine$_2$-Antagonist Therapy (DIAS) 597; (author) Oral Antihypertensives for Hypertensive Urgencies (TC) 352
**Gales, Marla J.** (coauthor) see **Gales, Barry J.,** 227
**Gallart, Lluis** (author) Can Drug Administration Errors Be Minimized? (L) 969
**Gallego, Concepción** (author) Interaction Between Probucol and Cyclosporine in Renal Transplant Patients (DIR) 940
**Gallimberti, Luigi** (coauthor) see **Schifano, Fabrizio,** 537
**Gallup, Edward L.** (coauthor) see **Whipple, Julianne K.,** 655
**Galvez, MA** (coauthor) see **Benito, Pedro,** 1198
**García, Benito** (coauthor) see **Carrión-Carrión, Carmen,** 1305; (coauthor) see **Gutierrez, Rosario,** 537
**García, Guadalupe** (author) Dystonic Reaction Associated with Sumatriptan (L) 1199
**García-Herola, A.** (coauthor) see **Kindelán-Jaquotot, Jose Maria,** 1304
**García-Lázaro, M.** (coauthor) see **Kindelán-Jaquotot, Jose Maria,** 1304
**Garnett, William R.** (author) Fluvastatin Cost Considerations (L) 1111
**Garton, Anne M.** (coauthor) see **Wiedrick, James E.D.,** 1109
**Garty, Ben Zion** (author) Erythema Multiforme and Hypersensitivity Myocarditis Caused by Ampicillin (CR) 730
**Gaughan, Linda M.** (coauthor) see **Whipple, Julianne K.,** 655
**Gavira, Rocio** (coauthor) see **Mataix, Angel L.,** 961
**Gea, Joaquim G.** (coauthor) see **Sauleda, Jaume,** 52
**Gearhart, Maureen O.** (author) Worsening of Liver Function with Fluconazole and Review of Azole Antifungal Hepatotoxicity (CR) 1177
**Gerber, David R.** (author) Optimizing Oxygen Delivery in Critical Illness (O) 1297
**Gericke, Kristin R.** (coauthor) see **Klose, Astrid D.,** 891
**Ghaeli, Padideh** (author) Triazolam Treatment Controversy (DIAS) 1038
**Ghalie, Richard** (author) Cyclosporine Monitoring Improves Graft-Versus-Host Disease Prophylaxis After Bone Marrow Transplantation (TM) 379
**Gidal, Barry E.** (author) Potential Pharmacokinetic Interaction Between Felbamate and Phenobarbital (CR) 455
**Gilmore, Linda L.** (coauthor) see **Eisele, George,** 849
**Gin, Alfred S.** (author) Comment: Single Daily Dosing of Aminoglycosides (L) 1412
**Glue, Paul** (author) Comment: Warfarin–Felbamate Interaction (L) 1412
**Goldberg, Harold I.** (coauthor) see **Christensen, Dale B.,** 99
**Goldman, Morton P.** (author) Authors' Reply: A Practical Alternative to Aminoglycoside Dosing (L) 809
**Goldspiel, Barry R.** (author) book review, 121; (author) Pharmaceutical Issues: Preparation, Administration, Stability, and Compatibility with Other Medications, (S) S23
**Gómez-Farran, Francesc** (coauthor) see **Llop, Roser,** 671
**Gonzalez, Edgar R.** (author) Over-the-Counter Histamine$_2$-Blocker Therapy (E) 392; (coauthor) see **Jones, Lori A.,** 841; (coauthor) see **Zarowitz, Barbara J.,** 245
**Gonzalo, Francisco Epelde** (author) Anaphylactic Shock Caused by Triamcinolone Acetonide (L) 1310
**Goodman, Norman L.** (coauthor) see **Rapp, Robert P.,** 1255
**Goodwin, S. Diane** (coauthor) see **Grasela, Thaddeus H. Jr.,** 252, 261; (editor) HIV and AIDS, 767
**Gora, Mary Lea** (coauthor) see **Andrews, Carlota O.,** 894
**Goss, Thomas F.** (author) Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area Under the Inhibitory Curve Is More Rapid for Ciprofloxacin than for Cefmenoxime (RPR) 863
**Gottlieb, Mark S.** (coauthor) see **Whipple, Julianne K.,** 446
**Grabenstein, John D.** (author) Correction: *ImmunoFacts* Review (L) 811
**Graber, Mark A.** (author) Sertraline–Phenelzine Drug Interaction: A Serotonin Syndrome Reaction (CR) 732
**Grandjean, Birgitte** (coauthor) see **Laursen, Torben,** 845
**Grasela, Thaddeus H., Jr.** (author) Alternatives to Intravenous Tetracycline Hydrochloride for Malignant Pleural Effusions (L) 968; (author) Use of Antifungal Therapy in Hospitalized Patients I. Results Prior to the Marketing of Fluconazole (PEP) 252; (author) Use of Antifungal Therapy in Hospitalized Patients II. Results After the Marketing of Fluconazole (PEP) 261; (coauthor) see **Welage, Lynda S.,** 515
**Gratz, Irwin** (coauthor) see **Larijani, Ghassem E.,** 179
**Grau, Enric** (author) Leukopenia Induced by Leuprolide Acetate Depot (L) 283
**Greenwood, Jan K.** (coauthor) see **Brown, Glen R.,** 626
**Greer, Richard A.** (author) book review, 674
**Grillo, Joseph A.** (coauthor) see **Gonzalez, Edgar R.,** 392
**Gualtieri, Richard J.** (coauthor) see **Cramer, Richard L.,** 458
**Guerriero, Stephanie** (coauthor) see **Ehrenpreis, Eli D.,** 1239
**Gunnarsdottir, Rannveig** (coauthor) see **Cleary, John D.,** 112
**Gutierrez, Rosario** (author) Vasculitis Associated with Amiodarone Treatment (L) 537; (coauthor) see **Carrión-Carrión, Carmen,** 1305

## H

**Hagley, Michael T.** (author) Adenosine Use in Pregnant Women with Supraventricular Tachycardia (CR) 1241; (author) Pronounced Metabolic Response to Modest Theophylline Overdose (CR) 195
**Haig, George M.** (coauthor) see **Pryka, Randy D.,** 1045
**Haines, Stuart T.** (author) Treatment of Infantile Spasms (PED) 779; (author) Twice-Daily Cefaclor Therapy (DIAS) 1353
**Hall, Kevin R.** (coauthor) see **Doering, Paul L.,** 390
**Hamili, Richard J.** (coauthor) see **Cadle, Richard M.,** 191
**Hammond, Connie M.** (author) Author's Reply: Single Daily Dosage of Lithium Carbonate (L) 1311; (author) Single Daily Dosage of Lithium Carbonate (DIAS) 472
**Hampton, Edward M.** (author) Intravenous Magnesium Therapy in Acute Myocardial Infarction (TC) 212; (coauthor) see **Whang, Robert,** 220
**Hanlon, Joseph T.** (coauthor) see **Landrum, Elizabeth M.,** 1172
**Hansen, Lori A.** (coauthor) see **Farver, Debra K.,** 1344
**Hansen, Robert W.** (author) Omnibus Budget Reconciliation Act of 1990 and Voluntarism: Logistic Regression Analysis of Pharmacist Responsibility (RPR) 1020
**Hapke, Ronald J.** (coauthor) see **Baciewicz, Anne M.,** 1310
**Haramburu, Françoise** (author) Strategy of Treatment of Pruritus During Pregnancy (RPR) 17
**Hart, Linda L.** (coauthor) see **King, Charles C.,** 59; (coauthor) see **McClinton-Adams, Jeannine L.,** 470; (coauthor) see **Park, Jennifer K.,** 57; (coauthor) see **Wildenradt, Suzanne Solem,** 475; (coeditor) see **Schroeder, Donna J.,** 54, 204, 336, 470
**Hartshorn, Edward A.** (editor) Drug Interactions and Reactions Update, 93, 236, 374, 643, 940
**Hartz, Arthur** (coauthor) see **Schectman, Gordon,** 29
**Hartzema, Abraham G.** (editor) Pharmacoepidemiology, 99, 252, 261, 515
**Hashimoto, Fred** (author) Hepatitis Following Treatments with Famotidine and then Cimetidine (CR) 37
**Hatoum, Hind T.** (author) Meta-Analysis of Controlled Trials of Drug Therapy in Mild Chronic Asthma: The Role of Inhaled Corticosteroids (PA) 1285
**Hatton, Jimmi** (author) Management of Bacterial Urinary Tract Infections in Adults (A) 1264
**Hatton, Randy C.** (coauthor) see **Levin, Anne C.,** 1371
**Hauben, Manfred** (author) Comment: Evening Primrose Oil in the Treatment of Rheumatoid Arthritis—Proper Application of Statistical Analysis (L) 973
**Haverkos, Gregory P.** (author) Fatal Seizures After Flumazenil Administration in a Patient with Mixed Overdose (CR) 1347
**Hay, Joel W.** (author) Comment: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist (L) 539
**Hayes, Peter** (coauthor) see **Henderson, Alan,** 1086
**Heiser, Jon F.** (author) book review, 1205
**Heller, Allen H.** (coauthor) see **Sramek, John J. Jr.,** 1143
**Helling, Dennis K.** (coauthor) see **Keith, Matthew R.,** 792
**Henderson, Alan** (author) Acetylcysteine as a Cytoprotective Antioxidant in Patients with Severe Sepsis: Potential New Use for an Old Drug (CC) 1086
**Henderson, Robert P.** (coauthor) see **Mezick, Sabrina L.,** 739
**Hewitt, Ross G.** (coauthor) see **Foisy, Michelle M.,** 1025
**Heyneman, Catherine A.** (author) Histamine$_2$-Antagonists in Allergic Disorders (DIAS) 742
**Hiatt, Jan** (coauthor) see **Schectman, Gordon,** 29
**Higa, Gerald M.** (author) Significance of Granulocyte Colony-Stimulating Factor-Induced Increases in LDH (L) 118
**Hill, Catherine L.** (coauthor) see **Alderman, Christopher P.,** 47
**Hilleman, Daniel E.** (coauthor) see **Mooss, Aryan N.,** 701
**Hipple, Thomas F.** (coauthor) see **Nahata, Milap C.,** 182
**Hirata, Wataru** (coauthor) see **Ohsawa, Tomoji,** 1303
**Hoehns, T. Brent** (coauthor) see **Graber, Mark A.,** 732
**Hoey, Lori L.** (author) Comment: Alcohol Withdrawal: What is the Benzodiazepine of Choice? (L) 972; (author) Does Ciprofloxacin Interact with Cyclosporine? (DIR) 93
**Holliday, Diane M.** (author) Heparin Dosing in the Morbidly Obese Patient (L) 1110
**Holmes, Mark D.** (coauthor) see **Roberts, Gregory W.,** 11
**Hooks, Michael A.** (author) Tacrolimus, A New Immunosuppressant—A Review of the Literature (NDD) 501
**Horie, Shigeo** (coauthor) see **Santa, Tomofumi,** 963
**Horiuchi, Yusuo** (coauthor) see **Ueno, Kazuyuki,** 281
**Horn, Susan D.** (coauthor) see **Evans, R. Scott,** 523
**Hornstra, Robijn K.** (coauthor) see **Marken, Patricia A.,** 1148
**Howard, Carol E.** (author) Use of Multiple-Dose Activated Charcoal in Phenytoin Toxicity (CR) 201; (coauthor) see **Capers, Christi C.,** 116
**Howard, Patricia A.** (author) Monitoring Warfarin Therapy with the International Normalized Ratio (TM) 242; (author) Treating Isolated Systolic Hypertension in the Elderly (G) 367
**Hunter, Claire B.** (coauthor) see **Mooss, Aryan N.,** 701
**Hunter, Walter J.** (author) Quality Improvement for Routine Screening and Diagnosis of Diarrheal Illness Identified from Adverse Drug Reaction Reporting (L) 1197
**Husain, Shakir** (coauthor) see **Mehndiratta, M.M.,** 285
**Huse, Daniel M.** (coauthor) see **Menzin, Joseph H.,** 271
**Hutchinson, Richard A.** (author) Need to Develop a Legal and Ethical Base for Pharmaceutical Care (O) 954
**Huynh, Lori A.** (author) Outcomes of Pregnancy and the Management of Immunosuppressive Agents to Minimize Fetal Risks in Organ Transplant Patients (DIAS) 1355
**Hwang, Soon Chul** (coauthor) see **Jeong, Chan Su,** 396

## I-J

**Iacono, Robert P.** (coauthor) see **Toyama, Suzanne C.,** 405
**Ibrahim, Zafar Y.** (author) Comment: Isoniazid-Induced Psychosis (L) 1311

**Idemyor, Vincent** (author) AIDS Epidemic: Can the African Countries Be Optimistic? (L) 286
**Iga, Tatsuji** (coauthor) see **Santa, Tomofumi,** 963
**Illum, Peter** (coauthor) see **Laursen, Torben,** 845
**Imhoff, Thomas E.** (coauthor) see **Haverkos, Gregory P.,** 1347
**Ippoliti, Cindy M.** (coauthor) see **Miller, Lisa J.,** 590
**Israel, Debra S.** (coauthor) see **Tisdel, Karen A.,** 805
**Israel, Marc K.** (coauthor) see **Scarfe, Mary A.,** 464
**Ito, Kiyomi** (coauthor) see **Santa, Tomofumi,** 963
**Jaffe, Ronen** (author) Adverse Interaction Between Clonidine and Verapamil (CR) 881
**Jamal, Aamir Z.** (coauthor) see **Mohammed, Suneel,** 285
**Jensen, Sigrid** (coauthor) see **Laursen, Torben,** 845
**Jeong, Chan Su** (author) Theophylline Disposition in Korean Patients with Congestive Heart Failure (IR) 396
**Jeong, Erwin W.S.** (coauthor) see **Chin, Alfred,** 35
**Jessen, Lois M.** (coauthor) see **Barone, Joseph A.,** 488
**Jewesson, Peter J.** (coauthor) see **Rayani, Shelina A.,** 852
**Jiménez, Manuel C.** (coauthor) see **Merino, Nieves,** 402
**Johnson, Gretchen L.** (author) Acute Renal Failure and Neurotoxicity Following Oral Acyclovir (CR) 460
**Johnson, Kjel A.** (coauthor) see **Trilli-Vidic, Lauren,** 1165
**Johnston, Thomas P.** (coauthor) see **Udeani, George O.,** 451
**Jolson, Heidi M.** (coauthor) see **Grasela, Thaddeus H. Jr.,** 968
**Jones, Daniel W.** (coauthor) see **Jeong, Chan Su,** 396
**Jones, Lori A.** (author) Assessment of 24-Hour Gastric pH Measurements in Trauma Patients Receiving Intravenous Famotidine by Intermittent Bolus Versus Continuous Infusion Administration (RPR) 841
**Jonville-Bera, Annie-Pierre E.** (author) Possible Pravastatin and Diuretics-Induced Diabetes Mellitus (L) 964
**Jørgensen, Jens Otto L.** (coauthor) see **Laursen, Torben,** 845
**Joseph, Joe** (author) Penetration of Intravenous and Oral Ciprofloxacin into Sterile and Empyemic Human Pleural Fluid (RPR) 313
**Joslin, Suzanne** (coauthor) see **Hoey, Lori L.,** 972
**Jurado, R.** (coauthor) see **Kindelán-Jaquotot, Jose Maria,** 1304

## K

**Kaizer, Herbert** (coauthor) see **Ghalie, Richard,** 379
**Kalachnik, John E.** (author) How Well Do Physicians, Pharmacists, and Psychologists Assess Tardive Dyskinesia Movements? (RPR) 185
**Kamada, Alan K.** (author) Salmeterol: Its Place in Asthma Management (PA) 1100; (author) Therapeutic Controversies in the Treatment of Asthma (PA) 904
**Kandrotas, Robert J.** (author) Author's Reply: Enoxaparin: The Low-Molecular-Weight Heparin for Prevention of Postoperative Thromboembolic Complications (L) 810; (author) Authors' Reply: Heparin Infusion Rates (L) 1312; (author) book review, 1316
**Kaplan, Barbara** (author) Chronic Hemodialysis Patients. Part 1: Characterization and Drug-Related Problems (RPR) 316; (author) Chronic Hemodialysis Patients. Part 2: Reducing Drug-Related Problems Through Application of the Focused Drug Therapy Review Program (RPR) 320; (coauthor) see **Verzino, Ellen M.,** 536
**Kaufman, Michele B.** (author) Adverse Effects Associated with Dexamethasone, Lorazepam and Granisetron (L) 1306; (coauthor) see **Garcia, Guadalupe,** 1199
**Kawabe, Kazuki** (coauthor) see **Santa, Tomofumi,** 963
**Kays, Michael B.** (coauthor) see **Friedrich, Lawrence V.,** 444
**Keith, Matthew R.** (author) Antiulcer Prescribing Program in a State Correctional System (PEC) 792
**Kelly, H. William** (coeditor) see **Milavetz, Gary,** 904, 1100, 1285
**Kelly, Michael W.** (coauthor) see **Yanchick, Jillmarie K.,** 970, 1245
**Kendall, Roger V.** (author) Comment: *N,N*-Dimethylglycine and L-Carnitine as Performance Enhancers in Athletes (L) 973
**Kendzierski, Donald L.** (coauthor) see **Hatoum, Hind T.,** 1285
**Keng, Arlene** (author) Evaluating the Accuracy of Citations in Drug Promotional Brochures (RPR) 1231
**Kennedy, Dianne L.** (coauthor) see **Grasela, Thaddeus H. Jr.,** 968
**Kerr, Harry D.** (coauthor) see **Brown, David F.,** 1307
**Kertland, Heather R.** (coauthor) see **Fagan, Susan C.,** 441
**Kim-Sing, Angela** (author) Palliative High-Dose Octerotide in a Case of Severe AIDS-Related Diarrhea (L) 806
**Kindelán-Jaquotot, Jose Maria** (author) Rifampin-Induced Severe Thrombocytopenia in a Patient with Pulmonary Tuberculosis (L) 1304
**King, Charles C.** (author) Epidural Administration of Methylprednisolone Acetate Preserved with Benzyl Alcohol (DIAS) 59
**Kintzel, Polly E.** (author) Otic Administration of Amphotericin B 0.25% in Sterile Water (CR) 333
**Kirkland, John L.** (coauthor) see **Lin, Tsu-Hui,** 570
**Kirkland, Rebecca T.** (coauthor) see **Lin, Tsu-Hui,** 570
**Klein, Julie** (coauthor) see **Taddio, Anna,** 585
**Klose, Astrid D.** (author) Fluorescein as a Circulation Determinant (DIAS) 891
**Knowles, Sandra** (author) Metronidazole Hypersensitivity (CR) 325
**Knox, Margot G.** (coauthor) see **Sketris, Ingrida S.,** 1227
**Koeller, Jim M.** (author) Introduction (S) S5; (author) Summary (S) S31; (editor) Pharmaceutical Issues of Paclitaxel (S)
**Koks, Cornelis H.W.** (coauthor) see **Burger, David M.,** 327
**Kolb, Kenneth W.** (coauthor) see **Tisdel, Karen A.,** 805
**Koren, Gideon** (coauthor) see **Taddio, Anna,** 585
**Korman, Lisa B.** (coauthor) see **Chapron, Dennis J.,** 874
**Kosirog-Glowacki, Jane L.** (author) Cyclophosphamide-Induced Facial Discomfort (CR) 197
**Kossey, Joyce L.** (author) Anaphylactoid Reactions Associated with Ondansetron (CR) 1029
**Kotaki, Hajime** (coauthor) see **Santa, Tomofumi,** 963
**Kraynak, Maura A.** (coauthor) see **Haines, Stuart T.,** 1353
**Krick, Stacie E.** (author) Pharmacy-Perceived Barriers to Cancer Pain Control: Results of the North Carolina Cancer Pain Initiative Pharmacist Survey (RPR) 857
**Krstenansky, Patrice M.** (author) Extrapyramidal Reaction Caused by Ondansetron (L) 280
**Kuhl, David A.** (author) Beta-Agonists in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (CC) 1379
**Kuhn, John G.** (author) Pharmacology and Pharmacokinetics of Paclitaxel, (S) S15
**Kumar, Neeraj** (coauthor) see **Mehndiratta, M.M.,** 285
**Kwok, Karl K.** (coauthor) see **Kossey, Joyce L.,** 1029
**Kyllonen, Kay S.** (coauthor) see **Wintermeyer, Susan M.,** 925

## L

**Lackner, Thomas E.** (author) Comment: A Practical Alternative to Conventional Aminoglycoside Dosing Methods (L) 809
**Lacombe, Sylvia** (coauthor) see **Marken, Patricia A.,** 1148
**Lake, Kathleen D.** (coauthor) see **Hoey, Lori L.,** 93
**Landrum, Elizabeth M.** (author) Prolonged Thrombocytopenia Associated with Procainamide in an Elderly Patient (CR) 1172
**Laporte, Joan-Ramon** (coauthor) see **Llop, Roser,** 671
**Lares-Asseff, Ismael** (author) Trimethoprim/Sulfamethoxazole Kinetics in Children with Biliary Atresia (L) 405
**Larijani, Ghassem E.** (author) Postoperative Nystagmus and Nausea (RPR) 179
**Laursen, Torben** (author) Nasal Absorption of Growth Hormone in Normal Subjects: Studies with Four Different Formulations (RPR) 845
**Learned-Coughlin, Susan M.** (author) Peripheral Neuropathy Induced by Metronidazole (L) 536
**Lee, Kenneth K.C.** (author) Pharmacists' Attitudes Toward Adverse Drug Reaction Reporting in Hong Kong (IR) 1400
**Lee, Susan** (author) book review, 1414
**Lettieri, John** (coauthor) see **Sramek, John J.,** 1143
**Levin, Anne C.** (author) Use of Nifedipine in the Hypertensive Diseases of Pregnancy (A) 1371
**Levin, Gary M.** (author) book review, 1414; (author) Comment: Single Daily Dosage of Lithium Carbonate (L) 1311
**Levine, Marc** (coauthor) see **McCormack, James P.,** 1112
**Levy, Gerhard** (author) Genesis of Clinical Pharmacokinetic/Pharmacodynamic Concepts: E.K. Marshall, Jr.'s Role (SC) 1300
**Lewis, Kelly S.** (coauthor) see **Whipple, Julianne K.,** 446, 655
**Lewis, Ronald H.** (coauthor) see **Maneatis, Thomas J.,** 539
**Lewis, William G.** (author) Systemic Absorption of Topical Phenytoin (L) 961
**Lieh-Lai, Mary** (coauthor) see **Biglin, Kevin E.,** 282
**Ligumsky, Moshe** (coauthor) see **Oren, Ran,** 883
**Limon, Lynn** (coauthor) see **Johnson, Gretchen L.,** 460
**Lin, Tsu-Hui** (author) Adult Height in Girls with Turner Syndrome Treated with Low-Dose Estrogens and Androgens (RPR) 570
**Lindenfeld, JoAnn** (coauthor) see **Stringer, Kathleen A.,** 97
**Lindley, Celeste M.** (coauthor) see **Krick, Stacie E.,** 857
**Lindoulsi, T.** (coauthor) see **Haramburu, Françoise,** 17
**Lindsay, Christine A.** (author) Stability and Activity of Intravenous Immunoglobulin with Neonatal Dextrose and Total Parenteral Nutrient Solutions (RPR) 1014
**Liu, Yong Qing** (coauthor) see **Lor, Edward,** 1035
**Livni, Ella** (coauthor) see **Garty, Ben Zion,** 730
**Livshits, Tatyana Azaz** (coauthor) see **Jaffe, Ronen,** 881
**Llop, Carles** (coauthor) see **Mateu, Javier,** 967
**Llop, Roser** (author) Gynecomastia Associated with Enalapril and Diazepam (L) 671
**Lober, Cheril A.** (coauthor) see **Carson, John J.,** 403
**Locatelli, Franco** (coauthor) see **Buggia, Isabella,** 1055
**Loftsson, Thorsteinn** (coauthor) see **Cleary, John D.,** 112
**LoGerfo, James P.** (coauthor) see **Christensen, Dale B.,** 99
**Lohman, Joseph J.H.M.** (author) book review, 1205
**Lombardi, Thomas P.** (author) book review, 287
**Long, Gwynn** (coauthor) see **Krstenansky, Patrice M.,** 280
**Lor, Edward** (author) Neurologic Sequelae Associated with Foscarnet Therapy (CR) 1035
**Lossos, Alexander** (coauthor) see **Lossos, Izidore S.,** 807
**Lossos, Izidore S.** (author) Hazards of Rapid Administration of Ceftriaxone (L) 807
**Loughlin, Kathleen A.** (author) Oral Treatment of Gonorrhea and Chlamydia (DIAS) 600
**Louisot, Pierre** (coauthor) see **Caben, Rémi,** 49
**Lourwood, David L.** (coauthor) see **Erramouspe, John,** 474
**Luby, Victoria** (coauthor) see **Robinson, Dave,** 1411
**Lugo, Ralph A.** (author) Stability of Diluted Dexamethasone Sodium Phosphate Injection at Two Temperatures (RPR) 1018
**Luisi, Andrea F.** (author) Cyclosporine for the Treatment of Pemphigus Vulgaris (DIAS) 1183
**Luoma, Tim** (coauthor) see **Slywka, Jodi,** 1312
**Lustig, Ahuva** (author) Pharmacists as Members of the Health Team in Israel: Sectoral Differences (IR) 276
**Lynch, Shalini S.** (coeditor) see **Schroeder, Donna J.,** 54, 204, 336, 470, 595, 736, 886, 1038

## M

**Maddix, Daniel S.** (author) Rifabutin: A Review with Emphasis on Its Role in the Prevention of Disseminated *Mycobacterium avium* Complex Infection (FF) 1250
**Maesner, Jon E.** (coauthor) see **Carlson, James A.,** 1236
**Magne, F.** (coauthor) see **Haramburu, Françoise,** 17
**Magnusson, Einar** (coauthor) see **Cleary, John D.,** 112
**Magraner, José** (coauthor) see **Rodilla, Francisco,** 672, 1305
**Mahoney, Janelle M.** (author) Pleural Effusion Associated with Chronic Dantrolene Administration (CR) 587
**Makela, Eugene H.** (coauthor) see **Bird, Rebecca D.,** 67
**Mallet, Jacques** (coauthor) see **Mallet, Louise,** 1169
**Mallet, Louise** (author) Immunization Requirements for Pharmacy Students (RPR) 1153; (author) Ticlopidine and Fatal Aplastic Anemia in an Elderly Woman (CR) 1169
**Maneatis, Thomas J.** (author) Comment: Ketorolac and Gastrointestinal Ulceration (L) 539; (coauthor) see **Baboolal, Susan M.,** 1201
**Manson, Sharon** (coauthor) see **Ghalie, Richard,** 379
**Marken, Patricia A.** (author) Preliminary Comparison of Predictive and Empiric Lithium Dosing: Impact on Patient Outcome (RPR) 1143
**Marshall, Judith M.** (author) Interaction of Histamine$_2$-Receptor Antagonists and Ethanol (DIAS) 55
**Martin, Ambroise** (coauthor) see **Caben, Rémi,** 49
**Martin, Diane P.** (coauthor) see **Christensen, Dale B.,** 99
**Martinusen, Shelagh M.** (coauthor) see **Rayani, Shelina A.,** 852
**Marx, Celeste M.** (coauthor) see **Reed, Michael D.,** 331
**Mason, Nancy A.** (coauthor) see **Kaplan, Barbara,** 316, 320
**Masuhara, Keisou** (coauthor) see **Ohsawa, Tomoji,** 1303
**Mataix, Angel L.** (author) Oral Acyclovir and Neurologic Adverse Effects in Endstage Renal Disease (L) 961
**Mateu, Javier** (author) Delayed Treatment of Vindesine Extravasation (L) 967; (author) Ifosfamide Extravasation (CR) 1243
**Matthie, James R.** (coauthor) see **Patel, Rakesh V.,** 565
**Matzke, Gary R.** (author) Pharmacotherapeutic Consequences of Recent Advances in Hemodialysis Therapy (RA) 512
**Mauro, Laurie S.** (author) Misadventures with Activated Charcoal and Recommendations for Safe Use (CC) 915; (coauthor) see **Kuhl, David A.,** 1379
**Mauro, Vincent F.** (coauthor) see **Chesser, Stephen L.,** 204; (coauthor) see **Mauro, Laurie S.,** 915
**Mazumdar, Debesh C.** (coauthor) see **Weir, Brian A.,** 199, 1203
**McAlister, Vivian** (coauthor) see **Sketris, Ingrida S.,** 962
**McCarthy, Margaret L.** (author) Estrogen Therapy of Uremic Bleeding (DIAS) 60
**McCarthy, Michelle W.** (author) Aprotinin for Prophylaxis of Blood Loss (DIAS) 1246
**McClinton-Adams, Jeannine L.** (author) Cancer Prevention with Beta Carotene (DIAS) 470
**McCormack, James P.** (author) Authors' Reply: Risk Reduction from Clinical Trials Adjusted on an Annual Basis (L) 1112
**McCraney, Scott A.** (coauthor) see **Rapp, Robert P.,** 1255
**McCrary, Kay E.** (coauthor) see **Marken, Patricia A.,** 1148
**McGhan, William F** (editor) Pharmacoeconomics, 105, 271, 384, 528, 659, 792
**McIntire, Lynn C.** (author) Ticarcillin/Clavulanate Desensitization Protocol (L) 1200
**McQueen, Kellie D.** (author) Multicenter Postmarketing Surveillance of Ondansetron Therapy in Pediatric Patients (PED) 85
**Mead, Paul S.** (coauthor) see **Maddix, Daniel S.,** 1250
**Meenhorst, Pieter L.** (coauthor) see **Burger, David M.,** 327
**Mehndiratta, M.M.** (author) Leptazol-Induced Seizures (L) 285
**Menke, Jennifer J.** (coauthor) see **Baciewicz, Anne M.,** 1111; (coauthor) see **Ibrahim, Zafar Y.,** 1311
**Menzin, Joseph H.** (author) Prevention of Deep-Vein Thrombosis Following Total Hip-Replacement Surgery with Enoxa-

parin Versus Unfractionated Heparin: A Pharmacoeconomic Evaluation (PEC) 271
**Merino, Nieves** (author) Multisystem Hypersensitivity Reaction to Carbamazepine (L) 402
**Methot, Michelle E.** (coauthor) see **Sketris, Ingrida S.,** 1227
**Mezick, Sabrina L.** (author) Is Somatostatin Effective in the Treatment of Acute Bleeding Caused by Esophageal Varices? (DIAS) 739
**Miconi, Lorella** (coauthor) see **Schifano, Fabrizio,** 537
**Mihm, Linda M.** (author) Tamoxifen-Induced Ocular Toxicity (DIAS) 740
**Milavetz, Gary** (coauthor) see **Sorofman, Bernard,** 1290; (editor) Pulmonary and Allergy, 904, 1100, 1285
**Miller, Lisa J.** (author) Treatment of Cyclophosphamide-Induced Hemorrhagic Cystitis with Prostaglandins (CR) 590
**Miller, Terry** (coauthor) see **Robinson, Dave,** 1411
**Mills, Glenn M.** (coauthor) see **Phillips, David E.,** 43
**Milton, Jerrod D.** (coauthor) see **McQueen, Kellie D.,** 85
**Min, David I.** (coauthor) see **Huynh, Lori A.,** 1355
**Miyagi, Susan L.** (coauthor) see **Camp, Kimberly A.,** 336
**Mohammed, Kader N.** (author) Nifedipine-Induced Exfoliative Dermatitis and Pedal Edema (L) 967
**Mohammed, Suneel** (author) Serum Sickness-Like Illness Associated with *N*-Acetylcysteine Therapy (L) 285
**Mohiuddin, Syed M.** (coauthor) see **Mooss, Aryan N.,** 701
**Montagut, Lluis Boada** (coauthor) see **Gonzalo, Francisco Epelde,** 1310
**Monte, Emilio** (coauthor) see **Gallego, Concepción,** 940
**Montminy, Patrice** (coauthor) see **Parent, Marc,** 284
**Mooss, Aryan N.** (author) Safety of Esmolol in Patients with Acute Myocardial Infarction Treated with Thrombolytic Therapy Who Had Relative Contraindications to Beta-Blocker Therapy (RPR) 701
**Morgan, Douglas E.** (coauthor) see **Teresi, Mary E.,** 576
**Morosco, Richard S.** (coauthor) see **Nahata, Milap C.,** 182
**Morse, Gene D.** (coauthor) see **Foisy, Michelle M.,** 1025
**Moser, Eileen M.** (coauthor) see **Fan-Havard, Patty,** 869
**Moser, Jason E.** (coauthor) see **Cimino, Michael A.,** 105
**Moye, Robert A.** (coauthor) see **Howard, Carol E.,** 201
**Munar, Myrna Y.** (author) book review, 1114
**Mungall, Dennis R.** (coauthor) see **Slywka, Jodi,** 1312

## N-O

**Nahata, Milap C.** (author) Conducting Pediatric Research (SC) 1105; (author) Effect of Preparation Method and Storage on Rifampin Concentration in Suspensions (RPR) 182; (author) Need for Conducting Research on Medications Unlabeled for Use in Pediatric Patients (E) 1103; (author) Pharmacist's Role in Improving Immunization Status Among Preschool Children (E) 952; (coauthor) see **Bates, Richard D.,** 757; (coauthor) see **Lugo, Ralph A.,** 1018; (coauthor) see **Wintermeyer, Susan M.,** 925, 1089
**Nawarskas, James J.** (coauthor) see **Mauro, Laurie S.,** 915
**Nelson, C. Don** (author) book review, 409
**Nesser, Mary Ellen** (coauthor) see **Seifert, Charles F.,** 1063
**Nickman, Nancy A.** (author) book review, 1206
**Nickoloff, Donna** (coauthor) see **Rayani, Shelina A.,** 852
**Nicol, David** (coauthor) see **Sketris, Ingrida S.,** 1227
**Nii, Leslie J.** (coauthor) see **Chin, Alfred,** 35
**Nilsen, A. Kari** (coauthor) see **Caldwell, James B.,** 806
**Nimmo, Cindy J. Reesor** (coauthor) see **Rayani, Shelina A.,** 852
**Nishihara, Kazuyo** (coauthor) see **Santa, Tomofumi,** 963
**Nix, David E.** (coauthor) see **Goss, Thomas F.,** 863
**Nogueras, Juan J.** (coauthor) see **Ehrenpreis, Eli D.,** 1239
**Occhipinti, Donna J.** (coauthor) see **Danziger, Larry H.,** 703
**Offer, Itamar** (coauthor) see **Garty, Ben Zion,** 730
**Oh, Julee** (coauthor) see **Fan-Havard, Patty,** 869
**Ohri, Linda K.** (author) Computer Resources for Student Use at US Colleges of Pharmacy (L) 970
**Ohsawa, Tomoji** (author) Reversal of Ranitidine-Induced Hypergastrinemia by Cimetidine (L) 1303
**Okada, Fumihiko** (author) New versus Old Placebos (L) 1201
**Oliphant, Catherine M.** (coauthor) see **Zanetti, Leslie A. Farquhar,** 282
**Omar, Sabiha J.** (coauthor) see **Robinson, Dave,** 1411
**O'Mara, Neeta Bahal** (author) Naltrexone in the Treatment of Alcohol Dependence (DIAS) 210
**Oren, Ran** (author) Indomethacin-Induced Colonic Ulceration and Bleeding (CR) 883
**Orovitg, Francisco** (coauthor) see **Rodilla, Francisco,** 1305
**Oster, Gerry** (coauthor) see **Menzin, Joseph H.,** 271
**Osterhaus, Jane T.** (coauthor) see **Clouse, Jon C.,** 659
**Otten, Nicolaas H.H.** (coauthor) see **Wiedrick, James E.D.,** 1109
**Otto, Carsten** (author) Syndrome of Inappropriate ADH Secretion Induced by Different Drugs (L) 1199
**Ou, Ching-Nan,** (coauthor) see **Lindsay, Christine A.,** 1014
**Ovesen, Per** (coauthor) see **Laursen, Torben,** 845
**Oymak, Oktay** (author) Reversible Neutropenia and Thrombocytopenia During Famotidine Treatment (L) 406

## P

**Paap, Christopher M.** (author) Comment: Vancomycin Serum Concentration Monitoring (L) 972
**Paladino, Joseph A.** (author) Pharmaceutical Care at Tayside, Scotland (L) 120; (author) Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia (PEC) 384
**Pallardó, Luis M.** (coauthor) see **Gallego, Concepción,** 940
**Palmer, Jonathan L.** (coauthor) see **Forster, Eliot R.,** 1203
**Parent, Marc** (author) Weight Gain Associated with Long-Term Oral Ketorolac-Tromethamine (L) 284
**Park, Jennifer K.** (author) Prophylactic Topical Antibiotics in Dentistry (DIAS) 57
**Parkin, Donald P.** (coauthor) see **Donald, Peter R.,** 1340
**Pasko, Mary T.** (coauthor) see **Grasela, Thaddeus H.,** 252, 261
**Pastó, Meritxell** (coauthor) see **Sauleda, Jaume,** 52
**Patel, Rakesh V.** (author) Estimation of Total Body and Extracellular Water Using Single- and Multiple-Frequency Impedance (RPR) 565
**Patterson, Betty D.** (author) Possible Interaction Between Metronidazole and Carbamazepine (L) 1303
**Payne, D. Keith** (coauthor) see **Phillips, David E.,** 43
**Peloquin, Charles A.** (author) Clarification: Controversies in the Management of *Mycobacterium avium* Complex Infection in AIDS (L) 808; (author) Infection Caused by *Mycobacterium tuberculosis* (A) 72
**Pere, J.C.** (coauthor) see **Haramburu, Françoise,** 17
**Pérez-Guillé, Gabriela** (coauthor) see **Lares-Asseff, Ismael,** 405
**Perhach, James L.** (coauthor) see **Glue, Paul,** 1412
**Perry, Paul J.** (coauthor) see **Graber, Mark A.,** 732
**Pestotnik, Stanley L.** (coauthor) see **Evans, R. Scott,** 523
**Peterson, Edward L.** (coauthor) see **Patel, Rakesh V.,** 565
**Petree, Jan** (coauthor) see **Krstenansky, Patrice M.,** 280
**Phillips, David E.** (author) Heparin-Induced Thrombotic Thrombocytopenia (CR) 43
**Pierce, Christine A.** (coauthor) see **Marken, Patricia A.,** 1148
**Pierce, J. Rush, Jr.** (author) Stroke Following Application of a Nicotine Patch (L) 402
**Pincus, Kelly T.** (coauthor) see **Ohri, Linda K.,** 970
**Piscitelli, Stephen C.** (coauthor) see **Danziger, Larry H.,** 703
**Pitcher, Anne** (coauthor) see **Roberts, Gregory W.,** 11
**Pitterle, Michael E.** (coauthor) see **Bond, C.A.,** 21
**Planells, Carmen** (coauthor) see **Gallego, Concepción,** 940
**Plastino, Kristen A.** (author) Possible Synergy Between Aminoglycosides and Vancomycin in the Treatment of *Staphylococcus epidermidis* Endocarditis? (DIAS) 737
**Pons, Jean-Claude** (coauthor) see **Bourget, Phillippe,** 1031
**Ponte, Charles D.** (author) Communication Strategies for the Pharmacist—Personal Axioms (L) 538; (author) Pharmaceutical Care and Women's Health Issues—The Challenge for the 1990s (L) 969
**Poon, Cathy Y.** (coauthor) see **Vaughan, Leigh M.,** 572
**Porta, Miquel S.** (coeditor) see **Hartzema, Abraham G.,** 99, 252, 261, 515
**Powers, James S.** (coauthor) see **Capers, Christi C.,** 116
**Premer, Marcie B.** (coauthor) see **Tom, Gary R.,** 889
**Price, Stephen D.** (coauthor) see **Wright, Julie M.,** 309, 1202
**Privitera, Michael D.** (author) Author's Reply: Clinical Rules for Phenytoin Dosing (L) 808
**Pruemer, Jane M.** (author) book review, 813
**Pryka, Randy D.** (author) Meropenem: A New Carbapenem Antimicrobial (FF) 1045; (author) Vancomycin Serum Concentration Monitoring: A Continued Debate (E) 1397
**Puig, Margarita M.** (coauthor) see **Gallart, Lluis,** 969
**Purdum, Preston P., III** (author) Oxaprozin-Induced Fulminant Hepatitis (CR) 1159
**Pylypchuk, George B.** (coauthor) see **Sharif, M. Nabi,** 720

## Q-R

**Quebbeman, Edward J.** (coauthor) see **Whipple, Julianne K.,** 446, 655
**Raebel, Marsha A.** (coauthor) see **Grasela, Thaddeus H.,** 252; (coeditor) see **Thompson, Dennis F.,** 63, 67, 212, 343, 353, 478, 483, 604
**Raehl, Cynthia L.** (coauthor) see **Bond, C.A.,** 21
**Ramakrishnan, Radha R.** (coauthor) see **Chin, Alfred,** 35
**Ranelli, Paul L.** (coauthor) see **Hansen, Robert W.,** 1020
**Rapp, Robert P.** (author) New Macrolide Antibiotics: Usefulness in Infections Caused by Mycobacteria Other than *Mycobacterium tuberculosis* (DSP) 1255
**Ravella, Ramón** (coauthor) see **Merino, Nieves,** 402
**Rayani, Shelina A.** (author) Implementation and Evaluation of a Standardized Herpes Simplex Virus Prophylaxis Protocol on a Leukemia/Bone Marrow Transplant Unit (RPR) 852
**Raymond, Claire H.** (coauthor) see **Hation, Jimmi,** 1264
**Raymond, Kenneth** (coauthor) see **Lee, Kenneth K.C.,** 1400
**Real, Esperanza** (coauthor) see **Grau, Enric,** 283
**Reece, Donna E.** (coauthor) see **Rayani, Shelina A.,** 852
**Reed, Michael D.** (author) Ondansetron for Treating Nausea and Vomiting in the Poisoned Patient (CR) 331; (editor) Pediatrics, 85, 633, 779, 925, 1089
**Regazzi, Mario B.** (coauthor) see **Buggia, Isabella,** 1055
**Reines, H. David** (coauthor) see **Jones, Lori A.,** 841
**Rello, Jordi** (coauthor) see **Saura, Pilar,** 1308
**Resman-Targoff, Beth H.** (coauthor) see **Delafuente, Jeffrey C.,** 650
**Resnick, Daniel** (coauthor) see **Danziger, Larry H.,** 703
**Revuelta, Katia** (coauthor) see **Matais, Angel L.,** 961
**Rhodes, Richard S.** (coauthor) see **Lewis, William G.,** 961
**Ricart-Engel, Wilfredo** (coauthor) see **Fernández-Real, Jose Manuel,** 1200
**Richner, Randel** (coauthor) see **Menzin, Joseph H.,** 271
**Richter, Werner O.** (coauthor) see **Otto, Carsten,** 1199
**Ritchie, David J.** (author) Update on the Management of Intestinal Cryptosporidiosis in AIDS (AIDS) 767
**Roberts, Gregory W.** (author) Clobazam and *N*-Desmethylclobazam Serum Concentrations in Endstage Renal Failure and Hemodialysis (L) 966; (author) Peripheral Intravenous Line Survival and Phlebitis Prevention in Patients Receiving IV Antibiotics: Heparin/Hydrocortisone Versus In-Line Filters (RPR) 11
**Roberts, R. Shane** (coauthor) see **Howard, Carol E.,** 201
**Robinson, Dave** (author) Anxiety Disorder and Pyridoxal Phosphate—A Possible Association (L) 1411
**Robinson, J. Daniel** (editor) Therapeutic Monitoring, 242, 379, 944
**Robison, Leon R.** (coauthor) see **Mohammed, Suneel,** 285
**Rodilla, Francisco** (author) Amphotericin B for Visceral Leishmaniasis Resistant to Pentavalent Antimonial Drugs in AIDS (L) 1305; (author) Current Treatment Recommendations for Cutaneous Larva Migrans (L) 672
**Rodriguez, Luis F.** (author) Benzocaine-Induced Methemoglobinemia: Report of a Severe Reaction and Review of the Literature (DIR) 643
**Rodriguez-Barradas, Maria** (coauthor) see **Cadle, Richard M.,** 191
**Rodvold, Keith A.** (coauthor) see **Danziger, Larry H.,** 703
**Rohatgi, Anshu** (coauthor) see **Mehndiratta, M.M.,** 285
**Romá, Eva** (coauthor) see **Gallego, Concepción,** 940
**Roth, John D.** (coauthor) see **Ament, Paul W.,** 40
**Rotschafer, John C.** (author) Single Daily Dosing of Aminoglycosides: A Commentary (E) 797
**Rotstein, Coleman M.** (coauthor) see **Cimino, Michael A.,** 105
**Rouch, Donna R.** (coauthor) see **Ohri, Linda K.,** 970
**Rovers, John P.** (author) Assessment of Methods and Outcomes: Using Modified Inpatient Ciprofloxacin Criteria in Community-Based Drug Use Evaluation (RPR) 714
**Rowinsky, Eric K.** (author) Update on the Antitumor Activity of Paclitaxel in Clinical Trials (S) 518; (coauthor) see **Finley, Rebecca S.,** 827
**Ruiz, Maria Dolores** (coauthor) see **Matais, Angel L.,** 961
**Rupp, Michael T.** (coauthor) see **Wolfgang, Alan P.,** 802
**Rybak, Michael J.** (coauthor) see **Loughlin, Kathleen A.,** 600; (coauthor) see **Rotschafer, John C.,** 797
**Ryder, Kenneth W.** (coauthor) see **Flack, John M.,** 175
**Ryu, Hwan Sun** (coauthor) see **Jeong, Chan Su,** 396

## S

**Sacristan, Jose Antonio** (author) Authors' Reply: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist (L) 539
**Saltiel, Emmanuel** (author) Comment: Enoxaparin—The Low-Molecular-Weight Heparin for Prevention of Postoperative Thromboembolic Complications (L) 810
**Samsó, Enric** (coauthor) see **Gallart, Lluis,** 969
**Sánchez, Jaime** (coauthor) see **Gallego, Concepción,** 940
**Sánchez, Pilar** (coauthor) see **Gallego, Concepción,** 940
**Sánchez, Santiago** (coauthor) see **Gallego, Concepción,** 940
**Sanchorawala, Vaishali** (coauthor) see **Fan-Havard, Patty,** 869
**Sands, Charles D.** (coauthor) see **Jeong, Chan Su,** 396
**Santa, Tomofumi** (author) Decreased Cyclosporine Absorption After Treatment with GoLytely Lavage Solution in a Kidney Transplant Patient (L) 963
**Sauleda, Jaume** (author) Probable Pentamidine-Induced Acute Pancreatitis (CR) 52
**Saura, Pilar** (author) Severe Bleeding in Postoperative Patients with Infections (L) 1308
**Sawada, Yasufumi** (coauthor) see **Santa, Tomofumi,** 963
**Sawin, Suzanne** (coauthor) see **Sramek, John J. Jr.,** 1143
**Saya, Frank** (coauthor) see **Saltiel, Emmanuel,** 810
**Scarfe, Mary A.** (author) Possible Drug Interaction Between Warfarin and Combination of Levamisole and Fluorouracil (CR) 464
**Schauben, Pamela** (coauthor) see **Frenia, Maureen L.,** 736
**Schectman, Gordon** (author) Telephone Contacts Do Not Improve Adherence to Niacin or Bile Acid Sequestrant Therapy (RPR) 29
**Schentag, Jerome J.** (coauthor) see **Goss, Thomas F.,** 863
**Schifano, Fabrizio** (author) Addictive Potential of Trimebutine (L) 537
**Schlicht, John R.** (author) Treatment of Bacterial Vaginosis (TC) 483
**Schroeder, Donna J.** (coauthor) see **Camp, Kimberly A.,** 336; (coauthor) see **Floren, Leslie Carstensen,** 1040; (coauthor)

see **Vita, Eleadon O.**, 1182; (coauthor) see **Yasuda, Joanne M.**, 338; (editor) DIAS Rounds, 54, 204, 336, 470, 595, 736, 886, 1038, 1182, 1245, 1353
**Schuckman, Hugh** (coauthor) see **Hagley, Michael T.**, 195
**Schumock, Glen Thomas** (coauthor) see **Hatoum, Hind T.**, 1285; (coauthor) see **Hutchinson, Richard A.**, 954
**Schweitzer, Michele S.** (author) Cromolyn Use in Young Children (DIAS) 886
**Seifart, Heiner I.** (coauthor) see **Donald Peter R.**, 1340
**Seifert, Charles F.** (author) Correction: Dexrazoxane (L) 1413; (author) Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity (A) 1063
**Seifert, Lynn L.** (coauthor) see **Wong, Wendy M.**, 890
**Seifert, Randall D.** (coauthor) see **Cutler, Neal R.**, 117
**Sempere, Jordi** (coauthor) see **Grau, Enric**, 283
**Serrano, I.** (coauthor) see **Kindelán-Jaquotot, Jose Maria**, 1304
**Shaddick, David J.** (coauthor) see **Rapp, Robert P.**, 1255
**Shaefer, Mark S.** (author) Interaction Between FK506 and Erythromycin (L) 280
**Sharif, M. Nabi** (author) Cough Induced by Quinapril with Resolution After Changing to Fosinopril (CR) 720
**Shear, Neil H.** (coauthor) see **Knowles, Sandra**, 325
**Shelden, Stacey L.** (coauthor) see **Purdum, Preston P. III**, 1159
**Sherman, Olga** (author) Possible Ciprofloxacin-Induced Acute Cholestatic Jaundice (CR) 1162
**Shibuya, Fuminori** (coauthor) see **Santa, Tomofumi**, 963
**Shiffman, Mitchell L.** (coauthor) see **Purdum, Preston P. III**, 1159
**Shimp, Leslie A.** (coauthor) see **Kaplan, Barbara**, 316, 320
**Shinohara, Y. Todd** (author) Vancomycin-Induced Neutropenia During Treatment of Endocarditis in a Pediatric Patient (CR) 723
**Shiokawa, Mieko** (coauthor) see **Ueno, Kazuyuki**, 281
**Siegert, Elisabeth A.** (coauthor) see **Landrum, Elizabeth M.**, 1172
**Sinha, Renu** (coauthor) see **Dick, Michael R.**, 837
**Sketris, Ingrida S.** (author) Effect of Calcium-Channel Blockers on Cyclosporine Clearance and Use in Renal Transplant Patients (RPR) 1227; (author) Increased Cyclosporine Bioavailability from a Microemulsion Formulation in a Liver Transplant Recipient (L) 962
**Skoutakis, Vasilios A.** (coauthor) see **Carter, Charles A.**, 810
**Slaughter, Richard L.** (author) Clinical Interventions Provided by Doctor of Pharmacy Students (ET) 665
**Slayter, Kathryn L.** (coauthor) see **Foisy, Michelle M.**, 1025
**Slywka, Jodi** (author) Comment: Heparin Infusion Rates (L) 1312
**Smith, Gary H.** (coauthor) see **Baker, Danial E.**, 1389
**Smith, Scott R.** (coauthor) see **Buchanan, Robert J.**, 528
**Smith, Steven P.** (coauthor) see **Fan-Havard, Patty**, 869
**Smith, Timothy M.** (author) Lack of Nephrotoxicity with the Administration of Amphotericin B in a Lipid Emulsion (L) 1307
**Smolik, Lynn M.** (coauthor) see **Rodriguez, Luis F.**, 643
**Smythe, Maureen A.** (author) Changing Perspectives of Stress Gastritis Prophylaxis (A) 1073
**Sohn, Kieho** (coauthor) see **Jeong, Chan Su**, 396
**Sommi, Roger W., Jr.** (coauthor) see **Marken, Patricia A.**, 1148
**Sorofman, Bernard** (author) Meta-Analysis and the Scientific Research that Precedes It (E) 1290
**Sorrell, Michael F.** (coauthor) see **Shaefer, Mark S.**, 280
**Soto, Jovier A.** (coauthor) see **Sacristán, José Antonio**, 539
**Spahn, Joseph D.** (coauthor) see **Kamada, Alan K.**, 1100
**Spinler, Sarah A.** (author) Lipoprotein(a): Physiologic Function, Association with Atherosclerosis, and Effects of Lipid-Lowering Drug Therapy (TC) 343; (coauthor) see **Cheng, Judy W.M.**, 604; (coauthor) see **Plastino, Kristen A.**, 737; (coauthor) see **Wittbrodt, Eric T.**, 236
**Sprague, Robert L.** (coauthor) see **Kalachnik, John E.**, 185
**Sramek, John J.**, (author) book review, 410; (author) Safety and Tolerance of Intravenous Nimodipine (RPR) 1143; (coauthor) see **Cutler, Neal R.**, 117
**St. Clair, Patricia** (coauthor) see **Cutler, Neal R.**, 117
**Stanislav, Steven W.** (coauthor) see **Marken, Patricia A.**, 1148
**Staugas, Rima E.M.** (coauthor) see **Roberts, Gregory W.**, 11
**Steadman, Brenda K.** (coauthor) see **Gales, Mark A.**, 597
**Stewart, Ronald B.** (editor) Geriatrics and Gerontology, 367
**Stock, Christopher J.** (author) book review, 975; (author) Comment: Alcohol Withdrawal: What is the Benzodiazepine of Choice? (L) 971
**Stoukides, Cheryl A.** (coauthor) see **Copeland, Debra A.**, 1042; (coauthor) see **Croze, Sheila M.**, 208; (coauthor) see **Ghaeli, Padideh**, 1038; (coauthor) see **Luisi, Andrea F.**, 1183; (coauthor) see **McCarthy, Margaret L.**, 60
**Strickland, Daniel** (coauthor) see **Flack, John M.**, 175
**Stringer, Kathleen A.** (author) Beyond Thrombolysis: Other Effects of Thrombolytic Drugs (A) 752; (author) The GUSTO Trial: Is the Open-Artery Hypothesis Proven? (E) 97
**Strozyk, William R.** (coauthor) see **Smith, Timothy M.**, 1307
**Sudan, Bernard J.L.** (author) Comment: Niacin, Nicotine and Flushing (L) 1113
**Sundaresan, Pavur R.** (coauthor) see **Sramek, John J.**, 1143
**Sungur, Cem** (author) Acute Hepatitis Caused by Tenoxicam (L) 1309; (author) Acute Rheumatic Fever Despite Clarithromycin Treatment for Beta-Hemolytic Streptococcal Tonsillitis (L) 1197
**Sylvia, Lynne M.** (coauthor) see **Foster, Jessica A.**, 1185

## T

**Taddio, Anna** (author) Acyclovir Excretion in Human Breast Milk (CR) 585
**Tagupa, Eumar T.** (coauthor) see **Watson, Jerry E.**, 467
**Tallian, Kimberly B.** (coauthor) see **Maddix, Daniel S.**, 1250
**Tanaka, Kazuhiko** (coauthor) see **Ueno, Kazuyuki**, 281
**Teng, Elton** (author) Lidocaine in Status Epilepticus (DIAS) 1248
**Teresi, Mary E.** (author) Attitudes of Healthcare Professionals Toward Patient Counseling on Drug–Nutrient Interactions (RPR) 576
**Thomas, Joe, III** (author) book review, 1317
**Thompson, Dennis F.** (author) Deferoxamine Treatment of Malaria (DIAS) 602; (author) Reassessment of Measuring Total Iron Binding Capacity in Acute Iron Overdose (TC) 63; (coauthor) see **Seifert, Charles F.**, 1063; (editor) Therapeutic Controversies, 63, 67, 212, 343, 353, 478, 483, 604
**Thomson, Peter A.** (coauthor) see **Slaughter, Richard L.**, 665
**Tietjen, Gretchen E.** (coauthor) see **Fagan, Susan C.**, 441
**Tilson, Hugh H.** (coeditor) see **Hartzema, Abraham G.**, 99, 252, 261, 515
**Timm, Edward G.** (coauthor) see **Welage, Lynda S.**, 515
**Tinklenberg, Jared** (coauthor) see **Robinson, Dave**, 1411
**Tisdel, Karen A.** (author) Warfarin–Felbamate Interaction: First Report (L) 805
**Todd, Christine Y.** (coauthor) see **Baciewicz, Anne M.**, 1310
**Toledo, Alejandra** (coauthor) see **Lares-Asseff, Ismael**, 405
**Toler, Steven M.** (author) Comment: Clinical Rules for Phenytoin Dosing (L) 808
**Tolfo, Luigi** (coauthor) see **Zogno, Maria G.**, 406
**Tom, Gary R.** (author) Hydrocortisone Cream in Clonidine Patch Dermatitis (DIAS) 889
**Tomlinson, Brian** (coauthor) see **Chan, Thomas Y.K.**, 119
**Torre Cisneros, J.** (coauthor) see **Kindelán-Jaquotot, Jose Maria**, 1304
**Torrecilla, Teresa** (coauthor) see **Grau, Enric**, 283
**Townsend, Raymond J.** (coeditor) see **McGhan, William F.**, 105, 271, 384, 528, 659, 792
**Toyama, Suzanne C.** (author) Is It Safe to Combine a Selective Serotonin Reuptake Inhibitor with Selegiline? (L) 405
**Traeger, Sheldon M.** (coauthor) see **Hagley, Michael T.**, 195
**Trausch, Diane E.** (coauthor) see **Kintzel, Polly E.**, 333
**Trikha, Gita** (coauthor) see **Johnson, Gretchen L.**, 460
**Trilli-Vidic, Lauren** (author) Lisinopril Overdose and Management Including Intravenous Angiotensin II: Case Report and Review of the Literature (CR) 1165
**Troyer, Scott D.** (coauthor) see **Dattani, Bella**, 206
**Truitt, Charlotte A.** (coauthor) see **Dattani, Bella**, 206
**Tsoi, Winnie W.Y.** (coauthor) see **Chan, Thomas Y.K.**, 1411
**Tsourounis, Candy** (coeditor) see **Schroeder, Donna J.**, 1182, 1245, 1353
**Turgan, Cetin** (coauthor) see **Oymak, Oktay**, 406
**Turi, Anthony R.** (coauthor) see **Carson, John J.**, 403

## U-V

**Udeani, George O.** (author) Compatibility of Oral Morphine Sulfate Solution with Enteral Feeding Products (RPR) 451
**Ueno, Kazuyuki** (author) Age-Dependent Changes of Renal Excretion of Theophylline in Asthmatic Children (L) 281
**van Jaarsveld, Pieter P.** (coauthor) see **Donald, Peter R.**, 1340
**Vance-Bryan, Kyle** (coauthor) see **Hoey, Lori L.**, 97
**Vaughan, Leigh M.** (author) New (Renamed) Critical Care Journal (L) 807; (author) Stability of Ceftazidime and Vancomycin Alone and in Combination with Heparinized and Nonheparinized Peritoneal Dialysis Solution (RPR) 572; (author) Sterilization of Talc USP for Intrapleural Use (L) 1309; (coauthor) see **Joseph, Joe**, 313
**Vecina, Santiago Tomás** (coauthor) see **Gonzalo, Francisco Epelde**, 1310
**Venitz, Jurgen** (coauthor) see **Jones, Lori A.**, 841
**Vercaigne, Lavern M.** (author) Recommended Treatment for Urinary Tract Infection in Pregnancy (O) 248
**Verzino, Ellen M.** (author) Verapamil–Aspirin Interaction (L) 536
**Villanueva, J.L.** (coauthor) see **Kindelán-Jaquotot, Jose Maria**, 1304
**Villegas, Fernando** (coauthor) see **Lares-Asseff, Ismael**, 405
**Vita, Eleadon O.** (author) Intralipid in Prophylaxis of Amphotericin B Toxicity (DIAS) 1182

## W

**Wagner, John G.** (author) Some Contributions and Guidance for Future Graduate Students (RC) 957
**Wagner, Mary L.** (coauthor) see **Zoe, Aneite**, 878
**Walawander, Cynthia A.** (coauthor) see **Grasela, Thaddeus H. Jr.**, 252, 261, 968; (coauthor) see **Welage, Lynda S.**, 515
**Walker-Renard, Pamela** (coauthor) see **Clewell, Jerry D.**, 54
**Wall, Hillary** (coauthor) see **Johnson, Gretchen L.**, 460
**Walters, Arthur S.** (coauthor) see **Zoe, Anette**, 878
**Watling, Sharon M.** (coauthor) see **Holliday, Diane M.**, 1110; (coauthor) see **Lee, Susan**, 1414
**Watson, Amy Rich** (author) High-Dose Interferon Alfa-2A for the Treatment of Chronic Hepatitis C (DIAS) 341
**Watson, Jerry E.** (author) Suicide Attempt by Aspirin Enema (CR) 467
**Watson, William A.** (coauthor) see **Wright, Julie M.**, 309, 1202
**Weart, C. Wayne** (coauthor) see **de Clavijo, Irene V.**, 633; (coauthor) see **Wilson, Marcus D.**, 617
**Weinstein, Alan** (coauthor) see **Ghalie, Richard**, 379
**Weir, Brian A.** (author) Aminoglycoside Nephrotoxicity Following Single-Dose Cystoscopy Prophylaxis (CR) 199; (author) Authors' Reply: Aminoglycoside Nephrotoxicity Following Single-Dose Cystoscopy Prophylaxis (L) 1203
**Weiss, Peter** (coauthor) see **Lackner, Thomas E.**, 809
**Welage, Lynda S.** (author) Risk Factors for Acute Renal Insufficiency in Patients with Suspected or Documented Bacterial Pneumonia (PEP) 515
**Wells, Barbara G.** (author) Amiloride in Lithium-Induced Polyuria (DIAS) 888
**Welty, Timothy E.** (author) book review, 287; (author) Impact of Vancomycin Therapeutic Drug Monitoring on Patient Care (RPR) 1335; (author) Prior Calcium-Channel Antagonist Use and Ischemic Stroke Outcomes (L) 671
**Wesley, Linda C.** (coauthor) see **O'Mara, Neeta Bahal**, 210
**Wesolowicz, Laurie A.** (coauthor) see **Beis, Sara**, 813
**Whang, David D.** (coauthor) see **Hampton, Edward M.**, 212; (coauthor) see **Whang, Robert**, 220
**Whang, Robert** (author) Magnesium Homeostasis and Clinical Disorders of Magnesium Deficiency (A) 220; (coauthor) see **Flack, John M.**, 175; (coauthor) see **Hampton, Edward M.**, 212
**Whipple, Julianne K.** (author) Difficulties in Diagnosing Narcotic Overdoses in Hospitalized Patients (RPR) 446; (author) Identification of Patient-Controlled Analgesia Overdoses in Hospitalized Patients: A Computerized Method of Monitoring Adverse Events (PI) 655
**White, Roger L.** (coauthor) see **Friedrich, Lawrence V.**, 444
**Whitney, Harvey A.K. Jr.** (author) Death with Indignity Legalized (E) 1395
**Whittaker, J. Scott** (coauthor) see **Kim-Sing, Angela**, 806
**Wiedrick, James E.D.** (author) Upper Gastrointestinal Bleeding Associated with Oral Ketorolac Therapy (L) 1109
**Wilcox, Charles S.** (coauthor) see **Heiser, Jon F.**, 1205
**Wildenradt, Suzanne Solem** (author) Antenatal Dexamethasone as Prophylaxis of Respiratory Distress Syndrome (DIAS) 475
**Wilkins, Penny** (coauthor) see **Teng, Elton**, 1248
**Williams, Barbara** (coauthor) see **Christensen, Dale B.**, 99
**Williams, Patricia B.** (author) book review, 812
**Wilson, Marcus D.** (author) Hypertension: Are Beta-Blockers and Diuretics Appropriate First-Line Therapies? (A) 617
**Wintermeyer, Susan M.** (author) Chronic Suppurative Otitis Media (PED) 1089; (author) Whole-Cell and Acellular Pertussis Vaccines (PED) 925
**Withers, Paul O.** (coauthor) see **Patel, Rakesh V.**, 565
**Wittbrodt, Eric T.** (author) Prevention of Anaphylactoid Reactions in High-Risk Patients Receiving Radiographic Contrast Media (DIR) 236
**Wolfgang, Alan P.** (author) The Health Security Act: A Case of Good News and Bad News (O) 802
**Wong, Roberta J.** (author) book review, 1114
**Wong, Wendy M.** (author) Minoxidil Use in Female Alopecia (DIAS) 890
**Wood, Chantal** (coauthor) see **Bavoux, Françoise**, 1307
**Wou, Ken** (author) Costs Associated with Recurrent Hypoglycemia Caused by Dispensing Error (L) 965
**Wright, Julie M.** (author) Authors' Reply: NSAID Use and Efficacy in the Emergency Department: Single Doses of Oral Ibuprofen Versus Intramuscular Ketorolac (L) 1202; (author) NSAID Use and Efficacy in the Emergency Department: Single Doses of Oral Ibuprofen Versus Intramuscular Ketorolac (RPR) 309
**Wright, Matthew R.** (coauthor) see **Sketris, Ingrida S.**, 962

## Y-Z

**Yamamoto, Koujiro** (coauthor) see **Santa, Tomofumi,** 963
**Yamreudeewong, Weeranuj** (coauthor) see **Lackner, Thomas E.,** 809
**Yanchick, Jillmarie K.** (author) Efficacy of Fluoxetine in Trichotillomania (DIAS) 1245; (author) Lysol: A Substance for Potential Abuse (L) 970
**Yanos, John** (coauthor) see **Holliday, Diane M.,** 1110
**Yarborough, Peggy** (coauthor) see **Canaday, Bruce R.,** 1292
**Yasavul, Unal** (coauthor) see **Oymak, Oktay,** 406
**Yasuda, Joanne M.** (author) Guanethidine for Reflex Sympathetic Dystrophy (DIAS) 338
**Yoshida, Eric M.** (coauthor) see **Kim-Sing, Angela,** 806
**Yoshimura, Norman N.** (coauthor) see **Chin, Alfred,** 35
**Zakian, Alain** (coauthor) see **Jonville-Bera, Annie-Pierre,** 964
**Zanetti, Leslie A. Farquhar** (author) Pentamidine-Induced Torsades de Pointes (L) 282
**Zangwill, Abby C. Bereskin** (coauthor) see **Floren, Leslie Carstensen,** 1040
**Zarowitz, Barbara J.** (author) Recent Advances in Critical Care (RA) 245; (coauthor) see **Patel, Rakesh V.,** 565; (coauthor) see **Smythe, Maureen A.,** 1073
**Zbehlik, Alicia J.** (coauthor) see **Rodriguez, Luis F.,** 643
**Zecca, Marco** (coauthor) see **Buggia, Isabella,** 1055
**Zenon, Golden J., III** (coauthor) see **Cadle, Richard M.,** 191
**Zhanel, George G.** (coauthor) see **Vercaigne, Lavern M.,** 248
**Zoanetti, Giovanni D.** (coauthor) see **Roberts, Gregory W.,** 966
**Zoe, Anette** (author) High-Dose Clonidine in a Case of Restless Legs Syndrome (CR) 878
**Zogno, Maria G.** (author) Hypoglycemia Caused by Maprotiline in a Patient Taking Oral Antidiabetics (L) 406
**Zupanc, Mary L.** (coauthor) see **Gidal, Barry E.,** 455
**Zusman, Shlomo Paul** (coauthor) see **Lustig, Ahuva,** 276

## ADVERTISER INDEX

**American College of Clinical Pharmacy,** PSAP, 924
**Amgen,** Epogen, 158, 164, 302, 541, 560, 700, 831, 1008, 1220; The Amgen Pharmacy Alliance, 436, 696, 834, 1004, 1138
**Apothecon,** Multisource From a Single Source, 1136, 1224
**Cactus Software, Inc.,** The Adverse Reaction Management System, 766
**Chapman & Hall,** American Journal of Therapeutics, 1003
**Christian Pharmacists Fellowship International,** membership, 943, 1284
**Diagnostek, Inc.,** MUE Manual, 174, 425
**Harvey Whitney Books,** books, journals, reprints, 125, 166, 420, 693, 995, 1131; CA/CTF, subscription, 6, 290, 830, 1137, 1225; combination subscription, 150, 172, 832, 1140; METS, 1212, 1226; Pharmacoepidemiology, 511; Principles of Pharmacoeconomics, 425; SIMKIN, 170, 1136, 1325; The Annals of Pharmacotherapy, PharmaCE, 122, 288, 416, 547, 682, 840, 815, 982, 1121, 1211, 1320, 1422, subscription, 5, 171, 301, 435, 559, 699, btw 728-729, 827, btw 856-857, btw 1016-1017, 1127, 1139, 1219, 1444; subscription, gift, btw 1312-1313; Therapeutics in the Elderly, 903, 1128, 1214, 1224, 1370
**Lederle Laboratories,** Ziac, ifc-Jan, ifc-Mar, ifc-May, ifc-J/A, ifc-Oct; icf-Dec; Zosyn, 129, ifc-Feb, ifc-Apr, ifc-Jun, ifc-Sep, ifc-Nov
**Miles Pharmaceuticals,** Cipro, ibc-Jan, ibc-May, ibc-Mar, ibc-J/A, ibc-Oct, ibc-Dec
**Parke-Davis,** Neurontin, 433, 557
**Personnel Placement, California,** California Clinical Trials, 295, Redwood Health Services, 295; **Colorado,** Sociometrics, Inc., 993; **Connecticut,** University of Connecticut, 296; **Florida,** University of Florida, 1123; **Georgia,** Mercer University, 821; **Illinois,** Memorial Health System, 1123, Memorial Medical Center, 154; **Japan,** Inte...ational Education Services, 296, 424, 1423; **Louisiana,** Louisiana Office of Employment Security, 296, Northeast Louisiana University, 994, Veterans Affairs Medical Center, 292, 423, 548, 684, 1424; **Maryland,** Otsuka America Pharmaceutical, Inc., 153; **Michigan,** University of Michigan, 549, Wayne State University, 1423; **Minnesota,** Mayo Medical Center, 4; **Missouri,** University of Missouri-Kansas City, 153, 683; **New York,** A&M Schwartz College of Pharmacy, 993, 994, Vassar Brothers Hospital, 683; **North Carolina,** Campbell University, 295, 1423; C...o, Procter & Gamble, 1425; **Rhode Island,** University of Rhode Island, 154; **Texas,** Northwest Texas Healthcare System, 994; **Virginia,** The Degge Group, Ltd., 295, Veterans Affairs Medical Center, 155; **West Virginia,** West Virginia University, 153, 821; **Wisconsin,** University of Wisconsin, 153, 295
**Pratt Pharmaceuticals,** Procardia XL, 8, ibc-Feb, 307, ibc-Apr, 563, ibc-Jun, 835, ibc-Sep, 1141, ibc-Nov, 1333
**US Bioscience,** Neutrexin, 411, 437, btw 560-561, btw 696-697
**Wyeth-Ayerst Laboratories,** Ativan Injection, 151, 293, 303, 545, 561, 697; Blunt Pointe. 156, 414, 676, 833, 1005, 1221; Oruvail, 3, 169

## INDEX ABBREVIATIONS

| | |
|---|---|
| A: | Article |
| AIDS: | HIV and AIDS |
| CC: | Critical Care |
| CN: | Clinical Nutrition |
| CR: | Case Reports |
| DIAS: | Drug Information Analysis Service |
| DIR: | Drug Interactions and Reactions Update |
| DSP: | Drug Selection Perspectives |
| E: | Editorial |
| ET: | Education and Training |
| FF: | Formulary Forum |
| G: | Geriatrics and Gerontology |
| ibc: | inside back cover |
| ifc: | inside front cover |
| IR: | International Reports |
| L: | Letters |
| NC: | News and Comments |
| NDD: | New Drug Developments |
| O: | An Opinion |
| obc: | outside back cover |
| PA: | Pulmonary and Allergy |
| PEC: | Pharmacoeconomics |
| PED: | Pediatrics |
| PEP: | Pharmacoepidemiology |
| PER: | Perspective |
| PI: | Pharmacoinformatics |
| RA: | Recent Advances |
| RC: | Rho Chi |
| RPR: | Research/Practice Reports |
| S: | Supplement |
| SC: | Special Contribution |
| SR: | Short Reports |
| TC: | Therapeutic Controversies |
| TM: | Therapeutic Monitoring |

Statement of ownership, management, and monthly circulation (11 issues, $120 annually) of *The Annals of Pharmacotherapy*, publication no. 1060-0280. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, P.O. Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies of each issue from October 93 to September 94 and no. of copies of September 94: A. total no. copies printed (net press run) 8118, 8000; B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 5425, 5498; C. total paid circulation 5425, 5498; D. free distribution 408, 459; E. total distribution (C + D) 5833, 5957; F. office use, left over, etc. 2285, 2043; G. total (E + F) 8118, 8000. No. of issues published annually: 11. Date of filing: 23 September 1994. Signed: Harvey A.K. Whitney, Jr., Publisher.